Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1A P H A S E 3 M U L TI C E N T E R, O P E N -L A B E L S T U D Y T O E V A L U A T E T H E 
S A F E T Y O F D AI L Y O R A L D O SI N G O F T A F A MI DI S M E G L U MI N E 
( P F - 0 6 2 9 1 8 2 6 -8 3) 2 0 M G O R 8 0 M G [ O R T A F A MI DI S ( P F - 0 6 2 9 1 8 2 6- 0 0) 6 1 M G] I N 
S U B J E C T S DI A G N O S E D W I T H T R A N S T H Y R E TI N C A R DI O M Y O P A T H Y 
( A T T R -C M) 
C o m p o u n d: P F - 0 6 2 9 1 8 2 6 
C o m p o u n d N a me: Tafa mi dis 
U nite d St ates ( U S) I n vesti g ati o n al Ne w 
Dr u g (I N D) N u m ber: I N D 7 1, 8 8 0 
E ur o pe a n Cli nic al Tri als D at a b ase 
( E u dr a C T) N u m ber: 2 0 1 6 - 0 0 0 8 6 8- 4 2 
Pr ot oc ol N u m ber: B 3 4 6 1 0 4 5 
P h ase: 3
T his d oc u me nt c o ntai ns c o nfi de ntial i nf or m ati o n bel o n gi n g t o [COMPANY_007].  E xce pt as ot her w ise a gree d t o i n w riti n g, 
b y acce pti n g or re vie wi n g t his d oc u me nt, y o u a gree t o h ol d t his i nf or mati o n i n c o nfi de nce a n d n ot c o p y or 
discl ose it t o ot hers (e xce pt w here re q uire d b y a p plica ble la w) or use it f or u na ut h orize d p ur p oses.  I n t he e ve nt 
of a n y act ual or s us pecte d breac h of t his o bli gati o n, [COMPANY_007] m ust be pr o m ptl y n otifie d. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733808] or y 
D oc u me nt Versi o n D ate S u m m ar y of C h a n ges a n d R ati o n ale 
A me n d me nt 5 
(c o u ntr y  s pecific) 24Ja n uar y  [ADDRESS_733809] or y , as descri be d i n 
A p pe n di x 7 .
A me n d me nt 4 
( Gl o bal) [ADDRESS_733810] e nr oll me nt fr o m 
1 4 0 0 t o 2 0 0 0 a n d A p pe n di x 5 c o u ntries 
partici pati n g i n C o h ort B. 
2. A d diti o n of bl o o d sa m ple c ollecti o n f or 
testi n g of car diac bi o mar kers N -ter mi nal 
pr o - h or m o ne brai n natri uretic pe pti de 
( N T -pr o B N P) a n d tr o p o ni n I.  
3. Clarificati o n t hat pre vi o usl y  e x peri me ntal 
t hera pi[INVESTIGATOR_558812] n a n d i n ote rse n re mai n 
st u d y  pr o hi bite d as c o m mercial t hera pi[INVESTIGATOR_014]. 
4. Clarificati o n of a d verse e ve nt m o nit ori n g 
tele p h o ne c o ntact f or s u bjects e nr olle d i n 
Ja pa n i n A p pe n di x 4. 2. 
5. Mi n or f or matti n g/ gra m mar/rea da bilit y  
i m pr o ve me nts i n ge neral. 
A me n d me nt 3 
( Gl o bal) [ADDRESS_733811] u d y  B 3 4 6 1 0 2 8. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 32. Tra nsiti o n of all s u bjects t o o pe n la bel 
6 1 m g d ose ( w here a vaila ble) as a res ult of 
t he pare nt st u d y d ose decisi o n 
c o nfir mati o n. 
3. Tra nsiti o n of I P pac ka gi n g fr o m bli n de d 
blister pac ks t o o pe n la bel b ottle 
pac ka gi n g. 
4. Re q uire d c o ntrace pti o n, hi g hl y effecti ve 
c o ntrace pti o n met h o ds, a n d defi niti o n of 
w o ma n of c hil d beari n g p ote ntial u p date d 
t o ali g n wit h ne w c o m m o n pr ot oc ol 
te m plate la n g ua ge. 
5. A d d ba n ke d bi os peci me n c ollecti o n f or 
ne w c o h ort. 
6. Mi n or f or matti n g/ gra m mar/rea da bilit y  
i m pr o ve me nts i n ge neral. 
A me n d me nt 2 
C o u ntr y  S pecific 
( Ger ma n y) 2 8 Marc h 2 0 1 7 1. A d diti o n of Ger ma n y t o t he Fra nce - o nl y 
c o u ntr y  s pecific pr oce d ures at M o nt h 3 
visit. 
A me n d me nt 1 
C o u ntr y  S pecific 
( Fra nce a n d 
Ger ma n y) 3 1 Ja n uar y  2 0 1 7 1. ( Fra nce a n d Ger ma n y) Title Pa ge: 
A d de d E ur o pea n Cli nical Trials Data base 
( E u dra C T) N u m ber. 
2. ( Fra nce a n d Ger ma n y) Pr ot oc ol S u m mar y, 
Secti o n 3 St u d y  Desi g n: S pecifie d st u d y  
will e n d [ADDRESS_733812] u d y  B 3 4 6 1 0 2 8 b y  t he l ocal 
C o m pete nt A ut h orit y. 
3. ( Fra nce o nl y) S c he d ule of Acti vities: 
A d de d t he f oll o wi n g pr oce d ures t o 
M o nt h 3 visit: 1) P h y sical e xa mi nati o n a n d 
wei g ht meas ure me nt 2) 1 2 -Lea d E C G 
3) Vital si g ns meas ure me nt 4) Bl o o d/ uri ne 
sa m ple c ollecti o n 5) Pre g na nc y  testi n g 
6) A d mi nister Ka nsas Ci t y  0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4Car di o m y o pat h y Q uesti o n naire ( K C C Q) 
7) Ne w Y or k Heart Ass ociati o n ( N Y H A) 
classificati o n 8) Dr u g c o m p lia nce a n d 
acc o u nta bilit y . 
4. ( Fra nce o nl y) S ecti o n 6. 2. 2 Tele p h o ne visit 
pr oce d ures: S pecifie d a d diti o nal 
pr oce d ures at M o nt h 3 visit. 
5. ( Fra nce o nl y) S ecti o n 7. 1. 2 P h y sical 
E xa mi nati o n a n d Hei g ht Meas ure me nts: 
S pecifie d brief p h ys ical e xa mi nati o n at 
M o nt h 3 visit. 
6. ( Fra nce o nl y) S ecti o n 7. 1. 3 Vital Si g ns: 
S pecifie d Vital si g ns meas ure me nt at 
M o nt h 3 visit. 
7. ( Fra nce o nl y) S ecti o n 7. 1. 4 
Electr ocar di o gra m: S pecif ie d E C G 
meas ure me nt at M o nt h 3 visit. 
8. ( Fra nce o nl y) S ecti o n 7. 1. 5 Cli nical 
La b orat or y  Tests: S pecifie d bl o o d/ uri ne 
sa m ple c ollecti o n f or He mat ol o g y , Ser u m 
C he mistr y , C oa g ulati o n, Uri nal y sis at 
M o nt h 3 visit. 
9. ( Fra nce o nl y) S ecti o n 7. 2 Pre g na nc y  
Testi n g: S pe cifie d pre g na nc y  test t o be 
perf or me d at M o nt h 3. 
1 0. ( Fra nce o nl y) S ecti o n 7. 4. 1 Ne w Y or k 
Heart Ass ociati o n Classificati o n: S pecifie d 
N Y H A classificati o n at M o nt h 3visit. 
1 1. ( Fra nce o nl y) S ecti o n 7. 4. 2 Ka nsas Cit y  
Car di o m y o pat h y Q uesti o n naire: S pecifie d 
K C C Q a d mi nistrati o n at M o nt h 3 visit. 
Ori gi nal pr ot oc ol 2 9 Ja n uar y  2 0 1 6 N ot a p plica ble ( N/ A) 
T his a me n d me nt i nc or p orates all re visi o ns t o date, i ncl u di n g a me n d me nts ma de at t he 
re q uest of c o u ntr y  healt h a ut h orities a n d i nstit uti o nal re vie w b oar ds (I R Bs)/et hics c o m mittees 
( E Cs). 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733813] y le G ui deli nes ................................ ................................ ................................ 3 1 
4. 3. 1. W o ma n of C hil d beari n g P ote ntial ( W O C B P) ................................ ............ 3 2 
4. 4. S p o ns or’s Q ualifie d Me dical Pers o n nel ................................ ................................ .. [ADDRESS_733814] S u p plies ................................ ................................ ............. 3 6 
5. 4. 1. D osa ge F or m(s ) a n d Pac ka gi n g ................................ ................................ .. 3 7 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733815] S u p plies ........................................ 4 1 
5. 8. C o nc o mita nt Treat me nt(s) ................................ ................................ ....................... 4 1 
5. 8. 1. Pr o hi bite d T hera pi[INVESTIGATOR_014]................................................................................... 4 1 
6. S T U D Y P R O C E D U R E S................................ ................................ ................................ ..... 4 2 
6. 1. Scree ni n g Visit ................................ ................................ ................................ ........ 4 2 
6. 1. 1. Scree ni n g Visit C o h ort A ( Da y  0) ................................ .............................. 4 2 
6. 1. 2. Scree ni n g Visit C o h ort B ( wit h disease d oc u me ntati o n) ( Da y  0) .............. 4 4 
6. 1. 3. Scree ni n g Visit ( Da y  - 3 0) C o h ort B S u bjects wit h o ut D oc u me ntati o n 
of Dia g n osis ................................ ................................ ................................ ..... 4 5 
6. 1. 4. Scree ni n g Visit ( Da y  0) C o h ort B ( wit h o ut disease d oc u me ntati o n)......... [ADDRESS_733816] u d y  Peri o d ................................ ................................ ................................ ............ 4 7 
6. 2. 1. Da y  1................................ ................................ ................................ ........... 4 7 
6. 2. 2. Tele p h o ne Visits ( M o nt hs 3, 9, 1 5, 2 1 , 2 7, 3 3, 3 9, 4 5, 5 1, 5 7) 2 
Wee ks ................................ ................................ ................................ ............... 4 8 
6. 2. 3. Cli nic Visits ( M o nt hs 6, 1 2, 1 8, 2 4, 3 0, 3 6, 4 2, 4 8, 5 4) [ADDRESS_733817] u d y  Visit ( M o nt h 6 0) [ADDRESS_733818] Wit h dra wal a n d Vital Stat us/ Tra ns pla nt/ Car diac Mec ha nical Assist 
De vice Stat us F oll o w - u p ........................................................................................... [ADDRESS_733819] or y ................................ ................................ .......................... 5 3 
7. 1. 2. P h y sical E xa mi nati o n a n d Hei g ht Meas ure me nts ................................ ...... 5 3 
7. 1. 3. Vital Si g ns ................................ ................................ ................................ .. 5 3 
7. 1. 4. Electr ocar di o gra m ................................ ................................ ....................... 5 4 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 77. 1. 5. Cli nical L a b orat or y  Tests ................................ ................................ ........... 5 5 
7. 2. Pre g na nc y  Testi n g ................................ ................................ ................................ ... 5 6 
7. 3. C o ntrace pti o n C hec k ................................ ................................ ............................... 5 6 
7. 4. Ot her Assess me nts ................................ ................................ ................................ .. 5 6 
7. 4. 1. Ne w Y or k Heart Ass ociati o n Classificati o n ................................ ............... 5 6 
7. 4. 2. K a nsas Cit y  Car di o m y o pat h y Q uesti o n naire ................................ .............. 5 7 
7. 4. 3. B o d y Mass I n de x/ M o difie d B o d y Mass I n de x ................................ ........... 5 7 
7. 4. 4. Testi n g f or L i g ht C hai n A m y l oi d ................................ ............................... 5 7 
7. 4. 5. Bi o ps y D oc u me nta ti o n of A m y l oi d De p ositi o n ................................ ......... 5 8 
7. 4. 6. T T R Ge n ot y pi n g ................................ ................................ ......................... 5 8 
7. 5. Ba n ke d Bi os peci me ns ................................ ................................ ............................. 5 8 
7. 5. 1. A d diti o nal Researc h ................................ ................................ .................... 5 9 
7. 6. Car diac Bi o mar kers N -Ter mi nal Pr o - H or m o ne Brai n Natri uretic Pe pti de 
(N T -pr o B N P) a n d Tr o p o ni n I ................................ ................................ .................... [ADDRESS_733820] u g -I n d uce d Li ver I nj ur y................................ ............ 6 3 
8. 7. H os pi[INVESTIGATOR_1314] o n ................................ ................................ ................................ ........ 6 4 
8. 8. Se verit y  Assess me nt ................................ ................................ ................................ 6 5 
8. 9. Ca usalit y  Assess me nt ................................ ................................ .............................. 6 5 
8. 1 0. E x p os ure D uri n g Pre g na nc y ................................ ................................ .................. 6 6 
8. 1 1. Occ u pati o nal E x p os ure ................................ ................................ ......................... 6 7 
8. 1 2. Wit h dra wal D ue t o A d vers e E ve nts ( See Als o t he Secti o n o n S u bject 
Wit h dra wal)................................ ................................ ................................ ............... 6 7 
8. 1 3. Eliciti n g A d verse E ve nt I nf or mati o n ................................ ................................ .... 6 7 
8. 1 4. Re p orti n g Re q uire me nts ................................ ................................ ........................ 6 7 
8. 1 4. 1. Seri o us A d verse E ve nt Re p orti n g Re q uire me nts ..................................... 6 8 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 88. 1 4 . 2. N o nseri o us A d verse E ve nt Re p orti n g Re q uire me nts ............................... 6 8 
8. 1 4. 3. S p o ns or’s Re p orti n g Re q uire me nts t o Re g ulat or y  A ut h orities ................ 6 8 
9. D A T A A N A L Y SI S/ S T A TI S TI C A L  M E T H O D S ................................ ............................... 6 8 
9. 1. Sa m ple Size Deter mi nati o n ................................ ................................ ..................... 6 9 
9. 2. A nal y sis of Ot her E n d p oi nts ................................ ................................ ................... 6 9 
9. 2. 1. M ortalit y  ( Car di o vasc ular -relate d)............................................................. 6 9 
9. 2. 2. H os pi[INVESTIGATOR_1314] o n ................................ ................................ ............................ 6 9 
9. 2. 3. Ka nsas Cit y  Car di o m y o pat h y Q uesti o n naire ................................ .............. 6 9 
9. 2. 4. Ne w Y or k Heart Ass ociati o n ................................ ................................ ...... 7 0 
9. 2. 5. B o d y Mass I n de x/ m o difie d B o d y Mass I n de x ................................ ........... 7 0 
9. 2. 6. Car diac Bi o mar kers N T -pr o B N P a n d Tr o p o ni n I ................................ ...... 7 0 
9. 3. Safet y A nal ys is ................................ ................................ ................................ ........ 7 0 
9. 3. 1. M ortalit y  ( All -ca use) ................................ ................................ .................. [ADDRESS_733821] r ocar di o gra m s................................ ................................ ..................... 7 2 
9. 4. I nteri m A nal ys is ................................ ................................ ................................ ...... 7 2 
9. 5. Data M o nit ori n g C o m mittee ................................ ................................ ................... 7 2 
1 0. Q U A LI T Y C O N T R O L  A N D Q U A LI T Y A S S U R A N C E................................................. 7 2 
1 1. D A T A H A N D LI N G A N D R E C O R D K E E PI N G ................................ ............................. 7 3 
1 1. 1. Case Re p ort F or ms/ Electr o nic Data R ec or d ................................ ......................... 7 3 
1 1. 2. Rec or d Rete nti o n ................................ ................................ ................................ ... 7 4 
1 2. E T HI C S ................................ ................................ ................................ .............................. 7 4 
1 2. 1. I nstit uti o nal R e vie w B oar d/ Et hics C o m mit tee ................................ ...................... [ADDRESS_733822] Recr uit me nt ................................ ................................ .............................. 7 5 
1 2. 5. Re p orti n g of Safet y I ss ues a n d Seri o us Breac hes of t he Pr ot oc ol or I C H 
G C P ................................ ................................ ................................ ........................... 7 6 
1 3. D E FI NI TI O N O F E N D O F T RI A L ................................ ................................ ................... 7 6 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733823] ot of T T R Perce nt Sta bilizati o n vs Tafa mi dis: T T R M olar Rati o 
b y  Treat me nt i n St u d y  B [ADDRESS_733824] u d y  Pr oce d ures ................................ ................................ .............................. 8 7 
A p pe n di x 4. 3. Fra nce C o ntrat U ni q ue ................................ ................................ ..................... 8 7 
A p pe n di x 5. C o u ntries Partici pat i n g i n C o h ort B ................................ ................................ .... 8 8 
A p pe n di x 6. C o u ntries t hat will Partici pate i n A p pe n di x 7 f or Ne wl y E nr olli n g 
S u bjects................................................................................................................. 8 9 
A p pe n di x 7. A d diti o nal Sa m ple a n d Ba n ke d Bi os peci me n C ollecti o n f or Ne wl y 
E nr olle d S u bjects i n C o u ntries L iste d i n A p pe n di x 6 .......................................... 9 0 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 0 P R O T O C O L S U M M A R Y 
B ac k gr o u n d a n d R ati o n ale: 
[COMPANY_007] is de vel o pi n g tafa mi dis, a n oral s mall m olec ule, f or t he treat me nt of tra nst h y reti n 
a m y l oi d diseases.  Tra nst h y reti n car di o m y o pat h y ( T T R -C M or A T T R -C M) occ urs w he n 
tra nst h y reti n ( T T R) a m yl oi d fi brils i nfiltrate t he m y ocar di u m, lea di n g t o de p osits of 
e xtracell ular a m yl oi d.  De p ositi o n of tra nst h y reti n fi brils occ urs bet we en t he m y ocar dial cells 
a n d pr o d uces a t hic ke ni n g a n d stiffe ni n g of t he m y o c a r dial tiss ue.  T his i nfiltrati o n of t he 
m y ocar di u m res ults i n diast olic d y sf u ncti o n pr o gressi n g t o restricti ve car di o m y o pat h y, 
c o n gesti ve heart fail ure, a n d ulti matel y  deat h. 
Tafa mi dis is a n o vel s pecific sta bilizer of b ot h wil d -t y pe a n d a m yl oi d o ge nic vari a nts of T T R.  
Tafa mi dis bi n ds t o T T R at t he t h y r o xi ne bi n di n g sites a n d i n hi bits T T R tetra mer diss ociati o n, 
t he rate -li miti n g ste p i n t he a m yl oi d o ge nic pr ocess.  I t is h y p ot hesize d t hat tafa mi dis w o ul d 
st o p or sl o w t he pr o gressi o n of A T T R -C M a n d t heref ore re prese nts a disease m o dif y i n g 
t hera p y. 
St u d y  B [ADDRESS_733825] u d y .  T he p ur p ose 
of t he a d diti o nal c o h ort is t o pr o vi de t hese patie nts earl y access t o tafa mi dis, u ntil l ocal 
a vaila bilit y  b y  prescri pti o n f or t he A T T R- C M i n dicati o n. 
A d diti o na ll y , a ne w f or m ulati o n w hic h is bi oe q ui vale nt t o tafa mi dis me gl u mi ne 8 0 m g ha s 
bee n de vel o pe d a n d is prese nte d as tafa mi dis 6 1 m g (as t he free aci d).  T his f or m ulati o n, 
w here a vaila ble, will re place t he tafa mi dis me gl u mi ne 8 0 m g d ose after pr ot oc ol 
a me n d me nt 3. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 1 O bjecti ves a n d E n d p oi nts: 
Pri mar y  O bjecti ves: 
T o o btai n a d diti o nal, l o n g- ter m, safet y  data f or tafa mi dis i n s u bjects wit h 
tra nst h y reti n a m yl oi d car di o m y o pat h y ( A T T R -C M). 
T o pr o vi de i n vesti gati o nal pr o d uct, tafa mi dis, t o e nr olle d s u bjects u ntil l oca l
a vaila bilit y  b y  prescri pti o n f or t he A T T R- C M i n dicati o n. 
Pri mar y  E n d p oi nts: 
Safet y  as meas ure d b y :
All- ca use m ortalit y. 
I n ci de nce of treat me nt -e mer ge nt a d verse e ve nts. 
Ot her E n d p oi nts: 
Car di o vasc ular -relate d m ortalit y .
Fre q ue nc y  of all -ca use h os pi[INVESTIGATOR_90730] i o n. 
Fre q ue nc y  of car di o vasc ular -relate d h os pi[INVESTIGATOR_1314] o n (i ncl u di n g heart fai l ure, 
arr h yt h mia, m y ocar dial i nfarcti o n, str o ke a n d ot her car di o vasc ular -relate d e ve nts). 
C ha n ge fr o m baseli ne at eac h visit i n Ka nsas Cit y  Car di o m y o pat h y Q uesti o n naire 
O verall S u mmar y  sc ore, d o mai n sc ores ( P h y sical li mitati o n, S y m pt o m sta bilit y , 
S y m pt o m f re q ue nc y , S y m pt o m b ur de n, T otal s y m pt o m, Self -efficac y , S ocial 
li mitati o n, a n d Q ualit y  of life), a n d Cli nical s u m mar y  sc ore. 
Ne w Y or k Heart Ass ociati o n ( N Y H A) classificati o n at eac h visit. 
C ha n ge fr o m baseli ne i n B o d y Mass I n de x/ m o difie d B o d y Mass I n de x ( B MI / m B MI) 
at eac h visit. 
C ha n ge fr o m baseli ne i n N -ter mi nal pr o -h or m o ne brai n natri uretic pe pti de 
( N T -pr o B N P) c o nce ntrati o n at eac h visit. 
C ha n ge fr o m baseli ne i n Tr o p o ni n I c o nce ntrati o n at eac h visit. 
Assess me nt of p h ys ical e xa mi nati o ns, use of c o nc o mita nt me dicati o ns, 
electr ocar di o gra ms ( E C Gs), cli nical la b orat or y  testi n g, vital si g ns at eac h visit. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733826] u d y Desi g n: 
T his is a P hase 3, o pe n -la bel l o n g -ter m e xte nsi o n safet y st u d y de si g ne d t o o btai n a d diti o nal 
safet y data f or tafa mi dis me gl u mi ne 2 0 m g a n d 8 0 m g ( or tafa mi dis 6 1 m g w here a vaila ble), 
a n d t o c o nti n ue t o pr o vi de e nr olle d s u bjects wit h tafa mi dis f or u p t o [ADDRESS_733827] u d y  partici pa nts will be e nr olle d i n 2 c o h orts: 
C o h ort A –S u bjects dia g n ose d wit h A T T R -C M w h o c o m plete d [ADDRESS_733828] u d y B 3 4 6 1 0 2 8. 
C o h ort B –S u bjects dia g n ose d wit h A T T R - C M w h o ha ve n ot pre vi o usl y partici pate d 
i n St u d y B 3 4 6 1 0 2 8 ( A p pe n di x 5). 
St u d y P artici p ati o n Fl o w 
S u bjects i n C o h ort A will be assi g ne d t o o pe n la bel treat me nt after pr ot oc ol a me n d me nt 3. 
D ur ati o n of St u d y P artici p ati o n 
St u d y  d urati o n is f or u p t o [ADDRESS_733829] u d y . 
Selecti o n of S u bjects: 
C o h ort A I ncl usi o n Crite ria: 
S u bjects i n C o h ort A m ust meet all of t he f oll o wi n g i ncl usi o n criteria t o be eli gi ble f or 
e nr oll me nt i nt o t he st u d y: 
1. Male a n d fe male s u bjects wit h T T R a m y l oi d car di o m y o pat h y w h o ha ve c o m plete d 
[ADDRESS_733830] u d y  treat me nt o n Pr ot oc ol B 3 4 6 1 0 2 8. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733831] d os e of assi g ne d treat me nt. 
Fe male s u bjects w h o are n ot of c hil d beari n g p ote ntial (ie, meet at least 1 of t he 
f oll o wi n g criteria): 
Ha ve u n der g o ne a d oc u me nte d h y sterect o m y  a n d/ or bilateral o o p h orect o m y ;
Ha ve me dicall y  c o nfir me d o varia n fail ure; or 
Ac hie ve d p ost me n o pa usal stat us, defi ne d as f oll o ws: cessati o n of re g ular me nses 
f or at least 1 2 c o nsec uti ve m o nt hs wit h n o alter nati ve pat h ol o gical or 
p h y si ol o gical ca use; stat us ma y  be c o nfir me d b y ha vi n g a ser u m 
f ollicle - sti m ulati n g h or m o ne ( F S H) le vel c o nfir mi n g t he p ost - me n o pa usal state. 
All ot her fe male s u bjects (i ncl u di n g fe males wit h t u bal li gati o ns) will be c o nsi dere d 
t o be of c hil d beari n g p ote ntial. 
C o h ort B I ncl usi o n Criteria: 
S u bjects i n C o h ort B m ust meet all of t he f oll o wi n g i ncl usi o n criteria t o be eli gi ble f or 
e nr oll me nt i nt o t he st u d y: 
1. Male or fe male s u bject of at least 1 8 ye ars of a ge ( or t he mi ni m u m c o u ntr y s pecific 
a ge of c o nse nt if > 1 8) a n d partici pates at a st u d y s ite i n a n eli gi ble c o u ntr y  liste d i n 
Pr o t oc ol A p pe n di x 5. 
2. E vi de nce of a pers o nall y  si g ne d a n d date d i nf or me d c o nse nt d oc u me nt i n dicati n g t hat 
t he s u bject has bee n i nf or me d of all perti ne nt as pects of t he st u dy. 
3. S u bjects w h o are willi n g a n d a ble t o c o m pl y wit h sc he d ule d visits, treat me nt pla n, 
la b orat or y  tests ,a n d ot her st u d y  pr oce d ures. 
4. A fe male s u bject is eli gi ble t o partici pate if s he is n ot pre g na nt or breastfee di n g, a n d 
at least 1 of t he f oll o wi n g c o n di ti o ns a p plies: 
Is n ot a W o ma n of C hil d beari n g P ote ntial ( W O C B P) (see defi niti o n 
Secti o n 4. 3. 1 ). 
O R 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 4 Is a W O C B P a n d usi n g a c o ntrace pti ve met h o d t hat is hi g hl y  effecti ve ( wit h a 
fail ure rate of < 1 % per year) (see Secti o n 4. 3 ) d uri n g t he i nter ve nti o n peri o d a n d 
f or at least [ADDRESS_733832] h yr eti n a m y l oi d osis (ie, ori gi nal 
la b orat or y  res ult, or c o p y). 
6. D oc u me ntati o n of dia g n osis a n d criteria use d (e g, c o n gesti ve h eart fail ure a n d 
sci nti gra p h y wit h tracer e g, 9 9 m T C D P D [ 9 9 m T C 3, 3 di p h os p h o n o 1, 2 pr o p a n o 
dic ar b o xylic aci d] , 9 9 m T C P Y P [ Pyr o p h os p h ate ] a n d als o 9 9 m T C H M D P 
[ hy dr oxy met hyle ne di p h os p h o n ate] or c o n gesti ve heart fail ure a n d prese nce of 
a m y l oi d de p osits i n bi ops y  tiss ue, e g, f at as pir ate, s aliv ary gl a n d, me di a n nerve 
c o n nective tiss ue s he at h, or c ar di ac [ a myl oi d de m o nstr ate d per a p pr o pri ate st ai n 
s uc h as C o n g o re d or alci a n bl ue st ai n ]). 
7. D oc u me ntati o n t hat pri mar y  (li g ht c hai n) a m y l oi d osis disease has bee n e v al uate d a n d 
r ule d o ut (ie, ori gi nal la b orat or y  res ult, or c o p y ). 
8. E vi de nce of N Y H A classificati o n I , II, III, or I V. 
C o h ort A E xcl usi o n Criteria: 
S u bjects i n C o h ort A wit h a n y  of t he f oll o wi n g c haracteristics/c o n diti o ns will n ot be i ncl u de d 
i n t he st u d y :
1. C h ro nic use of difl u nisal, T T R sta bilizer, ta ur o urs o de o x y c h olate, d o x yc yc li ne, 
di gitalis, patisira n, calci u m c ha n nel bl oc kers, i n vesti gati o nal dr u g(s) or ot her 
e x peri me ntal i nter ve nti o ns, ot her t ha n tafa mi dis, i n de pe n de ntl y or as part of a st u d y 
wit hi n [ADDRESS_733833] u gs ( N S AI Ds) [ Secti o n 5. 8. 1 ]. 
3. Li ver a n d/ or heart tra ns pla nt, or i m pla nt ed car diac mec ha nical assist de vice. 
4. Pre g na nt fe male s u bjects ( or pla n ni n g t o bec o me pre g na nt d uri n g t he st u d y i nter val); 
breastfee di n g fe male s u bjects; male s u bjects wit h part ners c urre ntl y pre g na nt. 
5. Re q uire i nitiati o n of treat me nt wit h calci u m c h a n nel bl oc kers. 
6. Uri nar y  rete nti o n re q uiri n g c hr o nic self- cat heterizati o n. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 5 7. Breac h of c o m plia nce wit h treat me nt/si g nifica nt pr ot oc ol vi olati o ns d uri n g c o n d uct of 
B [ADDRESS_733834] u d y .
C o h ort B E xcl usi o n Criteria: 
S u bjects i n C o h ort B wit h a n y  of t he f oll o wi n g c haracteristics/c o n diti o ns will n ot be i ncl u de d 
i n t he st u d y :
1. C hr o nic use of difl u nisal, T T R sta bilizer, ta ur o urs o de o x y c h olate, d o x yc yc li ne, 
di gitalis, patisira n, calci u m c ha n nel bl oc kers, i n vesti gati o nal dr u g(s) or ot her 
e x peri me ntal i nter ve nti o ns, ot her t ha n tafa mi dis, i n de pe n de ntl y or as part of a st u d y 
wit hi n [ADDRESS_733835] u gs ( N S AI Ds) [ Secti o n 5. 8. 1 ]. 
3. Li ver a n d/ or heart tra ns pla nt, or i m pla nte d car diac mec ha nical assist de vice. 
4. Re q uire i nitia ti o n of treat me nt wit h calci u m c ha n nel bl oc kers. 
5. Uri nar y  rete nti o n re q uiri n g c hr o nic self- cat heterizati o n. 
6. S u bjects wit h heart fail ure t hat i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or is o n t he basis of 
isc he mic heart disease (e g, pri or m y o car dial i nfarcti o n wit h d oc u me nte d hist or y  of 
car diac e nz y mes a n d E C G c ha n ges), or u nc orrecte d val v ular disease a n d n ot 
pri maril y  d ue t o tra nst h yreti n a m y l oi d car di o m y o pat h y .
7. S u bjects w h o are i n vesti gati o nal site staff me m bers directl y i n v ol ve d i n t he c o n d uct 
of t he st u d y  a n d t hei rfa mil y  me m bers, site staff me m bers ot her wise s u per vise d b y  t he 
i n vesti gat or, or s u bjects w h o are [COMPANY_007] e m pl o ye es directl y  i n v ol ve d i n t h e c o n d uct of 
t he st u d y .
8. Ot her se vere ac ute or c hr o nic me dical or ps yc hi atric c o n diti o n or la b orat or y 
a b n or malit y  t hat m a y  i ncrease t he ris k ass ociate d wit h st u d y  partici pati o n or 
i n vesti gati o nal pr o d uct a d mi nistrati o n, or t hat ma y  i nterfere wit h t he i nter p retati o n of 
st u d y  res ults a n d, i n t he j u d g me nt of t he i n vesti gat or, w o ul d ma ke t he s u bject 
i na p pr o priate f or e ntr y  i n to t his st u d y . 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733836] u d y Tre at me nts: 
S u bject eli gi bilit y  f or partici pati o n i n t he treat me nt p hase of t he pr ot oc ol will be deter mi ne d 
f oll o wi n g t he assess me nts at t he Scree ni n g visit.  S u bjects will be scree ne d f or eli gi bilit y  a n d 
t h ose, i n t he j u d g me nt of t he i n vesti gat or, w h o meet t he i ncl usi o n criteria a n d d o n ot meet t he 
e xcl usi o n criteria, will be e nr olle d.  T here will be treat me nt assi g n me n t stratificati o n b y  T T R 
ge n ot y p e ( varia nt or wil d -t y pe) f or C o h ort A. 
C o h ort A Treat me nt Assi g n me nts: 
At e nr oll me nt, s u bjects i n C o h ort A were assi g ne d t o bli n de d acti ve treat me nt; 2 0 m g or 
8 0 m g tafa mi dis o nce dail y , i n a d diti o n t o sta n dar d of care (e g, d i uretics) f or u p t o 6 0 m o nt hs 
base d o n t he f oll o wi n g:  
S u bjects recei vi n g [ADDRESS_733837] u d y B 3 4 6 1 0 2 8 c o nti n ue t he sa me 
bli n de d treat me nt assi g n me nt. 
S u bjects assi g ne d t o place b o i n St u d y  B 3 4 6 1 0 2 8 will be ra n d o mize d ( 1: 2) t o bli n de d 
[ADDRESS_733838] u d y  B 3 4 6 1 0 2 8 a n d 
ra n d o mize d t o 8 0 m g tafa mi dis will be per mitte do ne bli n de d d ose -re d ucti o n t o 
2 0 m g f or a d verse e ve nts relate d t o t olera bilit y. 
S u bjects i n C o h ort A will be assi g ne d t o o pe n la bel treat me nt after pr ot oc ol a me n d me nt 3. 
S u bjects recei vi n g 2 0 m g or 8 0 m g tafa mi dis me gl u mi ne will be assi g ne d t o 6 1 m g tafa mi dis, 
o nce dail y, i n a d diti o n t o sta n dar d of care (e g, di uretics), f or u p t o 6 0 m o nt hs.  S u bjects will 
be assi g ne d t o 8 0 m g tafa mi dis me gl u mi ne i n re gi o ns w here 6 1 m g  tafa mi dis is u na vaila ble. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 7 C o h ort B Treat me nt assi g n me nt: 
At e nr oll me nt, s u bjects i n C o hort B will be assi g ne d t o o pe n la bel 6 1 m g  tafa mi dis o nce 
dail y , i n a d diti o n t o sta n dar d of care (e g, di uretics), f or u p t o [ADDRESS_733839] S u p plies 
Tafa mi dis me gl u mi ne is a vaila ble i n 2 0 m g  s oft gel ca ps ules. Tafa mi dis free aci d is 
a vaila ble i n 6 1 m g  s oft gel ca ps ules. 
D os age Le vel ( C o m p o u n d) A p pe ar a nce N u m ber of C a ps ules Per D a y ( D ose) 
Tafa mi dis me gl u mi ne 2 0 m g 
( P F -0 6 2 9 1 8 2 6 -8 3) -bli n de d Yell o w, o bl o n g s oft gelati n 
ca ps ules 1( Tafa mi dis me gl u mi ne 2 0 m g ca ps ule) 
3( Place b o ca ps ules) 
Tafa mi dis me gl u mi ne 8 0 m g 
( P F -0 6 2 9 1 8 2 6- 8 3) -bli n de d Yell o w, o bl o n g s oft gelati n 
ca ps ules 4 ( Tafa mi dis me gl u mi ne 2 0 m g ca ps ules) 
Tafa mi dis free aci d 6 1 m g 
( P F 0 6 2 9 1 8 2 6 -0 0) -o pe n Re d dis h br o w n, o bl o n g s oft 
gelati n ca ps ules 1 ( Tafa mi dis free aci d 6 1 m g ca ps ule) 
Tafa mi dis me gl u mi ne 2 0 m g 
( P F0 6 2 9 1 8 2 6 -8 3) -o pe n Yell o w, o bl o n g s oft gelati n 
ca ps ules 1 ( Tafa mi dis me gl u mi ne 2 0 m g ca ps ule) 
Tafa mi dis me gl u mi ne 8 0 m g 
( P F 0 6 2 9 1 8 2 6 -8 3) -o pe n Yell o w, o bl o n g s oft gelati n 
ca ps ules 4 ( Tafa mi dis me gl u mi ne 2 0 m g ca ps ules) 
T he st u d y  will use a n E xter nal Data M o nit ori n g C o m mittee ( E -D M C) t hat will be 
re s p o nsi ble f or o n g oi n g m o nit ori n g of t he safet y of s u bjects i n t he st u d y  acc or di n g t o t he 
E- D M C C harter. 
St atistic al Met h o d: 
S a m ple Size R ati o n ale 
T here is n o f or mal sa m ple size calc ulati o n f or t his pr ot oc ol.   S u bjects w h o meet e nr oll me nt 
criteria are eli gi ble; U p t o [ADDRESS_733840] u d y  will als o be i ncl u de d. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733841] a n ne d I nteri m A n al ysis 
I nteri m a nal ys es will be perf or me d if re q uire d t o meet re g ulat or y  re q uire me nts (e g, a n n ual 
re p orti n g) a n d as re q ueste d b y  t he E xter nal Data M o nit ori n g C o m mittee.  Interi m a nal ys es 
ma y  als o be perf or me d d uri n g t he c o urse of t he st u d y  t o all o w f or t he re p orti n g of data t o t he 
scie ntific c o m m u nit y .0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 9 S C H E D U L E O F A C TI VI TI E S 
T he sc he d ule of acti vities ta ble pr o vi des a n o ver vie w of t he pr ot oc ol visits a n d pr oce d ures.  
Refer t o t he S T U D Y P R O C E D U R E S a n d A S S E S S M E N T S secti o ns of t he pr ot oc ol f or 
detaile d i nf or mati o n o n eac h pr oce d ure a n d ass ess me nt re q uire d f or c o m plia nce wit h t he 
pr ot oc ol. 
T he i n vesti gat or ma y  sc he d ule visits ( u n pla n ne d visits) i n a d diti o n t o t h ose liste d o n t he 
sc he d ule of acti vities, i n or der t o c o n d uct e val uati o ns or assess me nts re q uire d t o pr otect t he 
well -bei n g of t he s u bject. 
Visit I de ntifier Scree ni n g D a y [ADDRESS_733842] u d y 
f oll o w -u p e
P o p ulati o n C o h ort B u
( wit h o ut disease 
d oc u me ntati o n) C o h ort A a& 
C o h ort B a,u
( wit h disease 
d oc u me ntati o n) C o h o rts 
A & B (A p pe n dix 4. 2 
c o u ntry 
re q uire me nt )bC o h orts A & B 
Fre q ue nc y M o nt h [ADDRESS_733843] u d y 
Ter mi nati o n 2 8 da ys after 
las t d os e
Visit Wi n d o w fDa y -3 0 Da y 0 Da y 0 Da y 1 2 weeks 2 wee ks 2 
wee ks 2 wee ks 
I nf or me d c o nse nt a n d Release 
of Me dical I nf or mati o n F or m X X
I ncl usi o n/e xcl usi o n criteria X X X
De m o gra p h y X X
Me dical hist or y X X
P h ysical e xa mi nati o n (f ull) gX X X
P h ysical e xa mi nati o n ( brief) hXgX X
Hei g ht meas ure me nt iX X
Vital Si g ns jX X X X X
La b orat or y Testi n g k,l
He mat ol o g y X XlX X X
Ser u m C he mistr y X XlX X X
C oa g ulati o n X XlX X X
Reti n ol Bi n di n g Pr ote i n X XlX X X
Uri nal ysis X X X X X
Car diac bi o mar kers 
( N T -pr o B N P, tr o p o ni n I) x X  X X X  X 
Ser u m/ uri ne test f or pri mar y 
(li g ht c hai n) a m yl oi d osis X
Ge n ot y pi n g X
Tiss ue Bi o ps y X
Ba n ke d bi os peci me ns wXwXw
A d diti o nal C o u ntr y -s pecific 
Sa m ple a n d Ba n ke d 
Bi os peci me n C ollecti o n yX  X 
Pre g na nc y test f or w o me n of 
c hil d beari n g p ote ntial k X  X X X  X 
C o ntrace pti o n c hec k mX X X X X X X
E nr oll me nt /ra n d o mizati o n vX X
Dis pe nse tafa mi dis nX X X X X
First d ose of tafa mi dis Xo
Cli nical Assess me nts 
N Y H A Classificati o n X X X X X
K C C Q X X X X X
1 2 -lea d E C G pX X X A n n ual pXq
H os pi[INVESTIGATOR_1314] o n deter m i nati o n rX X X X
I P c o m plia nce/acc o u nta bilit y X X X X
D oc u me ntati o n of Vital, 
Tra ns pla nt, C M A D Stat us s,t X  X  X X X  X  X t0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733844] u d y 
f oll o w -u p e
P o p ulati o n C o h ort B u
( wit h o ut disease 
d oc u me ntati o n) C o h ort A a& 
C o h ort B a, u
( wit h disease 
d oc u me ntati o n) C o h o rts 
A & B (A p pe n dix 4. 2 
c o u ntry 
re q uire me nt )bC o h orts A & B 
Fre q ue nc y M o nt h [ADDRESS_733845] u d y 
Ter mi nati o n 2 8 da ys after 
las t d os e
Visit Wi n d o w fDa y -3 0 Da y 0 Da y 0 Da y 1 2 weeks 2 wee ks 2 
wee ks 2 wee ks 
C o nc o mita nt Treat me nts X  X  X      X
A d verse E ve nt Re p orti n g X  X  X        Xe
A b bre viati o ns: = o n g oi n g/ c o nti n u o us e ve nt; E C G = electr ocar di o gr a m ; K C C Q = Ka nsas Cit y Car di o m y o pat h y 
Q uesti o n naire; N Y H A = Ne w Y or k Heart Ass ociati o n. 
a. C o h ort A : Scree ni n g Visit/ Da y [ADDRESS_733846] u d y.  S u bjects pr o vi di n g c o nse nt a n d f ulfilli n g t he i ncl usi o n/e xcl usi o n criteria will be e nr olle d, ra n d o mize d, a n d 
dis pe nse d st u d y me dicati o n f or St u d y B [ADDRESS_733847] s will be i nstr ucte d t o start 
self - a d mi nistrati o n of tafa mi dis t he f oll o wi n g da y ( Da y 1).  If m ore t ha n [ADDRESS_733848] be perf or me d o n D a y 0 pri or t o e nr oll me nt.  S u bjects i n C o h ort A will be 
assi g ne d t o o pe n la bel treat me nt after pr ot oc ol a me n d me nt 3. 
C o h ort B : S u bjects w h o ha v e t he f oll o wi n g a vaila ble at scree ni n g ( d oc u me ntati o n of t he ge netic testi n g f or 
tra nst h yreti n a m yl oi d osis, d oc u m e ntati o n of dia g n osis a n d criteria use d a n d d oc u me ntati o n t hat pri mar y li g ht c hai n 
a m yl oi d osis disease has bee n e val uate d a n d r ule d o ut) ma y ha ve all scree ni n g pr oce d ures perf or me d o n Da y 0.  I n 
a d diti o n t o pr o vi di n g c o nse nt a n d f ulfilli n g t he i ncl usi o n/e xcl usi o n criteria will be e nr olle d a n d dis pe nse d st u d y 
me dicati o n f or St u d y B [ADDRESS_733849] u d y sit e.  F or c o u ntries liste d i n A p pe n dix 4. 2 o nly: S u bjects are re q uire d t o ret ur n t o t he 
st u dy site f or a d diti o n al pr oce d ures at M o nt h 3. 
c. Cl i nic visits will be perf or me d at M o nt hs 6, [ADDRESS_733850] wit h dra wal (f or a n y reas o n), or 
st u d y disc o nti n uati o n b y t he S p o ns or. 
e. S u bjects s h o ul d be f oll o we d f or [ADDRESS_733851] a n y A E/ S A E i nf or mati o n a n d 
perf or m a c o ntrace pti o n c hec k.  T his f oll o w -u p ma y be c o n d ucte d a t t he st u d y site or b y p h o ne. 
f. Visit wi n d o ws are base d o n t ele p h o ne or cli nic visit da ys relati ve t o start of st u d y treat me nt ( Da y 1). 
g. C o h ort A: F ull p h ysical e xa mi nati o n (i ncl u di n g wei g ht a n d vital si g ns) res ults fr o m t he E n d of St u d y visit fr o m 
B [ADDRESS_733852] be perf or me d o n Da y 0. 
C o h ort B: A f ull p h ysical e xa mi nati o n is re q uire d o n Da y 0. 
h. Brief p h ysical e xa mi nati o ns, i ncl u di n g assess me nt of ge neral a p peara nce, a n d car di o vasc ular, res p irat or y, a n d 
gastr oi ntesti nal s yste ms, are t o be perf or me d at cli nic visits ( M o nt hs 6, 1 2, 1 8, 2 4, 3 0, 3 6, 4 2, 4 8, 5 4).  F or c o u ntries 
liste d i n A p pe n dix 4. 2 o nly: Brief p hysic al ex a mi n ati o n i ncl u di n g wei g ht me as ure me nt will be perf or me d at M o nt h 3 
visit. 
i. Meas ure me nt of hei g ht i n ce nti meters (c m) will be perf or me d at t he Scree ni n g Da y [ADDRESS_733853] olic bl o o d press ure a n d p ulse rate (s u pi [INVESTIGATOR_199165] [ADDRESS_733854] 2 mi n utes pri or t o 
assess me nt), res pi[INVESTIGATOR_1313] o n rate a n d b o d y te m perat ure. 
k. C o h ort A: Cli nical la b orat or y testi n g i ncl u des ser u m c he mistr y, he mat ol o g y, c oa g ul ati o n, uri nal ysis, a n d pre g na nc y 
testi n g.  C oa g ulati o n (I nter nati o nal n or malize d rati o [I N R] a n d Pr ot hr o m bi n ti me [ P T]) wi ll be deter mi ne d at t he site’s 
l ocal la b orat or y.  S u bjects w h o alrea d y c o nfir me d me n o pa use wit h a n F S H test i n St u d y B [ADDRESS_733855] is a p plica ble o nl y t o s u bjects ne wl y f ulfilli n g t he 1 2 c o nsec uti ve m o nt hs of a me n or r hea 
re q uire d t o ma ke t he dia g n osis of me n o pa use. 
C o h ort B : Cli nical la b orat or y testi n g i ncl u des ser u m c he mistr y, he mat ol o g y, c oa g ula ti o n, uri nal ysis, a n d pre g na nc y 
testi n g.  C oa g ulati o n (I nter nati o nal n or malize d rati o [I N R] a n d Pr ot hr o m bi n ti me [ P T]) wil l be deter mi ne d at t he site’s 
l ocal la b orat or y.  F S H test ma y be use d t o c o nfir m a p ost me n o pa usal state i n w o me n n ot usi n g h or m o nal c o ntrace pti o n 
or h or m o ne re place me nt t hera p y ( H R T).  Fe males o n H R T a n d w h ose me n o pa usal stat us is i n d o u bt will be re q uire d t o 
use o ne of t he n o nestr o ge n h or m o nal hi g hl y effecti ve c o ntrace pti o n met h o ds if t he y wis h t o c o nti n ue t heir H R T d uri n g 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733856] u d y 
e nr oll me nt. 
l. C o h ort A: Cli n ical la b orat or y test res ults fr o m St u d y B [ADDRESS_733857] be perf or me d pri or t o e nr oll me nt a n d ra n d o miz ati o n. 
C o h ort B: Cli nical la b orat or y tests are re q uire d at Da y [ADDRESS_733858] y of tafa mi dis o n Da y 0 f or self -a d mi nistrati o n at h o me be gi n ni n g o n Da y 1 (ie , first 
d ose).  At tele p h o ne visits ( M o nt hs 3, 9, 1 5 , 2 1, 2 7, 3 3, 3 9, 4 5, 5 1, 5 7) s u p plies of tafa mi dis will be s hi p pe d t o s u bjects 
fr o m t he cli nical site b y s pecialize d I P c o urier.  Tafa mi dis will n ot be dis pe nse d if t he pr ot oc ol s pecifie d tele p h o ne call 
visit has n ot occ urre d.  S u bjects will ret ur n f or cl i nic visits e ver y 6 m o nt hs ( M o nt hs 6, 1 2, 1 8, 2 4, 3 0, 3 6, 4 2, 4 8, 5 4) f or 
e val uati o n a n d will recei ve a s u p pl y of tafa mi dis f or self -a d mi nistrati o n at h o me.  Tafa mi dis will n ot be dis pe nse d at 
cli nic visi ts if t he pr ot oc ol s pecifie d cli nic visit pr oce d ures ha ve n ot bee n perf or me d. 
o. S u bjects wil l self -a d mi nister st u d y me dicati o n at h o me at t he sa me ti me e ver y da y be gi n ni n g o n Da y 1. 
p. 1 2 -lea d E C G will be perf or me d o n a n a n n ual basis (e ver y 1 2 m o nt hs) at cli n ic visits M o nt hs [ADDRESS_733859] u d y visit or Earl y Disc o nti n uati o n visit.  F or c o u ntries liste d i n A p pe n dix 4. 2 o nly: A n a d diti o n al 
E C G w ill be perf or me d at t he M o nt h [ADDRESS_733860] u d y visit. 
r. Sites will deter mi ne at eac h visit (tele p h o ne, cli nic, e n d of st u d y, or earl y disc o nti n uati o n) w het h er t he s u bject has bee n 
h os pi[INVESTIGATOR_18552] d (i ncl u di n g t he reas o n f or h os pi[INVESTIGATOR_1314] o n). 
s. W he n t he Vital Stat us is deter mi ne d , t he s u bject s h o ul d be as ke d if t he y h a ve u n der g o ne a heart a n d/ or li ver tra ns pla nt 
or i m pla ntati o n of car diac mec ha nical assist de vice.  I f a s u bject i n dicates t hat t he y ha ve ha d a tra ns pla nt a n d t he y are 
still e nr olle d i n t he st u d y, t he y s h o ul d be re m o ve d fr o m t he st u d y. 
t. I n t he e ve nt of ear l y  st u d y disc o nti n uati o n, t he site staff will f oll o w -u p o n t he s u bject’s vital stat us/tra ns pla nt stat us 
6 0 m o nt hs after ra n d o mizati o n/assi g n me nt date. 
u. O nl y c o u ntries liste d i n A p pe n di x 5ma y  scree n/e nr oll s u bjects i n C o h ort B. U p o n a vaila bilit y of Da y -[ADDRESS_733861] u d y site f or Da y 0 visit pr oce d ures. 
v. C o h ort A : O n Da y 0, s u bjects i n C o h ort A will be bli n dl y assi g ne d t o tafa mi d is me gl u mi ne 2 0 m g or 8 0 m g. 
C o h ort B : O n Da y 0, s u bjects i n C o h ort B will be assi g ne d t o o pe n la bel tafa mi dis 6 1 m g ( or tafa mi dis me gl u mi ne 
8 0 m g if u na vaila ble). 
w. C o h ort B o nl y: C ollect a ge n o mic ba n ke d bi os peci me n.  If misse d, c ollect at t he ne xt a vaila bl e ti me p oi nt w he n 
bi os peci me ns are bei n g c ollecte d i n c o nj u ncti o n wit h a s u bject visit. 
x. Car diac bi o mar kers N T -pr o B N P a n d Tr o p o ni n I sa m ple c ollecti o n effecti ve after Pr ot oc ol A me n d me nt 4.  St u d y 
s u bjects e nr olle d pri or t o Pr ot oc ol A me n d me nt [ADDRESS_733862] h yreti n a m yl oi d osis. T his c ollecti o n i ntr o d uce d i n Pr ot oc ol A me n d me nt 5 is rele va nt o nl y t o 
s u bjects partici pati n g i n c o u ntries liste d i n A p pe n di x 6.  0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733863] h y reti n -me diat e d a m yl oi d osis ( A T T R - C M) i n a d ults t o re d uce 
ca r di o vasc ular m ortalit y a n d car di o vasc ular -relate d h os pi[INVESTIGATOR_1314] o n.  Tafa mi dis is als o 
a p pr o ve d f or t he treat me nt of A T T R- C M i n Ja pa n. 
Tafa mi dis is c urre ntl y  a p p r o ve d f or treat me nt of A T T R -P N i n 4 1 c o u ntries a n d is 
c o m merciall y a vaila ble i n t he f oll o wi n g 2 6 c o u ntries: Ar ge nti na, A ustria, Bel gi u m, Brazil, 
B ul garia, Czec h Re p u blic, De n mar k, Fi nla n d, Fra nce, Ger ma n y, Greece, H u n gar y, Israel, 
Ital y, Ja pa n, Lic hte nstei n, L u xe m b o ur g, Net herla n ds, N or wa y , P ola n d, P ort u gal, R o ma nia, 
Sl o ve nia, S pai n, S we de n a n d U nite d Ki n g d o m. 
1. 2. B ac k gr o u n d 
Tra nst h y reti n a m yl oi d disease is a rare a n d fatal c o n diti o n c haracterize d b y t he de p ositi o n of 
a m y l oi d deri ve d fr o m tra nst h y reti n (a plas m a pr otei n) i n vari o us or ga ns a n d tiss ues.  
De p osi ti o n of T T R a m y l oi d is ass ociate d wit h t w o dist i nct cli nical prese ntati o ns: 
tra nst h y reti n fa milial a m y l oi d p ol y ne ur o pat h y  ( A T T R -P N) w he n t he peri p heral ner ves are 
pri maril y  affecte d a n d tra nst h y reti n a m yl oi d car di o m y o pat h y ( A T T R -C M) w he n t he heart is 
pri ma ril y  affecte d.  B ot h A T T R -P N a n d A T T R -C M are as s ociate d wit h ge netic varia nts of 
tra nst h y reti n b ut A T T R -C M ma y  als o occ ur i n t he a bse nce of a n y  ge netic m utati o n, a n d ma y  
be d ue t o wil d -t y pe T T R a m y l oi d de p os iti o n.  
A T T R -C M occ urs w he n T T R a m y l oi d fi brils i nfiltrate t he m y ocar di u m, lea di n g t o de p osits 
of e xtracell ular a m yl oi d.  De p ositi o n of tra nst h y reti n fi brils occ urs bet wee n t he m y ocar dial 
cells a n d pr o d uces a t hic ke ni n g a n d stiffe ni n g of t he m y ocar dial ti ss ue.  T his i nfiltrati o n of 
t he m y ocar di u m res ult s i n diast olic d y sf u ncti o n pr o gressi n g t o restr icti ve car di o m y o pat h y , 
c o n gesti ve heart fail ure, a n d ulti matel y  deat h. 
Tafa mi dis is a n o vel s pecific sta bilizer of b ot h wil d- t y pe a n d a m yl oi d o ge nic varia nts of T T R.  
Tafa mi dis bi n ds t o T T R at t he t h y r o xi ne bi n di n g sites a n d i n hi bits T T R tetra mer diss ociati o n, 
t he rate -li miti n g ste p i n t he a m yl oi d o ge nic pr ocess.  B y  sta bilizi n g t he tetra meric nati ve state 
of T T R, tafa mi dis i ncreases t he acti vati o n barrier ass ociat e d wit h tetra mer diss ociati o n a n d 
t heref ore mi mics t he tetra meric sta bilizati o n effect o bser ve d wit h nat urall y occ urri n g 
pr otecti ve tra ns -s u p press or varia nts.  It is h y p ot hesize d t hat tafa mi dis w o ul d st o p or sl o w t he 
pr o gressi o n of A T T R -C M a n d t heref ore re prese nt a disease m o dif y i n g t hera p y . 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733864] u d y  ( C o h ort B).  T he 
p ur p ose of t he a d diti o nal c o h ort is t o pr o vi de t hese patie nts ear l y  access t o tafa mi dis, u ntil 
l ocal a vaila bilit y b y prescri pti o n f or t he A T T R -C M i n dicati o n.  A d diti o nall y , a ne w 
f or m ulati o n w hic h is bi oe q ui vale nt t o tafa mi dis me gl u mi ne 8 0 m g  has bee n de vel o pe d a n d is 
pre se nte d as tafa mi dis 6 1 m g (as t he free aci d).  T h is f or m ulati o n, w here a vaila ble, will 
re place t he tafa mi dis me gl u mi ne [ADDRESS_733865] u d y  f or s u bjects dia g n ose d wit h 
A T T R -C M w h o c o m plete d 3 0 m o nt hs of partici pati o n i n S t u d y B 3 4 6 1 0 2 8 ( C o h ort A) a n d 
s u bjects dia g n ose d wit h A T T R -C M w h o ha ve n ot pre vi o usl y  partici pate d i n t he B 3 4 6 1 0 2 8 
( C o h ort B). 
1. 3. D ose R ati o n ale 
At e nr oll me nt, s u bjects i n C o h ort A were assi g ne d t o 2 0 m g a n d 8 0 m g  tafa mi dis me gl u mi ne 
i n a bli n de d ma n ner .  At e nr oll me nt, s u bjects i n C o h ort B will be assi g ne d t o o pe n la bel 
6 1 m g tafa mi dis ( or 8 0 m g tafa mi dis me gl u mi ne if u na vaila ble). 
T he [ADDRESS_733866] u die d i n A T T R -P N; it has bee n s h o w n t o 
be effecti ve i n dela y i n g pr o gressi o n of s y m pt o matic AT T R -P N disease a n d is t he a p pr o ve d 
d ose.  B ot h t he [ADDRESS_733867] s wit h 
T T R -car di o m y o pat h y ( A T T R -C M) . 
T he rati o nale f or t he [ADDRESS_733868] u d y p o p ulati o n of 9 healt h y  a d ult Asia n me n. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733869] u d y B 3 4 6 1 0 4 0 ( Fi g ure 1) s u g gest t hat aplatea u is 
ac hie ve d as t he m olar rati o ( M R) of tafa mi dis: T T R plas ma c o nce ntrati o n i ncreases.  Base d 
u p o n t he data a vaila ble pri or t o c o n d ucti n g St u d y B 3 4 6 1 0 4 0, it was be lie ve d t hat e x p os ures 
ac hie ve d f oll o wi n g a tafa mi dis d ose of 2 0 m g o nce dail y ( Q D) were s ufficie nt t o a p pr oac h 
t he T T R perce nt sta bilizati o n platea u.  T he data fr o m St u d y B [ADDRESS_733870] t hat d oses 
hi g her t ha n 2 0 m g pr o vi de a greater de gree of sta bilizati o n, as meas ure d b y t he urea -base d 
T T R sta bilizati o n assa y .  W hile t he l o n g -ter m ris k -be nefit of d oses hi g her t ha n 2 0 m g o nce 
dail y ( Q D) is u n k n o w n, it is reas o na ble t o p ost ulate t hat greater T T R sta bilizati o n has t he 
p ote ntial t o pr o vi de a d diti o nal efficac y. 
I n or der t o calc ulate m olar rati os at vari o us tafa mi dis e x p os ures, a T T R c o nce ntrati o n m ust 
be ass u me d.  Mea n T T R c o nce ntrati o ns o bser ve d at baseli ne i n St u d y  F x - 0 0 5 ( 2 4. 7 m g/ d L) 
a n d i n patie nts wit h V [ADDRESS_733871] u d y  F x 1 B -2 0 1 ( 1 3. 5 m g / d L) a n d t h e Tra nst h yreti n 
A m y l oi d Car diac St u d y  ( T R A C S) ( 1 4. 9 m g/ d L) are ass u me d f or t he calc ulati o ns t hat f oll o w: 
a 2 0 m g Q D tafa mi dis d ose at stea d y state pr o d uces a mea n M R i n t he ra n ge of 1. 2 t o 3. 2 
fr o m mea n mi ni m u m c o nce ntrati o n at stea d y state ( C mi n,ss ) t o ma xi m u m c o nce ntrati o n at 
stea d y  state ( C ma x,ss ), w hic h is bel o w t he platea u re gi o n of t he data de p icte d i n Fi g ure 1.  
Mea n C mi n,ss t o C ma x,ss f oll o wi n g tafa mi dis d oses of [ADDRESS_733872] a biliz ati o n vs T af a mi dis: T T R M ol ar R ati o b y 
Tre at me nt i n St u d y B 3 4 6 1 0 4 0 
S o urce: B 3 4 6 1 0 4 0 C S R Fi g ure 1 4. 4. 7. 2. 1. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733873] u dies B 3 4 6 1 0 2 8 
a n d B 3 4 6 1 0 4 5.  T he ne w f or m ulati o n of 6 1 m g tafa mi dis as t he free aci d i n a si n gle gelati n 
ca ps ule is bei n g i ntr o d uce d t o patie nts t o pr o vi de t he hi g her d ose i n a si n gle ca ps ule.  
C o m plete i nf or mati o n f or t his c o m p o u n d ma y  be f o u n d i n t he si n gle refe re nce safet y 
d oc u me nt ( S R S D), w hic h f or t his st u d y  is t he I n vesti gat or’s Br oc h ure (I B). 
Ba n ke d bi os peci me ns will be c ollecte d f or t he p ur p ose of c o n d ucti n g rese arc h; s pecific uses 
are descri be d i n t he Ba n ke d Bi os peci me ns secti o n. C o m pari n g t he de o x yri b o n ucleic aci d 
( D N A), ri b o n ucleic aci d ( R N A), pr otei n, a n d meta b olite variati o n patter ns of s u bjects w h o 
res p o n d well a n d t h ose w h o res p o n d p o orl y t o treat me nt ma y hel p t o better defi ne t he m ost 
a p pr o priate gr o u p of s u bjects i n w hic h t o tar get a gi ve n treat m e nt.  C ollecti n g bi os peci me ns 
f or e x pl orat or y  p har mac o ge n o mic/ ge n o mic/ bi o mar ker a nal ys es a n d retai ni n g t he m i n t he 
Bi os peci me n Ba n ki n g S yste m ( B B S) ma ke it p ossi ble t o better u n dersta n d t he i n vesti gati o nal 
pr o d uct’s mec ha nis m of act i o n a n d t o see k e x pla nat i o ns f or differe nces i n, f or e xa m ple, 
e x p os ure, t olera bilit y , safet y , a n d/ or efficac y  n ot a ntici pate d pri or t o t he be gi n ni n g of t he 
st u d y.  Ba n ke d bi os peci me ns retai ne d i n t he B B S als o ca n be use d i n researc h o n A T T R -C M.  
Pr o vi di n g t hese bi os peci me ns is a re q uire d st u d y acti vit y  f or st u d y  sites a n d s u bjects, u nless 
pr o hi bite d b y  l ocal re g ulati o ns or et hics c o m mittee ( E C) decisi o n. 
2. S T U D Y O B J E C TI V E S A N D E N D P OI N T S 
2. 1. O bjecti ves 
Pri m ar y O bjecti ves: 
T o o btai n a d diti o nal, l o n g -ter m, safet y  d ata f or tafa mi dis i n s u b jects wit h 
tra nst h y reti n a m yl oi d car di o m y o pat h y ( A T T R -C M). 
T o pr o vi de i n vesti gati o nal pr o d uct, tafa mi dis, t o e nr olle d s u bjects u ntil l o cal 
a vaila bilit y  b y  prescri pti o n f or t he A T T R- C M i n dicati o n. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 2 6 2. 2. E n d p oi nts 
Pri m ar y E n d p oi nts 
Safet y  as meas ure d b y: 
All- ca us e m ortalit y. 
I n ci de nce of treat me nt -e mer ge nt a d verse e ve nts. 
Ot her E n d p oi nts 
Car di o vasc ular -relate d m ortalit y .
Fre q ue nc y  of all -ca use h o s pi[INVESTIGATOR_1314] o n. 
Fre q ue nc y  of car di o vasc ular -relate d h os pi[INVESTIGATOR_1314] o n (i ncl u di n g heart fail ure, 
arr h y t h mia, m y ocar dial i nfa rcti o n, str o ke a n d ot her car di o vasc ular- relate d e ve nts). 
C ha n ge fr o m baseli ne at eac h visit i n Ka nsas Cit y  Car di o m y o pat h y Q uesti o n naire 
O verall S u m mar y sc ore, d o mai n sc ores ( P h y sical li mitati o n, S y m pt o m sta bilit y , 
S y m pt o m fre q ue nc y ,S y m pt o m b ur de n, T otal s y m pt o m, Self -efficac y , S ocial 
li mitati o n, a n d Q ualit y  of life), a n d Cli nical s u m mar y  sc ore. 
Ne w Y or k Heart Ass ociati o n classificati o n at eac h visit. 
C ha n ge fr o m baseli ne i n B o d y Mass I n de x/ m o difie d B o d y Mass I n de x at eac h visit. 
C ha n ge fr o m baseli ne i n N T -pr o B N P c o nce ntrati o n at eac h visit. 
C ha n ge fr o m baseli ne i n Tr o p o ni n I c o nce ntrati o n at eac h visit. 
Assess me nt of p h ys ical e xa mi nati o ns , use of c o nc o mita nt me dicati o ns, 
electr ocar di o gra ms ( E C Gs), cli nical la b orat or y  testi n g, vital si g ns at eac h visit. 
F or t h ose seri o us a d verse e ve nts ( S A Es) t hat are ha n dle d as disease -relate d e n d p oi nts ( w hic h 
ma y  i ncl u de deat h), a n e xter nal data m o nit ori n g c o m mittee ( E -D M C) will c o n d uct u n bli n de d 
re vie ws o n a re g ular basis t hr o u g h o ut t he trial ( Data M o nit ori n g C o m mittee ). 
3. S T U D Y D E SI G N 
T his is a P hase 3, o pe n -la bel l o n g -ter m e xte nsi o n safet y st u d y desi g ne d t o o btai n a d diti o nal 
saf et y data f or tafa mi dis me gl u mi ne 2 0 m g  a n d 8 0 m g ( or tafa mi dis 6 1 m g w here a vaila ble), 
a n d t o c o nti n ue t o pr o vi de e nr olle d s u bjects wit h tafa mi dis f or u p t o [ADDRESS_733874] u d y d ue t o c o m mercial access t o prescri pti o n tafa mi dis i n t heir 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733875] u d y  partici pa nts will be e nr olle d i n 2 c o h orts: 
C o h ort A –S u bjects dia g n ose d wit h A T T R -C M w h o c o m plete d [ADDRESS_733876] u d y B 3 4 6 1 0 2 8. 
C o h ort B –S u bjects dia g n ose d wit h A T T R -C M w h o ha ve n ot pre vi o usl y partici pate d 
i n St u d y B 3 4 6 1 0 2 8 ( A p pe n di x 5). 
Fi g ure 2.Fl o wc h art of St u d y P artici p ati o n 
S u bjects i n C o h ort A will be assi g ne d t o o pe n l a bel treat me nt after pr ot oc ol a me n d me nt 3. 
4. S U B J E C T S E L E C TI O N 
T his st u d y  ca n f ulfill its o bjecti v es o nl y  if a p pr o priate s u bjects are e nr olle d.  T he f oll o wi n g 
eli gi bilit y  criteria are desi g ne d t o select s u bjects f or w h o m partici pati o n i n t he st u d y  is 
c o nsi de re d a p pr o priate.  All rele va nt me dical a n d n o n me dical c o n diti o ns s h o ul d be ta ke n i nt o 
c o nsi derat i o n w he n deci di n g w het her a partic ular s u bject is s uita ble f or t his pr ot oc ol. 
S u bject eli gi bilit y s h o ul d be re vie we d a n d d oc u me nte d b y  a n a p pr o priate me m ber of t he 
i n vesti gat or’s st u d y tea m bef ore s u bjects are i ncl u de d i n t he st u d y .
4. 1. I ncl usi o n Criteri a 
4. 1. 1. C o h ort A I ncl usi o n Criteri a 
S u bjects i n C o h ort A m ust meet all of t he f oll o wi n g i ncl usi o n criteria t o be eli gi ble f or 
e nr oll me nt i nt o t he st u d y: 
1. Male a n d fe male s u bjects wit h T T R a m y l oi d car di o m y o pat h y w h o ha ve c o m plete d 
[ADDRESS_733877] u d y  pr oce d ures. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733878] d ose of assi g ne d treat me nt. 
Fe male s u bjects w h o are n ot of c hil d beari n g p ote ntial (ie, meet at least 1 of t he 
f oll o wi n g criteria): 
Ha ve u n der g o ne a d oc u me nte d h y sterect o m y a n d/ or bilateral o o p h orect o m y ;
Ha ve me dicall y c o nfir me d o varia n fai l ure; or 
Ac hie ve d p ost me n o pa usal stat us, defi ne d as f oll o ws: cessati o n of re g ular me nses 
f or at least 1 2 c o nsec uti ve m o nt hs wit h n o alter nati ve pat h ol o gical or 
p h y si ol o gical ca use; stat us m a y be c o nfir me d b y ha vi n g a ser u m 
f ollicle -sti m ulati n g h or m o ne ( F S H) le vel c o nfir mi n g t he p ost- me n o pa usal state. 
All ot her fe male s u bjects (i ncl u di n g fe males wit h t u bal li gati o ns) will be c o nsi dere d 
t o be of c hil d beari n g p ote ntial. 
4. 1. 2. C o h ort B I ncl usi o n Criteri a 
S u bjects i n C o h ort B m ust meet all of t he f oll o wi n g i ncl usi o n criteria t o be eli gi ble f or 
e nr oll me nt i nt o t he st u d y: 
1. Male or fe male s u bject of at least 1 8 ye ars of a ge ( or t he mi ni m u m c o u ntr y s pecific 
a ge of c o nse nt if > 1 8) a n d partici pates at a st u d y  site i n a n eli g i ble c o u ntr y  liste d i n 
Pr ot oc ol A p pe n di x 5. 
2. E vi de nce of a pers o nall y  si g ne d a n d date d i nf or me d c o nse nt d oc u me nt i n dicati n g t hat 
t he s u bject has bee n i nf or me d of all perti ne nt as pec ts of t he st u d y . 
3. S u bjects w h o are willi n g a n d a ble t o c o m pl y wit h sc he d ule d visits, treat me nt p la n, 
la b orat or y  tests ,an d ot her st u d y  pr oce d ures. 
4. A fe male s u bject is eli gi ble t o partici pate if s he is n ot pre g na nt or breastfee di n g, a n d 
at least 1 of t he f o ll o wi n g c o n diti o ns a p plies: 
Is n ot a W o ma n of C hil d beari n g P ote ntial ( W O C B P) (see defi niti o n 
Secti o n 4. 3. 1 ). 
O R 
Is a W O C B P a n d usi n g a c o ntrace pti ve met h o d t hat is hi g hl y  effecti ve ( wit h a 
fail ure rate of < 1 % per year) (see Secti o n 4. 3 ) d uri n g t he i nter ve nti o n peri o d a n d 
f or at least [ADDRESS_733879] u d y  i nter ve nti o n. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733880] h yr eti n a m y l oi d os is (ie, ori gi nal 
la b orat or y  res ult, or c o p y). 
6. D oc u me ntati o n of dia g n osis a n d criteria use d (e g, c o n gesti ve heart fail ure a n d 
sci nti gra p h y wit h tracer e g, 9 9 m T C D P D [ 9 9 m T C 3, 3 di p h os p h o n o 1, 2 pr o p a n o 
dic ar b oxylic aci d] , 9 9 m T C P Y P [ Pyr o p h os p h ate ] a n d als o 9 9 m T C H M D P 
[ hy dr oxy met hyle ne di p h os p h o n ate] or C o n gesti ve heart fail ure a n d prese nce of 
a m y l oi d d e p osits i n bi o ps y  tiss ue, e g, f at as pir ate, s aliv ary gl a n d, me di a n nerve 
c o n nective tiss ue s he at h, or c ar di ac [ a myl oi d de m o nstr ate d per a p pr o pri ate st ai n 
s uc h as C o n g o re d or alci a n bl ue st ai n ]) .
7. D oc u me ntati o n t hat pri mar y  (li g ht c hai n) a m y l oi d osis diseas e has bee n e val uate d a n d 
r ule d o ut (ie, ori gi nal la b orat or y  res ult, or c o p y ). 
8. E vi de nce of N Y H A c lassificati o n I, II, III, or I V. 
4. 2. E xcl usi o n Criteri a 
4. 2. 1. C o h ort A E xcl usi o n Criteri a 
S u bjects i n C o h ort A wit h a n y  of t he f oll o wi n g c haracteristics/c o n diti o ns will n ot be i ncl u de d 
i n t he st u d y :
1. C hr o nic use of difl u nisal, T T R sta bilizer, ta ur o urs o de o x y c h olate, d o x y c y cli ne, 
di gitalis, patisira n, calci u m c ha n nel bl oc kers, i n ves ti gati o nal dr u g(s) or ot her 
e x peri me ntal i nter ve nti o ns, ot her t ha n tafa mi dis, i n de pe n de ntl y or as part of a st u d y  
wit hi n [ADDRESS_733881] u gs ( N S A I Ds) [ Secti o n 5. 8. 1 ]. 
3. Li ver a n d/ or heart tra ns pla nt, or i m pla nte d car diac mec ha nical assist de vice. 
4. Pre g na nt fe males ( or pla n ni n g t o bec o me pre g na nt d uri n g t he st u d y  i nter val); 
breastfee di n g fe males; male s u bjects wit h part ners c urre ntl y pre g na nt. 
5. Re q uire i nitiati o n of treat me nt wit h cal ci u m c ha n nel bl oc kers. 
6. Uri nar y  rete nti o n re q uiri n g c hr o nic self- cat heterizati o n. 
7. Breac h of c o m pl ia nce wit h treat me nt/si g nifica nt pr ot oc ol vi olati o ns d uri n g c o n d uct of 
B [ADDRESS_733882] was acc o u nta ble. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733883] u d y .
4. 2. 2. C o h ort B E xcl usi on Criteri a 
S u bjects i n C o h ort B wit h a n y  of t he f oll o wi n g c haracteristics/c o n diti o ns will n ot be i ncl u de d 
i n t he st u d y :
1. C hr o nic use of difl u nisal, T T R sta biliz er, ta ur o urs o de o x yc h olate, d o x yc yc li ne, 
di gitalis, patisira n , calci u m c ha n nel bl oc kers, i n vesti g ati o nal dr u g(s) or ot her 
e x peri me ntal i nter ve nti o ns, ot her t ha n tafa mi dis, i n de pe n de ntl y or as part of a st u d y 
wit hi n [ADDRESS_733884] u gs ( N S AI D s) [ Secti o n 5. 8. 1 ]. 
3. Li ver a n d/ or heart tra ns pla nt, or i m pla nte d car diac mec ha nical assist de vice. 
4. Re q uire i nitiati o n of treat me nt wit h calci u m c ha n nel bl oc kers. 
5. Uri nar y  rete nti o n re q uiri n g c hr o nic self -cat heterizati o n. 
6. S u bjects wit h heart fail ure t hat i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or is o n t he basis of 
isc he mic heart disease (e g, pri or m y o car dial i n farcti o n wit h d oc u me nte d hist or y  of 
car diac e nz y mes a n d E C G c ha n ges), or u nc orrecte d val v ular di sease a n d n ot 
pri maril y  d ue t o tra nst h yreti n a m y l oi d car di o m y o pat h y .
7. S u bjects w h o are i n vesti gati o nal site staff me m bers directl y i n v ol ve d i n t he c o n d uct 
of t he st u d y  a n d t heir fa mil y  me m bers, site staff me m bers ot her wise s u per vise d b y  t he 
i n vesti gat or, or s u bjects w h o are [COMPANY_007] e m pl o y ees directl y  i n v ol ve d i n t he c o n d uct of 
t he st u d y .
8. Ot her se vere ac ute or c hr o nic me di cal or ps yc hi atric c o n diti o n or la b orat or y 
ab n or malit y  t hat ma y  i ncrease t he ris k ass ociate d wit h st u d y  partici pati o n or 
i n vesti gati o nal pr o d uct a d mi nistrati o n, or t hat ma y  i nterfere wit h t he i nter pretati o n of 
st u d y  res ults a n d, i n t he j u d g me nt of t he i n ve sti gat or, w o ul d ma ke t he s u bject 
i na p pr o pria te f or e ntr y  i nt o t his st u d y . 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733885] u d y  w h o are, i n 
t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or, se x uall y  acti ve a n d at ris k f or p re g na nc y  wit h t heir part ner(s) 
m ust a gree t o use a hi g hl y  effecti ve met h o d of c o ntrace pti o n c o nsiste ntl y a n d c orrectl y f or 
t he d urati o n of t he acti ve treat me nt peri o d a n d f or at least [ADDRESS_733886] of c o ntrace pti o n met h o ds (see bel o w) a n d will 
c o nfir m t hat t he s u bject has bee n i nstr ucte d i n its c o nsiste n t a n d c orrect use.  At ti me p oi nts 
i n dicate d i n t he Sc he d ule of Acti vitie s, t he i n vesti gat or or desi g nee will i nf or m t he s u bject of 
t he nee d t o use hi g hl y effecti ve c o ntrace pti o n c o nsiste nt l y  a n d c orrectl y  a n d d oc u me nt t he 
c o n versat i o n a n d t he s u bject’s affir mati o n i n t he s u bject’s c hart (s u bjects nee ds t o affir m 
t heir c o nsiste nt a n d c orrect use of at least 1 of t he selecte d met h o ds of c o ntrace pti o n).  I n 
a d diti o n, t he i n vesti gat or or desi g n ee will i nstr uct t he s u bject t o call i m me di atel y  if t he 
selecte d c o ntrace pti o n met h o d is disc o nti n ue d or if pre g na nc y  is k n o w n or s us pecte d i n t he 
s u bject or t he part ner. 
Hi g hl y effecti ve met h o ds of c o ntrace pti o n are t h ose t hat, al o ne or i n c o m bi nati o n, r es ult i n a 
fail ure rate of less t ha n 1 % per ye ar w he n use d c o nsiste ntl y  a n d c orrectl y  (ie, perfect use) a n d 
i ncl u de t he f oll o wi n g: 
1. I m pla nta ble pr o gest o ge n- o nl y  h or m o ne c o ntrace pti o n ass ociate d wit h i n hi biti o n of 
o v ulati o n. 
2. I ntra uteri ne de vice (I U D). 
3. I ntra u teri ne h or m o ne -releasi n g s ys te m (I U S). 
4. Bila teral t u bal occl usi o n. 
5. Vasect o mize d part ner: 
Vasect o mize d part ner is a hi g hl y effecti ve c o ntrace pti ve met h o d pr o vi de d t hat t he 
part ner is t he s ole se x ual part ner of t he w o ma n of c hil d beari n g p ote ntial a n d t he 
a bse nce of s per m has bee n c o nfir me d.  If n ot, a n a d diti o nal hi g hl y  effecti ve 
met h o d of c o ntrace pti o n s h o ul d be use d.  T he s per mat o ge nesis c y cle is 
a p pr o xi matel y  9 0 d a y s. 
6. C o m bi ne d (estr o ge n -a n d pr o gest o ge n - c o ntai ni n g) h or m o nal c o ntrace pti o n ass ociate d 
wit h i n h i biti o n of o v ulati o n: 
oral; 
i ntra va gi nal; 
tra ns der mal; 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 3 2 i njecta ble. 
7. Pr o gest o ge n - o nl y h or m o ne c o ntrace pti o n ass ociate d wit h i n hi biti o n of o v u lati o n: 
Oral; 
I njecta ble. 
8. Se x ual a bsti ne nce: 
Se x ual a bsti ne nce is c o nsi dere d a hi g hl y effecti ve met h o d o nl y  if defi ne d as 
refrai ni n g fr o m heter ose x ual i nterc o ur se d uri n g t he e ntire peri o d of ris k ass ociate d 
wit h t he st u d y  i nter ve nti o n.  T he relia bilit y  of se x ual a bsti ne nce nee ds t o be 
e val uate d i n relati o n t o t he d urati o n of t he st u d y a n d t he preferre d a n d us ual 
lifest y le of t he partici pa nt. 
4. 3. 1. W o m a n of C hil d be ari n g P ote nti al ( W O C B P) 
A w o ma n is c o nsi dere d fertile f oll o wi n g me narc he a n d u ntil bec o mi n g p ost me n o p a usal 
u nless per ma ne ntl y sterile (see bel o w). 
If fertilit y  is u nclear (e g, a me n orr hea i n a d olesce nts or at hletes) a n d a me nstr ual c y cle ca n n ot 
be c o nfir me d bef o re t he first d ose of st u d y  i nter ve nti o n, a d diti o nal e val uati o n s h o ul d be 
c o nsi dere d. 
W o me n i n t h e f oll o wi n g cate g ories are n ot c o nsi dere d W O C B P: 
1. Pre me n o pa usal fe male wit h 1 of t he f oll o wi n g: 
D oc u me nte d h y sterect o m y ;
D oc u me nte d bilateral sal pi n gect o m y ;
D oc u me nte d bilateral o o p h orect o m y. 
F or i n di vi d uals wit h per ma ne nt i nfertilit y  d ue t o a n alter nate me dical ca use ot her t ha n 
t he a b o ve, (e g, m ulleria n a ge nesis, a n dr o ge n i nse nsiti vit y ), i n vesti gat or discreti o n 
s h o ul d be a p plie d t o deter mi ni n g st u d y  e ntr y .
N ote: D oc u me ntati o n f or a n y  of t he a b o ve cate g ories ca n c o me fr o m t he site 
pers o n nel’s re vie w of t he p artici pa nt’s me dical rec or ds, me dical e xa mi nati o n, or 
me dical hist or y  i nter vie w.   T he met h o d of d oc u me ntati o n s h o ul d be rec or de d i n t he 
partici pa nt’s me dical re c or d f or t he st u d y. 
2. P ost me n o pa usal fe male: 
A p ost me n o pa usal state is defi ne d as a ge 6 0 ye ars or ol der or n o me nses f or 
1 2 m o nt hs wit h o ut a n alte r nati ve me dical ca use. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 3 3 A hi g h f ollicle -sti m ulati n g h or m o ne ( F S H) le vel i n t he p ost me n o pa usal ra n ge 
ma y  be use d t o c o nfir m a p ost me n o pa usal state i n w o me n n ot usi n g h or m o nal 
c o ntrace pti o n or h or m o ne re place me nt t hera p y  ( H R T). 
Fe males o n H R T a n d w h ose me n o pa usal stat us is i n d o u bt will be re q uire d t o 
use o ne of t he n o nestr o ge n h or m o nal hi g hl y effecti ve c o ntrace pti o n met h o ds 
if t he y  wis h t o c o nti n ue t heir H R T d uri n g t he st u d y .  Ot her wise, t he y  m ust 
disc o nti n ue H R T t o all o w c o nfir mati o n of p ost me n o pa usal stat us bef ore st u d y  
e nr oll me nt. 
4. 4. S p o ns or’s Q u alifie d Me dic al Pers o n nel 
T he c o ntact i nf or mati o n f or t he s p o ns or's a p pr o priatel y  q ualifie d me dical pers o n nel f or t he 
st u d y  is d oc u me nte d i n t he st u d y  c o ntact list l oca te d i n t he st u d y  p ortal. 
T o facilitate access t o a p pr o priatel y q ualifie d me dical pers o n nel o n st u d y- relate d me dical 
q uesti o ns or pr o ble ms, s u bjects are pr o vi de d wit h a c o ntact car d.  T he c o ntact car d c o ntai ns, 
at a mi ni m u m, pr ot oc ol a n d i n vesti gati o nal c o m p o u n d i de ntifiers, s u bject st u d y  n u m bers, 
c o ntac t i nf or mati o n f or t he i n vesti gati o nal site, a n d c o ntact details f or a c o ntact ce nter i n t he 
e ve nt t hat t he i n ves ti gati o nal site staff ca n n ot be reac he d t o pr o vi de a d vice o n a me dical 
q uesti o n or pr o ble m ori gi nati n g fr o m a n ot her healt hcare pr ofessi o nal n ot i n v ol ve d i n t he 
s u bject’s partici pati o n i n t he st u d y . 
T he c o ntact n u m ber ca n als o be use d b y i n vesti gati o nal st aff if t he y  are see ki n g a d vice o n 
me dical q uesti o ns or pr o ble ms; h o we ver, it s h o ul d be use d o nl yi n t he e ve nt t hat t he 
esta blis he d c o m m u nicati o n pat h wa y s bet wee n t he i n vesti gati o nal site a n d t he st u d y  tea m are 
n ot a vaila ble.  It is t heref ore i nte n de d t o a u g me nt, b ut n ot re place, t he esta blis he d 
c o m m u nicati o n pat h wa ys bet wee n t he i n vesti gati o nal site a n d t he st u d y tea m f or a d vice o n 
me dical q uesti o ns or pr o ble ms t hat ma y  arise d uri n g t he st u d y .  T he c o ntact n u m ber is n ot 
i nte n de d f or use b y t he s u bject direc tl y , a n d if a s u bject calls t hat n u m ber, he or s he will be 
directe d bac k t o t he i n vesti gati o nal site. 
5. S T U D Y T R E A T M E N T S 
F or t he p ur p oses of t his st u d y , a n d per I nter nati o nal C o nfere nce o n Har m o nizati o n (I C H) 
g ui deli nes i n vesti gati o nal pr o d uct is defi ne d as a p har mace utical f or m of a n acti ve i n gre die nt 
or place b o bei n g teste d or use d as a refere nce i n a cli nical trial, i ncl u di n g a pr o d uct wit h a 
mar keti n g a ut h orizati o n w he n use d or asse m ble d (f or m ulate d or pac ka ge d) i n a wa y  differe nt 
fr o m t he a p pr o ve d f or m, or w he n use d f or a n u na p pr o ve d i n dicati o n, or w he n use d t o gai n 
f urt her i nf or mati o n a b o ut a n a p p r o ve d use (I C H E 6 1. 3 3). 
5. 1. All oc ati o n t o Tre at me nt 
I n vesti gat ors will c o nfir m t he eli gi bilit y  of eac h s u bject t o meet i ncl usi o n/e xcl usi o n criteria.  
S u bject eli gi bilit y f or partici pati o n i n t he treat me nt p hase of t he pr ot oc ol will be deter mi ne d 
f oll o wi n g t he assess me nts d uri n g t he Scree ni n g visit.  S u bjec ts will be scree ne d f or eli gi bilit y 
a n d t h ose, i n t he j u d g me nt of t he i n vesti gat or, w h o meet t he i ncl usi o n crite ria a n d d o n ot meet 
t he e xcl usi o n criteria, will be e nr olle d i nt o t he st u d y. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733887] i n C o h ort A w h o has si g ne d t he i nf or me d c o nse nt d oc u m e nt (I C D) will be 
assi g ne d t he sa me s u bject i de ntificati o n n u m ber fr o m t he pare nt st u d y  B 3 4 6 1 0 2 8 b y  a n 
I nteracti ve Res p o nse Tec h n ol o g y  (I R T) s y ste m.  Eac h s u bject i n C o h ort B will be assi g ne d a 
ne w s u bject i d e ntificati o n n u m ber b y  t he I nteracti ve Res p o nse Tec h n ol o g y (I R T) s y ste m. 
All ocati o n of s u bjects t o treat me nt gr o u ps will pr ocee d t hr o u g h t he use of a n I R T s ys te m 
u nless ot her wise directe d b y  t he S p o ns or t o e ns ure patie nt safet y a n d st u d y c o nti n uit y .  T he 
site pers o n nel (st u d y c o or di nat or or s pecifie d de si g nee) will be re q uire d t o e nter or select 
i nf or mati o n i ncl u di n g b ut n ot li mite d t o t he user’s i de ntificati o n ( I D) a n d pass w or d, t he 
pr ot oc ol n u m ber, t he s u bject n u m ber a n d t he date of birt h of t he s u bject. T he site pers o n nel 
will t he n be pr o vi de d wit h a treat me nt assi g n me nt a n d dis pe nsa ble u nit ( D U) or c o ntai ner 
n u m ber.  T he I R T S ys te m will pr o vi de a c o nfir mati o n re p ort c o ntai ni n g t he s u bject n u m ber 
a n d D U or c o ntai ner n u m ber assi g ne d. 
Cli nic visits will be at 6 - m o nt h i nter vals ( M o nt h 6, 1 2, 1 8 etc.).  S u bjects m ust ret ur n f or 
t heir a p p oi nt me nt bef ore t heir st u d y  dr u g s u p pl y is e x ha uste d.  S u bjects m ust bri n g all of 
t heir st u d y  me dicati o n a n d t heir S u bject Dail y  D osi n g Diar y  t o eac h cli nic visit.  T he site w ill 
c ollect all st u d y me dicati o n dis pe nse d at t h e pre vi o us visit a n d dis pe nse a ne w set of st u d y 
me dicati o n a n d a S u bject Dail y  D osi n g Diar y  t o t he s u bject. 
T he re is a [ADDRESS_733888] i nf or mati o n a n d 
f urt her details o n t he use of t he I R T s y ste m. 
N ote: T he I R T is t he s o urce of t he s u bject n u m ber.  T he I R T s y ste m will pr o vi de t he s u bject 
n u m ber at t he e n d of t he first I R T s u bjec t tra nsacti o n. 
5. 1. 1. C o h ort A Tre at me nt Assi g n me nt 
T here will be treat me nt assi g n me nt stratificati o n b y T T R ge n ot y pe ( varia nt or wil d -t y pe) 
o nl y  f or C o h ort A. 
At e nr oll me nt, s u bjects i n C o h ort A were assi g ne d t o bli n de d acti ve treat me nt i n t his st u d y ; 
tafa mi dis me gl u mi ne 2 0 m g or 8 0 m g  o nce dai l y , i n a d diti o n t o sta n dar d of care 
(e g, di uretics) f or u p t o 6 0 m o nt hs base d o n t he f oll o wi n g: 
S u bjects recei vi n g tafa mi dis me gl u mi ne [ADDRESS_733889] u d y B 3 4 6 1 0 2 8 c o nti n ue 
t he sa me bli n de d treat me nt assi g n me nt. 
S u bje cts assi g ne d t o place b o i n St u d y B 3 4 6 1 0 2 8 will be ra n d o mize d ( 1: 2) t o bli n de d 
tafa mi dis me gl u mi ne [ADDRESS_733890] u d y B 3 4 6 1 0 28 a n d ra n d o mize d t o tafa mi dis me gl u mi ne 8 0 m g  will be per mitte d 
o ne bli n de d d ose -re d ucti o n t o 2 0 m g f or a d verse e ve nts relate d t o t olera bilit y .
S u bjects i n C o h ort A will be assi g ne d t o o pe n la bel treat me nt after pr ot oc ol a me n d me nt 3. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 3 5 S u bjects recei vi n g ta fa mi dis me gl u mi ne 2 0 m g or 8 0 m g will be assi g ne d t o tafa mi dis 6 1 m g, 
o nce dail y, i n a d diti o n t o sta n dar d of care (e g, di uretics), f or u p t o [ADDRESS_733891] u d y Tre at me nts 
5. 1. 2. C o h ort B Tre at me nt Assi g n me nt 
At e nr oll me n t, s u bjects i n C o h ort B will be assi g ne d t o o pe n la bel 6 1 m g  tafa mi dis o nce 
dail y , i n a d diti o n t o sta n dar d of care (e g, di uretics), f or u p t o [ADDRESS_733892] ma y  i ncl u de t he f oll o wi n g: 
1. A seri o us, u ne x pecte d/ u nliste d, treat me nt-relate d e ve nt f or reas o ns of s u bject safet y; 
2. A n ur ge nt safet y meas ure ta ke n b y t he i n vesti gat or or [COMPANY_007] t o pr o tect s u bjects 
a gai nst i m me diate hazar d t o healt h; 
3. A p ote ntiall y  life t hreate ni n g dr u g i nteracti o n; 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733893]’s c o n diti o n.  I n 
t his case, a n atte m pt s h o ul d be ma de t o c o ntact t he st u d y  cli ni cia n or a n ot her me m ber 
of t he st u d y  tea m. 
W he ne ver p ossi ble, t he i n vesti gat or or s u b- i n vesti gat or s h o ul d c o ns ult wit h a me m ber of t he 
st u d y  tea m (e g, t he cli nical trial ma na ger, st u d y cli nicia n or t he me dical m o nit or) pri or t o 
brea ki n g t he bli n d f or a n i n d i vi d ual s u bject.  After re vie wi n g a n d a p pr o vi n g t he 
i n vesti gat or’s re q uest, t he st u d y  cli nicia n will pr o vi de writte n a ut h orizati o n (e mail) t o t he 
i n vesti gat or t o brea k t he bli n d. 
If u n a ble t o c o ntact a me m ber of t he st u d y tea m, t he i n vesti gat or ma y  brea k t he bli n d f or a 
gi ve n s u bject e x perie nci n g a seri o us a d verse e ve nt ( S A E) or ot her me dical e mer ge n c y  w here 
k n o wle d ge of t he treat me nt assi g n me nt will affect treat me nt decisi o ns. 
Brea ki n g t he bli n d will be d o ne electr o nicall y a n d i nstr ucti o ns will be gi ve n at a trai ni n g 
sessi o n f or t he pr ot oc ol. 
W he n t he bli n di n g c o de is br o ke n, t he reas o n m ust be f ull y d oc u me nte d a n d e ntere d o n t he 
case re p ort f or m ( C R F).  I n di vi d ual s u bjects w h ose bli n d is br o ke n will be disc o nti n ue d fr o m 
t he st u d y  as descri be d i n Secti o n 6. 2. [ADDRESS_733894] 8 0 % of t he d a y s of st u d y  partici pati o n. 
5. 4. I n vesti g ati o n al Pr o d uct S u p plies 
C o h ort A bli n de d treat me nt assi g n me nt: 
I n or der t o ac hie ve t he pr o per d osa ge a n d mai ntai n t he bli n d i n t he st u d y , ca ps ules will be 
dis pe nse d i n a bli n de d f as hi o n t o ac hie ve a dail y  d ose of [ADDRESS_733895] us 2 ca ps ules of 
bli n de d tafa mi dis me gl u mi ne 2 0 m g, or 4 ca ps ules o f bli n de d tafa mi dis me gl u mi ne 2 0 m g .  
(Ta ble 1). 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 3 7 C o h ort A a n d B o pe n la bel treat me nt assi g n me nt: 
After pr ot oc ol a me n d me nt 3, all s u bjects will be assi g ne d t o o pe n la bel treat me nt.  Eac h d ose 
of tafa mi dis 6 1 m g or tafa mi dis me gl u m i ne 2 0 m g c o nsists of 1 ca ps ule.  Eac h d ose of 
taf a mi dis me gl u mi ne 8 0 m g c o nsists of 4 ca ps ules.   (Ta ble 1). 
T a ble 1.I n vesti g ati o n al Pr o d uct S u p plies 
D os a ge Le vel ( C o m p o u n d) A p pe ar a nce N u m ber of C a ps ules Per D a y ( D ose) 
Tafa mi dis me gl u mi ne 2 0 m g 
( P F -0 6 2 9 1 8 2 6 -8 3) -bli n de d Yell o w, o bl o n g s oft gelati n 
ca ps ules 1( Tafa mi dis me gl u mi ne 2 0 m g ca ps ule) 
3( Place b o ca ps ules) 
Tafa mi dis me gl u mi ne 8 0 m g 
( P F -0 6 2 9 1 8 2 6 -8 3) -bli n de d Yell o w, o bl o n g s oft gelati n 
ca ps ule s4( Tafa mi dis me gl u mi ne 2 0 m g ca ps ules) 
Tafa mi dis free aci d 6 1 m g 
( P F 0 6 2 9 1 8 2 6 -0 0) -o pe n Re d dis h br o w n, o bl o n g s oft 
gelati n ca ps ules 1 ( Tafa mi dis free aci d 6 1 m g ca ps ule) 
Tafa mi dis me gl u mi ne 2 0 m g 
( P F 0 6 2 9 1 8 2 6- 8 3) -o pe n Yell o w, o bl o n g s oft gelati n 
ca ps ules 1 ( Tafa mi dis me gl u mi ne 2 0 m g ca ps ule) 
Tafa mi dis me gl u mi ne 8 0 m g 
( P F 0 6 2 9 1 8 2 6 -8 3) - o pe n Yell o w, o bl o n g s oft gelati n 
ca ps ules 4 ( Tafa mi dis me gl u mi ne 2 0 m g ca ps ules) 
5. 4. 1. D os a ge F or m(s) a n d P ac k a gi n g 
C o h ort A Bli n de d D osa ge F or m a n d Pac ka gi n g: 
Bli n de d P F - 0 6 2 9 1 8 2 6 (tafa mi dis me gl u mi ne) will be pr o vi de d as s oft gel ca ps ules f or oral 
a d mi nistrati o n (Ta ble 1).  T he ca ps ules will be s u p plie d i n se parate blister car ds a n d la bele d 
acc or di n g t o l ocal re g ulat or y  re q uire me nts. 
Tafa mi dis me gl u mi ne [ADDRESS_733896] wallets t o all o w f or fle xi bilit y  i n cli nic visit sc he d uli n g (t otal of 
[ADDRESS_733897] y). 
S u bjects s h o ul d be i nstr ucte d t o o nl y d ose fr o m [ADDRESS_733898] wallet. 
C o h ort A & B O pe n La bel D osa ge F or m a n d Pac ka gi n g: 
After pr ot oc ol a me n d me nt 3, st u d y  treat me nt will be pr o vi de d as s oft gel ca ps ules f or oral 
ad mi nistrati o n ( Ta ble 1).  T he ca ps ules will be s u p plie d i n b ottles a n d la bele d acc or di n g t o 
l ocal re g ulat or y  re q uire me nts. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 3 8 F or o pe n -la bel treat me nt assi g n me nt, s u bjects will be dis pe nse d 1 cart o n at eac h visit 
c o ntai ni n g eit her: 
3 x b ottles of tafa mi dis 6 1 m g ca ps ules ( [ADDRESS_733899] y  per 
cart o n); or 
3 x b ottles of tafa mi dis me gl u mi ne 2 0 m g  ca ps ules ( [ADDRESS_733900] y  per cart o n); or 
1 2 x b ottles of tafa mi dis me gl u mi ne 2 0 m g  ca ps ules ( [ADDRESS_733901] y  per cart o n). 
5. 4. 2. Pre p ar ati o n a n d Dis pe nsi n g 
I n vesti gati o nal pr o d uct will be dis pe nse d at t he Scree ni n g visit ( Da y 0) a n d at e ver y  s pecifie d 
tele p h o ne or cli nic visit t hereafter usi n g a n I R T s yste m.  A q ualifie d staff me m ber will 
dis pe nse t he i n vesti gati o nal pr o d uct cart o ns pr o vi de d. 
S u bje cts will be gi ve n a s u p pl y  ( Secti o n 5. 4. 1 ) of tafa mi dis o n Da y 0 f or self -a d mi nistrati o n 
at h o me be gi n ni n g o n Da y 1 (ie, first d o se) .  At tele p h o ne visits ( M o nt hs 3, 9, 1 5, 2 1, 2 7, 3 3, 
3 9, 4 5, 5 1, 5 7) s u p plies of I P will be s hi p pe d t o s u bjects fr o m t he cli nical site b y  a 
s pecialize d I P c o urier.  A n y  I P s hi p pe d directl y  t o s u bject f oll o wi n g a tele p h o ne visit will be 
dis pe nse d at t he sit e per t he pr ocess liste d a b o ve a n d m o nit ore d f or te m perat ure d uri n g 
s hi p pi n g pr ocess t hr o u g h del i ver y .  S u bjects will ret ur n f or cli nic visits e ver y  6 m o nt hs 
( M o nt hs 6, 1 2, 1 8, 2 4, 3 0, 3 6, 4 2, 4 8, 5 4) f or e val uati o n a n d will recei ve a s u p pl y  of I P f or 
self -a d mi nistrati o n at h o me. 
I P will n ot be dis pe nse d if t he pr ot oc ol s pecifie d tele p h o ne visit pr o ce d ures ha ve n ot bee n 
perf or me d.  Details of pr oce d ures f or s hi p pi n g b y s pecialize d I P c o urier will be i ncl u de d i n 
t he I P s hi p pi n g refere nce g ui de.  I P will n ot be dis pe nse d at cli nic visits if t he pr ot oc ol 
s pecifie d cli nic visit pr oce d ures ha ve n ot bee n p erf or me d. 
5. 5. A d mi nistr ati o n 
C o h ort A bli n de d treat me nt: S u bjects will be i nstr ucte d t o ta ke [ADDRESS_733902] u d y  me dicati o n w h ole, a n d will 
n ot ma ni p ulate or c he w t he me dicati o n pri or t o s wall o wi n g. 
C o h ort A & B o pe n la bel treat me nt: S u bjects will be i n str ucte d t o ta ke [ADDRESS_733903] u d y  me dicati o n w h ole, a n d will 
n ot ma ni p ulate or c he w t he me dicati o n p ri or t o s wall o wi n g. 
S u bjects will be i nstr ucte d t o d ose at a c o nsiste nt ti me eac h da y .  S u bjects s h o ul d n ot ta ke a n 
e xtra d ose of me dicati o n i n t he e ve nt t hat a d ose fr o m a pre vi o us da y  is misse d a n d s h o ul d 
res u me d osi n g as i nstr ucte d a b o ve at t he ne xt pla n ne d d osi n g ti me. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733904] Dail y  D osi n g Diar y  a n d t he site staff will rec or d t his d osi n g ti me i n 
t he case re p ort f or m ( C R F).  At t he e n d of eac h visit, sites will i nstr uct s u bjects, i n writi n g o n 
t he fr o nt of t he S u bject Dail y  D osi n g Diar y , w he n t o ta ke t heir me dicati o n pri or t o t heir ne xt 
st u d y  visit. 
5. 5. 1. D ose -re d ucti o n 
A o ne -ti me d ose re d ucti o n t o [ADDRESS_733905]’s safet y is n ot 
c o m pr o mise d b y  c o nti n ui n g treat me nt, t h e n t he s u bject ma y  re q uest bli n de d treat me nt 
re -assi g n me nt t o a l o wer d ose.  O nl y  s u bjects assi g ne d t o [ADDRESS_733906]’s st u d y- s pecific i de ntificati o n ( S SI D) n u m ber i nt o 
t he I R T s ys te m a n d re q uest bli n de d d ose -re d ucti o n.  T he I R T s ys te m will pr o vi de a ne w 
c o ntai ner n u m ber f or bli n de d treat me nt re- assi g n me nt f or t his s u bject. 
If t he s u bject was recei vi n g t he [ADDRESS_733907]’s vital 
stat us/tra ns pla nt stat us 6 0 m o nt hs after ra n d o mizati o n i nt o B 3 4 6 1 0 4 5. 
C o h ort A & B o pe n l a bel d ose re d ucti o n 
I n t he e ve nt t hat s u bjects e x perie nce a d verse e ve nts t hat ma y  be ass ociate d wit h t he 
t olera bilit y  of treat me nt wit h tafa mi dis t hat ma y  i m pact d osi n g a d here nce, t he y  s h o ul d ret ur n 
t o t he cli nic wit h t heir me dicati o n. If t he i n vesti gat or assesses t hat t he t olera bilit y  iss ue is 
persiste nt a n d a ntici pate d t o i m pact d osi n g a d here nce a n d t hat t he s u bject’s saf et y is n ot 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733908]’s st u d y s pecific i de ntif icati o n ( S SI D) n u m b er i nt o 
t he I R T s ys te m a n d re q uest a n o pe n la bel d ose re d ucti o n.  T he I R T s y ste m will pr o vi de a 
ne w c o ntai ner n u m ber f or o pe n la bel treat me nt re -assi g n me nt f or t his s u bject. 
If t olera bilit y  iss ues c o nti n ue after t he re- assi g n me nt, t he i n vesti gat or has t he o pti o n t o 
disc o nti n ue d osi n g f or t his s u bject a n d t o ter mi nate st u d y  partici pati o n.  I n t he e ve n t of earl y 
st u d y  disc o nti n uati o n, t he site staff will f oll o w u p o n t he s u bject’s vital stat us/tra ns pla nt 
stat us [ADDRESS_733909] be ca pa ble of meas uri n g a n d d oc u me nti n g (e g, via a l o g), at a 
mi ni m u m, dail y  mi ni m u m a n d ma xi m u m te m perat ures f or all site st ora ge l ocati o ns (as 
a p plica ble, i ncl u di n g fr oze n, refri gerate d a n d/ or r o o m te m perat ure pr o d ucts).  T his s h o ul d be 
ca pt ure d fr o m t he ti me of i n ves ti gati o nal pr o d uct recei pt t hr o u g h o ut t he st u d y .  E ve n f or 
c o nti n u o us m o nit ori n g s yste ms, a l o g or site pr oce d ure t hat e ns ures acti ve dail y  e val uati o n 
f or e xc ursi o ns s h o ul d be a vaila ble.  T he o perati o n of t he te m perat ure m o nit ori n g de vic e a n d 
st ora ge u nit (e g, refri gerat or), as a p plica ble, s h o ul d be re g ularl y  i ns pecte d t o e ns ure it is 
mai ntai ne d i n w or ki n g or der. 
A n y  e xc ursi o ns fr o m t he pr o d uct la bel st ora ge c o n diti o ns s h o ul d be re p orte d u p o n disc o ver y .  
T he site s h o ul d acti vel y p urs ue o p ti o ns f or ret ur ni n g t he pr o d uct t o t he st ora ge c o n diti o ns as 
descri be d i n t he cli nical s u p pl y  la bel, as s o o n as p os si ble.  De viati o ns fr o m t he st ora ge 
re q uire me nts, i ncl u di n g a n y  acti o ns ta ke n, m ust be d oc u me nte d a n d re p orte d t o t he s p o ns or.  
O nce a n e xc ur si o n is i de ntifie d, t he i n vesti gati o nal pr o d uct m ust be q uara nti ne d a n d n ot use d 
u ntil t he s p o ns or pr o vi des d oc u me n tati o n of per missi o n t o use t he i n vesti gati o nal pr o d uct.  It 
will n ot be c o nsi dere d a pr ot oc ol de viati o n if t he s p o ns or a p pr o ves t he use of t he 
i n vesti gati o nal pr o d uct after t he te m perat ure e xc ursi o n.  Use of t he i n vesti gati o nal pr o d uct 
pri or t o s p o ns or a p pr o val will be c o nsi dere d a pr ot oc ol de viati o n. 
S pecific details re gar di n g i nf or mati o n t he site s h o ul d re p ort f or eac h e xc ursi o n will be 
pr o v i de d t o t he site.  Site staff will i nstr uct s u bjects o n t he pr o per st ora ge re q uire me nts f or 
ta ke h o me i n vesti gati o n al pr o d ucts. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733910] u g acc o u nta bilit y  f or m/rec or d.  At eac h sc he d ule d cli nic visit, be gi n ni n g at t he 
M o nt h [ADDRESS_733911] (e g, at t he site).  If destr ucti o n is a ut h orize d t o ta ke place at t he st u d y  site, t he 
i n vesti gat or m ust e ns ure t hat t he materials are destr o y e d i n c o m plia nce wit h a p plica ble 
e n vir o n me ntal re g ulati o ns, i nstit uti o nal p olic y , a n d a n y  s pecial i nstr ucti o ns pr o vi de d b y  
[COMPANY_007], a n d all destr ucti o n m ust be a de q uatel y d oc u me nte d. 
5. 8. C o nc o mit a nt Tre at me nt(s) 
Treat me nts ta ke n wit hi n [ADDRESS_733912] h yreti n ( Al mei da 2 0 0 4). 1  Per mitte d N S AI Ds 
i ncl u de: acet yl salic y lic aci d, et o d olac, i b u pr ofe n, i n d o met haci n, ket o pr o fe n, na b u met o ne, 
na pr o xe n, ni mes uli de, pir o xica m, a n d s uli n dac.  Use of a n y ot her N S AI Ds re q uire s 
a gree me nt wit h t he S p o ns or’s cli nicia n or me dical m o nit or. 
1. Use of a n y i n vesti gati o nal t hera p y d uri n g t he st u d y is n ot per mitte d. 
2. Use of difl u nisal, i n oterse n, or patisira n d uri n g t he st u d y  is pr o hi bite d. 
3. Use of ta ur o urs o de o x yc h olate a n d d o x yc ycli ne is n ot per mitte d. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 2 4. Di gitalis a n d calci u m c ha n nel bl oc kers (e g, vera pa mil, diltiaze m) are pr o hi bite d 
c o nc o mita nt me dicati o ns beca use t he y  bi n d t o a m y l oi d fi brils a n d m a y  lea d t o 
i ncrease d t o xicit y  ( Gertz 1 9 8 5 , R u bi n o w 1 9 8 1 , Ra pezzi 2 0 1 0 ). 2,5,[ADDRESS_733913] u d y  treat me nt ( Da y 1). 
6. 1. Scree ni n g Visit 
6. 1. 1. Scree ni n g Visit C o h ort A ( D a y 0) 
Scree ni n g V isit ( Da y 0) is t he M o nt h [ADDRESS_733914] u d y .  S u bjects pr o vi di n g 
c o nse nt a n d f ulfilli n g t he i ncl usi o n/e xcl usi o n criteria will be e nr olle d, ra n d o mize d, a n d 
dis pe nse d st u d y  me dicati o n f or St u d y  B 3 4 6 1 0 4 5 at t he sa me visit.  S u bjects will be 
i nstr ucte d t o start self -a d mi nistrati o n of tafa mi dis t he f oll o wi n g da y  ( Da y 1). 
If m ore t ha n [ADDRESS_733915] u d y -relate d pr oce d ure s. 
T he f oll o wi n g pr oce d ures will be c o n d ucte d d uri n g t he Scree ni n g/ Da y 0 visit: 
All i ncl usi o n a n d e xcl usi o n criteria will be r e vie we d t o e ns ure eli gi bilit y  f or 
partici pati o n i n t his st u d y  [ St u d y  B 3 4 6 1 0 4 5 o nl y] .
De m o gra p h y ( date of birt h, a ge, ge n der a n d ra ce) [ St u d y  B 3 4 6 1 0 4 5 o nl y] .
C o m plete me dical hist or y (i ncl u di n g hist or y  of heart fail ure) [ St u d y  B 3 4 6 1 0 4 5 o nl y ]. 
F ull p h y sical e xa mi nati o n i ncl u di n g wei g ht a n d h ei g ht meas ure me nts will be 
perf or me d.  If m ore t ha n [ADDRESS_733916] be perf or me d o n Da y 0. 
Meas ure vital si g ns (s ys t olic a n d diast olic bl o o d press ure s u pi [INVESTIGATOR_050] a n d sta n di n g, p ulse 
rate s u pi [INVESTIGATOR_050] a n d sta n di n g, res pi[INVESTIGATOR_1313] o n rate, a n d b o d y te m perat ure). 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 3 Si n gle 1 2 -lea d E C G -perf or m E C G pri or t o a n y bl o o d c ollecti o n or bl o o d press ure 
meas ure me nts. 
C ollect bl o o d, a n d uri ne sa m ples f or t he f oll o wi n g cli nical la b orat ories.  If m or e t ha n 
[ADDRESS_733917] be perf or me d pri or t o e nr oll me nt a n d ra n d o mizati o n. 
He mat ol o g y ;
Ser u m C he mistr y ;
C oa g ulati o n (I nter nati o nal n or malize d rati o [I N R], Pr ot hr o m bi n ti me [ P T]); 
Uri nal y sis; 
Uri ne pre g na nc y  test –f or w o me n of c hil d beari n g p ote ntial; 
F ollicle -sti m ulati n g h or m o ne ( F S H) test – f or fe male s u bjects of n o n- c hil d beari n g 
p ote ntial w h o ha ve n ot ha d a h y sterect o m y, bilateral o o p h orect o m y, or me dicall y 
c o nfir me d o varia n fail ure.  S u bjects w h o alrea d y c o nfir me d me n o pa use wit h a n 
F S H test i n St u d y B [ADDRESS_733918] is 
a p plica ble o nl y t o s u bjects ne wl y f ulf illi n g t he 1 2 c o nsec uti ve m o nt hs of 
a me n orr hea re q uire d t o ma k e t he dia g n osis of me n o pa use. 
C o ntrace pti o n c hec k. 
Ne w Y or k Heart Ass ociati o n ( N Y H A) classificat i o n. 
A d mi nister Ka nsas Cit y  Car di o m y o pat h y Q uesti o n naire. 
D oc u me ntati o n of vital stat us a n d tra ns p la nt or car diac mec ha nical assist de vice 
stat us. 
D oc u me ntati o n of c o nc o mita nt me dicati o ns. 
A d verse e ve nt re p orti n g. 
Treat me nt all ocati o n/ Ra n d o mizati o n a n d di s pe nse bli n de d i n vesti gati o nal pr o d uct.  
[ St u d y  B 3 4 6 1 0 4 5 o nl y] .
I nstr ucti o ns t o s u bjects t o self-a d mi nister bli n de d i n vesti gati o nal pr o d uct at h o me at 
t he sa me ti me e ver y  da y  be gi n ni n g o n Da y 1.  [ St u d y  B 3 4 6 1 0 4 5 o nl y] .0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 4 6. 1. 2. Scree ni n g Visit C o h ort B ( wit h dise as e d oc u me nt ati o n) ( D a y 0) 
S u bjects pr o vi di n g c o nse nt a n d f ulfilli n g t he i ncl usi o n/e xcl usi o n criteri a will be e nr olle d a n d 
dis pe nse d st u d y  me dicati o n f or St u d y B 3 4 6 1 0 4 5 at t he sa me visit.  S u bjects will be 
i nstr ucte d t o start self -a d mi nistrati o n of tafa mi dis t he f oll o wi n g da y  ( Da y 1). 
Writte n s u bject i nf or me d c o nse nt will be o btai ne d pri or t o a n y st u d y -relate d pr oce d ures. 
T he f oll o wi n g pr oce d ures will be c o n d ucte d d uri n g t he Scree ni n g/ Da y 0 visit: 
All i ncl usi o n a n d e xcl usi o n criteria will be re vie we d t o e ns u re eli gi bilit y  f or 
partici pati o n i n t he st u d y .
C o m plete De m o gra p h y. 
C o m plete me dical hist or y (i ncl u di n g hist or y  of heart fail ure). 
F ull p h y sical e xa mi nati o n i nc l u di n g wei g ht a n d hei g ht meas ure me nts will be 
perf or me d. 
Meas ure vital si g ns (s ys t olic a n d dias t olic bl o o d press ure s u pi [INVESTIGATOR_050] a n d sta n di n g, p ulse 
rate s u pi [INVESTIGATOR_050] a n d sta n di n g, res pi[INVESTIGATOR_1313] o n rate, a n d b o d y  te m perat ure). 
Si n gle 1 2 -lea d E C G -perf or m E C G pri or t o a n ybl o o d c ollecti o n or bl o o d press ure 
meas ure me nts. 
C ollect bl o o d, a n d uri ne sa m ples f or t he f oll o wi n g cli nical la b orat ories: 
He mat ol o g y ;
Ser u m C he mistr y ;
C oa g ulati o n (I nter nati o nal n or malize d ra ti o [I N R], Pr ot hr o m bi n ti me [ P T]); 
N T -pr o B N P a n d tr o p o ni n I; 
Uri nal y sis; 
Uri ne pre g na nc y  test –f or w o me n of c hil d beari n g p ote ntial; 
F ollicle -sti m ulati n g h or m o ne ( F S H) test –m a y  be use d t o c o nfir m a 
p ost me n o pa usal state i n w o me n n ot usi n g h or m o nal c o ntrace pti o n or h or m o ne 
re place me nt t hera p y ( H R T).  Fe males o n H R T a n d w h ose me n o pa usal stat us is i n 
d o u bt will be re q uire d t o use o ne of t he n o nestr o ge n h or m o nal h i g hl y effecti ve 
c o ntrace pti o n met h o ds if t he y  wis h t o c o nti n ue t heir H R T d uri n g t he st u d y.  
Ot her wise, t he y  m ust disc o nti n ue H R T t o all o w c o nfir mati o n of p ost me n o pa usal 
stat us bef ore st u d y e nr oll me nt ( Secti o n 4. 3. 1 ). 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 5 C ollect ba n ke d bi os peci me n. 
C o ntrace pti o n c hec k. 
A d mi nister Ka nsas Cit y  Car di o m y o pat h y Q uesti o n naire. 
Ne w Y or k Heart Ass ociati o n ( N Y H A) classificati o n. 
C ollect d oc u me ntati o n of t he ge netic testi n g f or tra nst h y reti n a m yl oi d osis (ie, ori gi nal 
la b orat or y  res ult, or c o p y).  T he ori gi nal la b orat or y  res ult, or c o p y  will be part of t he 
s o urce d oc u me ntati o n. 
C ollect d oc u me ntati o n of dia g n osis a n d criteria use d (e g, c o n gesti ve heart fail ure a n d 
sci nti gra p h y wit h tracer e g, 9 9 m T C D P D [ 9 9 m T C 3, 3 di p h os p h o n o 1, 2 pr o pa n o 
dicar b o x yl ic aci d], 9 9 m T C P Y P [ P y r o p h os p hate] a n d als o 9 9 m T C H M D P 
[ h y dr o x y m et h y le ne di p h os p h o nate] or prese nce of a m y l oi d de p osits i n bi o ps y  tiss ue, 
s uc h as fat as pi[INVESTIGATOR_337], sali var y  gla n d, me dia n ner ve c o n necti ve tiss ue s heat h, or car diac 
[a m y l oi d de m o nstrate d per a p pr o priate stai n s uc h as C o n g o re d or alcia n bl ue stai n]).  
T he ori gi nal la b orat or y  res ult, or c o p y  will be part of t he s o urce d oc u me ntati o n. 
C ollect d oc u me ntati o n t hat pri mar y  (li g ht c hai n) a m y l oi d osis disease has bee n 
eval uate d a n d r ule d o ut (ie, ori gi nal la b orat or y  res ult, or c o p y ).  T he ori gi nal 
la b orat or y  res ult, or c o p y will be part of t he s o urce d oc u me ntati o n. 
D oc u me ntati on of vital stat us a n d tra ns pla nt or car diac mec ha nical assist de vice 
stat us. 
D oc u me ntati o n of c o nc o mita nt me dicati o ns. 
F or c o u ntries liste d i n A p pe n di x 6:A d diti o n al s a m ple c ollecti o n pr oce d ures will be 
perf or me d at Scree ni n g ( D ay 0) . See A p pe n dix 7f or p r oce d ure det ails. 
A d verse e ve nt re p orti n g. 
Treat me nt all ocati o n a n d dis pe nse bli n de d i n vesti gat i o nal pr o d uct. 
I nstr ucti o ns t o s u bjects t o self- a d mi nister bli n de d i n vesti gati o nal pr o d uct at h o me at 
t he sa me ti me e ver y  da y  be gi n ni n g o n Da y 1. 
6. 1. 3. Scree ni n g Vis it ( D a y -3 0) C o h ort B S u bjects wit h o ut D oc u me nt ati o n of Di a g n osis 
Writte n s u bject i nf or me d c o n se nt will be o btai ne d pri or t o a n y  st u d y -relate d pr oce d ures. 
T he f oll o wi n g pr oce d ures will be c o n d ucte d d uri n g t he Scree ni n g/ Da y  - 3 0 visit: 
All i ncl usi o n a n d e xc l usi o n criteria will be re vie we d t o e ns ure eli gi bilit y  f or 
partici pati o n i n t he st u d y .0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 6 C o m plete De m o gra p h y. 
C o m plete Me dical Hist or y  (i ncl u di n g hist or y  of heart fail ure). 
C ollect sa m ples f or disease dia g n osis: 
Ge n ot y pi n g; 
Ser u m a n d uri ne test f or pri mar y  li g ht c hai n a m yl oi d osis; 
Tiss ue Bi o ps y. 
D oc u me ntati o n of vital stat us a n d tra ns pla nt or car diac mec ha nical assist de vice 
stat us. 
D oc u me ntati o n of c o nc o mita nt me dicati o ns. 
A d verse e ve nt re p orti n g. 
6. 1. 4. S cree ni n g Visit ( D a y 0) C o h ort B ( wit h o ut dise ase d oc u me nt ati o n) 
T he f oll o wi n g pr oce d ures will be c o n d ucte d d uri n g t he Scree ni n g/ Da y 0 visit: 
All i ncl usi o n a n d e xcl usi o n criteria will be re vie we d t o e ns ure eli gi bilit y f or partici pati o n i n 
t his st u d y .
F ull p h y sical e xa mi nati o n i ncl u di n g wei g ht a n d hei g ht meas ure me nts will be 
perf or me d. 
Meas ure vital si g ns (s ys t olic a n d diast olic bl o o d press ure s u pi [INVESTIGATOR_050] a n d s ta n di n g, p ulse 
rate s u pi [INVESTIGATOR_050] a n d sta n di n g, res pi[INVESTIGATOR_1313] o n rate, a n d b o d y te m perat ure). 
Si n gle 1 2 -lea d E C G pe rf or m E C G pri or t o a n y bl o o d c ollecti o n or bl o o d press ure 
meas ure me nts. 
C ollect bl o o d, a n d uri ne sa m ples f or t he f oll o wi n g cli nical la b orat ories: 
He mat o l o g y ;
Ser u m C he mistr y ;
C oa g ulati o n (I nter nati o nal n or malize d rati o [I N R], Pr ot hr o m bi n ti me [ P T]); 
N T - pr o B N P a n d tr o p o ni n I ;
Uri nal y sis; 
Uri ne pre g na nc y  test –f or w o me n of c hil d beari n g p ote ntial; 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 7 F ollicle -sti m ulati n g h or m o ne ( F S H) test –m a y  be use d t o c o n fir m a 
p ost me n o pa usal state i n w o me n n ot usi n g h or m o nal c o ntrace pti o n or h or m o ne 
re place me nt t hera p y ( H R T).  Fe males o n H R T a n d w h ose me n o pa usal s tat us is i n 
d o u bt will be re q uire d t o use o ne of t he n o nestr o ge n h or m o nal hi g hl y effecti ve 
c o ntrace pti o n met h o ds if t he y  wis h t o c o nti n ue t heir H R T d uri n g t he st u d y.  
Ot her wise, t he y  m ust disc o nti n ue H R T t o all o w c o nfir mati o n of p ost me n o pa usal 
stat us bef or e st u d y e nr oll me nt ( Secti o n 4. 3. 1 ). 
C ollect ba n ke d bi os peci me n. 
C o ntrace pti o n c hec k. 
Ne w Y or k Heart Ass ociati o n ( N Y H A) classific ati o n. 
A d mi nister Ka n sas Cit y  Car di o m y o pat h y Q uesti o n naire. 
D oc u me ntati o n of vital stat us a n d tra ns pla nt or car diac mec ha nical assist de vice 
stat us. 
D oc u me ntati o n of c o nc o mi ta nt me dicati o ns. 
F or c o u ntries liste d i n A p pe n di x 6:A d diti o n al s a m ple c ol lecti o n pr oce d ures will be 
perf or me d at Scree ni n g ( D ay 0) .See A p pe n dix 7f or pr oce d ure det ails. 
A d verse e ve nt re p orti n g. 
Treat me nt all ocati o n a n d dis pe nse i n vesti gati o nal pr o d uct. 
I nstr ucti o ns t o s u bjects t o self- a d mi nister b li n de d i n vesti gati o nal pr o d uct at h o me at 
t he sa me ti me e ver y  da y  be gi n ni n g o n Da y 1. 
6. 2. St u d y Peri o d 
T he f oll o wi n g c hr o n ol o g y  of acti vities is s u g geste d f or cli nic visits: 
E C G –Perf or m E C G pri or t o vital si g n a n d bl o o d s peci me n c ollecti o n. 
Vital Si g ns –O bt ai n bl o o d press ure/ p ulse rate pri or t o bl o o d s peci me n c ollecti o n. 
Bl o o d sa m ple c ollecti o n f or cli nical la b orat ories. 
All ot her pr oce d ures s h o ul d be o btai ne d after bl o o d s peci me n c ollecti o ns, u nless sa m pli n g is 
deter mi ne d b y t he st u d y pers o n nel t o p ote ntia ll y i m pact t he res ults. 
6. 2. 1. D a y [ADDRESS_733919] at h o me. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 8 6. 2. 2. Tele p h o ne Visits ( M o nt hs 3, 9, 1 5, 2 1, 2 7, 3 3, 3 9, 4 5, 5 1, 5 7) [ADDRESS_733920] u d y site. 
T he site will c o ntact t he s u bject b y  p h o ne at a ti me a gree d wit h t he s u bject t o c ollect 
t he f oll o wi n g i nf or mati o n si nce t he cli nic visit: 
D oc u me ntati o n of c o nc o mita nt me dicati o ns; 
A d verse e ve nts re p orti n g; 
H os pi[INVESTIGATOR_1314] o n deter mi nati o n.  Sites will deter mi ne w het her t he s u bject has bee n 
h os pi[INVESTIGATOR_18552] d a n d t he reas o n f or h os pi[INVESTIGATOR_1314] o n; 
C o ntrace pti o n c hec k; 
D oc u me ntati o n of vital st at us a n d t ra ns pla nt or car diac mec ha nical assist de vice 
stat us. 
At t he e n d of t he p h o ne call, t he ne xt cli nic a p p oi nt me nt will be c o nfir me d a n d t he 
s u bject will be re mi n de d t o rec or d a d verse e ve nts a n d me dicati o n use i n t he S u bject 
Dail y  D osi n g Diar y .  T he s u bject w ill be re mi n de d t o ret ur n t o t he cli nic wit h all 
dis pe nse d st u d y me dicati o n. 
St u d y  site will dis pe nse i n vesti gati o nal pr o d uct b y s pecialize d I P c o urier.  T he I P 
c o urier will als o c ollect all pre vi o usl y dis pe nse d ( use d a n d u n use d) i n vesti gati o nal 
pr o d uct fr o m t he s u bject a n d ret ur n t o t he site f or acc o u nta bilit y .
F or c o u ntries liste d i n A p pe n di x 4. 2 :s u bjects will be re q uire d t o ret ur n t o t he st u dy 
site at M o nt h 3. Tele p h o n e visit pr oce d ures will be perf or me d.  T he f ol l o wi n g 
a d diti o n al pr oce d ures will als o be perf or me d at t he M o nt h 3 visit: 
Brief p hysic al ex a mi n ati o n i ncl u di n g wei g ht me as ure me nt; 
C ollect all dis pe nse d ( use d a n d u n use d) i nvesti g ati o n al pr o d uct; 
Si n gle [ADDRESS_733921] i o n or bl o o d 
press ure me as ure me nts; 
Me as ure vit al si g ns (syst olic a n d di ast olic bl o o d press ure s u pi [INVESTIGATOR_050] a n d st a n di n g, 
p ulse r ate s u pi [INVESTIGATOR_050] a n d st a n di n g, res pir ati o n r ate, a n d b o dy te m per at ure); 
C ollect bl o o d a n d ur i ne s a m ples f or t he f oll o wi n g cli nic al l a b or at ories: 
He m at ol o gy; 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 9 Ser u m C he mistry; 
C o a g ul ati o n (I N R, P T); 
N T -pr o B N P a n d tr o p o ni n I; 
Uri n alysis. 
Uri ne pre g n a ncy test –f or w o me n of c hil d be ari n g p ote nti al. 
A d mi nister K a ns as City C ar di o my o p at hy Q uesti o n n aire. 
N Y H A cl assific ati o n. 
Rec or d c a ps ule c o u nt f or d osi n g a d here nce. 
Dis pe nse bli n de d i nvesti g ati o n al pr o d uct. 
6. 2. 3. Cli nic Visits ( M o nt hs 6, 1 2, 1 8, 2 4, 3 0, 3 6, 4 2, 4 8, 5 4) 2 Wee ks 
T he f oll o wi n g pr oce d ures will be perf or me d f or all s u b jects at cli nic visits: 
Brief p h y sical e xa mi nati o n i ncl u di n g wei g ht meas ure me nt. 
C ollect all dis pe nse d ( use d a n d u n use d) i n vesti gati o nal pr o d uct. 
Si n gle 1 2 -Lea d E C G -perf or m E C G pri or t o a n y bl o o d c ollecti o n or bl o o d press ure 
meas ure me nts ( T o be perf or me d a n n uall y  at M o nt hs 1 2, 2 4, 3 6, 4 8 or earl y 
disc o nti n uati o n). 
Meas ure vital si g ns (s ys t olic a n d diast olic bl o o d press ure s u pi [INVESTIGATOR_050] a n d sta n di n g, p ulse 
rate s u pi [INVESTIGATOR_050] a n d sta n di n g, res pi[INVESTIGATOR_1313] o n rate, a n d b o d y te m perat ure). 
C ollect bl o o d a n d uri ne sa m ples f or t he f oll o wi n g cli nical la b orat orie s: 
He mat ol o g y ;
Ser u m C he mistr y ;
C oa g ulati o n ( I N R, P T); 
N T -pr o B N P a n d tr o p o ni n I ;
Uri nal y sis; 
Uri ne pre g na nc y  test –f or w o me n of c hil d beari n g p ote ntial. 
A d mi nister Ka nsas Cit y  Car di o m y o pat h y Q uesti o n naire. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 5 0 N Y H A classificati o n. 
C o ntrace pti o n c hec k. 
D oc u me n tati o n of c o nc o mita nt me dicati o ns. 
Rec or d ca ps ule c o u nt f or d osi n g a d here nce. 
A d verse e ve nt re p orti n g. 
H os pi[INVESTIGATOR_1314] o n deter mi nati o n.  Sites will deter mi ne w het her t he s u bject has bee n 
h os pi[INVESTIGATOR_18552] d a n d t he reas o n f or h os pi[INVESTIGATOR_27967] o n. 
D oc u me ntati o n of vital stat us, tra ns pla nt or car diac mec ha nical assi st de vice stat us. 
Dis pe nse bli n de d i n vesti gati o nal pr o d uct. 
Sc he d ule a date a n d ti me f or t he ne xt tele p h o ne visit. 
6. 2. 4. E n d of St u d y Visit ( M o nt h 6 0) [ADDRESS_733922] u d y Disc o nti n uati o n: 
F ull p h y sical e xa mi nati o n i ncl u di n g wei g ht meas ure me nt. 
C ollect all dis pe nse d i n vesti gati o nal pr o d uct. 
Si n gle [ADDRESS_733923] u d y  visit. 
Meas ure vital si g ns (s ys t olic a n d diast olic bl o o d press ure s u pi [INVESTIGATOR_050] a n d sta n di n g, p ulse 
ra te s u pi [INVESTIGATOR_050] a n d sta n di n g, res pi[INVESTIGATOR_1313] o n rate, a n d b o d y te m perat ure). 
C o ntrace pti o n c hec k. 
C ollect bl o o d a n d uri ne sa m ples f or t he f oll o wi n g: 
He mat ol o g y ;
Ser u m C he mistr y ;
C oa g ulati o n (I N R, P T); 
N T -pr o B N P a n d tr o p o ni n I ;0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 5 1 Uri nal y sis; 
Uri ne pre g na nc y  test –f or w o me n of c hil d beari n g p ote ntial. 
Ka nsas Cit y  C ar di o m y o pat h y  Q uesti o n naire. 
N Y H A classificati o n. 
D oc u me ntati o n of c o nc o mita nt me dicati o ns. 
Rec or d ca ps ule c o u nt f or d osi n g a d here nce. 
Ad verse e ve nt re p orti n g. 
H os pi[INVESTIGATOR_1314] o n deter mi nati o n. 
D oc u me ntati o n of vi tal stat us, tra ns pla nt or car diac mec ha nical a ssist de vice stat us. 
Sc he d ule date a n d ti me f or t he p ost- st u d y  f oll o w -u p visit. 
6. 3. P ost -st u d y F oll o w -u p Visit 
S u bjects s h o ul d be f oll o we d f or [ADDRESS_733924] a n y 
A E/ S A E i n f or mati o n a n d perf or m a c o ntrace pti o n c hec k.  T his p ost -st u d y  f oll o w -u p ca n be 
c o n d ucte d at t he st u d y site or b y tele p h o ne.  S u bjects w h o ha ve n ot f oll o we d c o ntrace pti o n 
re q uire me nts as deter mi ne d at t he ti me of t he p ost -st u d y  tele p h o ne call will be as ke d t o 
c o nfir m pre g na nc y  stat us. 
T he f oll o wi n g i n f or mati o n will be c ollecte d: 
A d verse e ve nt re p orti n g (see Secti o n 8). 
C o ntrace pti o n c hec k. 
6. 4. S u bject Wit h dr a w al a n d Vit al St at us/ Tr a ns pl a nt/ C ar di ac Mec h a nic al Assist De vice 
St at us F oll o w -u p 
S u bj ects ma y  wit h dra w fr o m t he st u d y  at a n y  ti me at t heir o w n re q uest, or t he y  m a y  be 
wit h dra w n at a n y ti me at t he discreti o n of t he i n vesti gat or or s p o ns or f or safet y or be ha vi oral 
reas o ns, or t he i na bilit y  of t he s u bject t o c o m pl y wit h t he pr ot oc ol re q uire d sc he d ule of st u d y 
visits or pr oce d ures at a gi ve n st u d y si te. 
A release of Me dical I nf or mati o n F or m will be re q uire d of all s u bjects f or t he p ur p ose of 
access t o me dical rec or ds as well as f or o btai ni n g vital s tat us/tra ns pla nt/car diac mec ha nical 
assist de vice stat us f oll o w -u p wit h t he s u bject’s pri mar y  p h y sicia n or wit h deat h re gistries.  
T he si g ni n g of t his Release of Me dical I nf or mati o n F or m is i n a d diti o n t o t he I nf or me d 
C o nse nt D oc u me nt.  I n s o me cases, site s ma y  c o m bi ne t hese t w o f or ms i nt o a si n gle f o r m, as 
is t heir sta n dar d practice. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733925] (ie, i n di vi d ual 
i de ntifie d i n t he Release of Me dical I nf or mati o n F or m) ca n n ot be reac he d, atte m pts wil l be 
ma de t o ascertai n t he vital stat us/tra ns p la nt/car diac mec ha nical assist de vice stat us of t he 
s u bject b y  searc hi n g t he a p pr o priate nati o nal or re gi o nal vital stat us re gistr y  or ot her rele va nt 
data bases, w here a vaila ble a n d all o wa ble b y l ocal la w.  De pe n di n g o n t he l ocal la w, t his 
searc h will be c o n d ucte d b y  t he e nr olli n g p h ys icia n or a desi g nee at t he st u d y  site. 
If a s u bject d oes n ot ret ur n f or a sc he d ule d visit, e ver y  eff ort s h o ul d be ma de t o c o ntact t he 
s u bject.  T he site s h o ul d ma ke a mi ni m u m of [ADDRESS_733926]’s vital sta t us/tra ns pla nt/car diac mec ha nical assist de vic e stat us t hr o u g h 
[ADDRESS_733927] u d y  visit (if a p plica ble) a n d t o 
ret ur n all u n use d i n vesti gati o nal pr o d uct(s), a n d f ol l o w -u p wit h t he s u bject re gar di n g a n y 
u nres ol ve d a d verse e ve nts ( A Es). 
If t he s u bject wit h dra ws fr o m t he st u d y , a n d als o wit h dra ws c o nse nt f or discl os ure of f ut ure 
i nf or mati o n, n o f urt her e val uati o ns s h o ul d be perf or me d, a n d n o a d diti o nal data s h o ul d be 
c o llecte d, e xce pt f or ascertai ni n g vital stat us/tra ns pla nt/car diac mec ha nical assist de vice 
stat us at [ADDRESS_733928]’s re prese ntati ve ref uses or is p h ysicall y u na vaila ble, 
t he site s h o ul d d oc u me nt a n d si g n t he reas o n f or t he s u bject’s fail ure t o wit h dra w c o nse nt i n 
writi n g. 
6. 4. 1. S u bject Wit h dr a w al f or He art or Li ver Tr a ns pl a nt ati o n or I m pl a nt ati o n of 
C ar di ac Mec h a nic al Assist De vice 
S u bjects ma y  be o n a tra ns pla nt list at t he ti m e of ra n d o mizati o n/e nr oll me nt i n t he st u d y .  
Ho we ver, if a s u bject c h o oses t o acce pt a d o n or o r ga n tra ns pla nt d uri n g t he st u d y  or 
u n der g oes i m pla ntati o n of a car diac mec ha nical assist de vice, t he y  will st o p ta ki n g bli n de d 
st u d y  me dicati o n a n d be disc o nti n ue d fr o m st u d y  partici pati o n pri or t o t he tra ns pla nt 
o perati o n.  Vital stat us/tra ns pla nt stat us f or t he s u bject will be esta blis he d t hr o u g h [ADDRESS_733929] de vice will be ha n dle d i n t he 
statistical a nal y sis as descr i be d i n Secti o n 9. 2. 1 .0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733930] u d y  or Earl y  Disc o nti n uati o n Visit, i ncl u di n g assess me nt of t he f oll o wi n g b o d y  s ys te ms: 
Ge neral a p peara nce Ne ur ol o gical 
Hea d a n d nec k Car di o vasc ular 
E y es A b d o me n 
Ears S ki n 
N ose M usc ul os keletal 
T hr oat Res p irat or y 
Ge nit o uri nar y 
Brief p h ys ical e xa mi n ati o ns, i ncl u di n g assess me nt of ge neral a p peara nce, car di o vasc ular, 
res pi[INVESTIGATOR_1305] y , a n d gastr oi ntesti nal s y ste ms, are t o be perf or me d at all cli nic visits ( M o nt hs 6, 
1 2, 1 8, 2 4, 3 0, 3 6, 4 2, 4 8, 5 4).  Brief p hysic a l ex a mi n a ti o n a n d wei g ht me as ure me nt will als o 
be perf or me d at M o nt h 3 ( C o u ntries liste d i n A p pe n dix 4. 2 ). 
Meas ure me nt of hei g ht i n ce nti meters (c m) will be perf or me d at t h e Scree ni n g visit o nl y .
7. 1. 3. Vit al Si g ns 
Vital si g ns (i ncl u d i n g b o d y  te m perat ure, s y st olic a n d diast olic b l o o d press ure, p ulse rate a n d 
res pi[INVESTIGATOR_1313] o n rate) will be assesse d a n d rec or de d at t he Scree ni n g visit, at e ver y  cli nic visit, a n d 
at t he E n d of St u d y / Earl y Disc o nti n uati o n visit.  Vit al Si g ns will als o be assess e d at 
M o nt h 3( C o u ntries liste d i n A p pe n dix 4. 2 ). 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733931]’s ar m s u p p orte d at t he 
le vel of t he heart, a n d rec or de d t o t he nearest m m H g.  T he sa me ar m ( prefera bl y t he 
d o mi na nt ar m) will be use d t hr o u g h o ut t he tria l.  T he s u bject s h o ul d be s u pi [INVESTIGATOR_050] f or at least 
[ADDRESS_733932] ass u mes t he sta n d i n g p ositi o n. 
T he sa me size bl o o d press ure c u ff, w hic h has bee n pr o perl y cali brate d, will be use d t o 
meas ure bl o o d press ure at eac h ti me p oi nt.  T he use of a ut o mate d de vic es f or meas uri n g B P 
a n d p ulse rate is acce pta ble, alt h o u g h w he n perf or me d ma n uall y , p ulse rate will be meas ure d 
i n t he brac hial/ra dial arter y  f or at least 3 0 sec o n ds. 
W he n t he ti mi n g of t hese meas ure me nts c oi nci des wit h a bl o o d c ollecti o n, bl o o d press ure 
a n d p ulse rate s h o ul d be o btai ne d pri or t o t he n o mi nal ti me of t he bl o o d c ollecti o n. 
7. 1. 4. Electr oc ar di o gr a m 
A 1 2 -lea d electr ocar di o gra m ( E C G) will be perf or me d f or all s u bjects at Scree ni n g a n d 
a n n ual visits at M o nt hs 1 2, 2 4, 3 6, 4 8, 6 0 or earl y ter mi nati o n vis it.  A 1 2 -le a d E C G will als o 
be perf or me d at M o nt h 3 ( C o u ntries liste d i n A p pe n dix 4. 2 ).  W here p ossi ble, E C Gs will be 
perf or me d pri or t o bl o o d press ure or p ulse meas ure me nts or bl o o d c ollecti o n.  All sc he d ule d 
E C Gs s h o ul d be perf or me d after t he s u bject has reste d q uietl y  f or at least 5 mi n utes i n a 
s u pi [INVESTIGATOR_050] p os iti o n. 
T he f oll o wi n g E C G para meters will be as sesse d: P R, R R, Q R S, Q T, a n d Q Tc ( B a n d F) 
i nter val (c orrecte d E C G Q T I nter val usi n g t he Bazett’s or Fri dericia’s c orrecti o n), heart rate, 
a n d o verall i nter pretati o n, wit h rec or di n g of a n y a b n or mal fi n di n gs.  T e n -sec o n d r h y t h m 
stri ps will acc o m pa n y eac h E C G.  F or t he Scree ni n g visit, eac h E C G will be rec or de d a n d 
rea d l ocall y  b y  t he cli nical site, a n d t he cli nical si g nifica nce of E C G fi n di n gs will be assesse d 
b y  t he i n vesti gat or. 
I n a d diti o n, f or o verall a nal y sis of t he E C G para meters, eac h E C G will be di g italize d a n d 
se nt t o a n i n de pe n de nt E C G la b orat or y  t hat will c o n d uct a ce ntralize d re vie w of t he res ults 
f or c o nfir mati o n b y  a n i n de pe n de nt car di ol o gist. 
I n s o me cases, it ma y be a p pr o priate t o re peat a b n or mal E C Gs t o r ule o ut i m pr o per lea d 
place me nt as c o ntri b uti n g t o t he E C G a b n or malit y .  It is i m p orta nt t hat lea d s are place d i n t he 
sa me p ositi o ns eac h ti me i n or der t o ac hie ve precise a n d c o nsiste nt E C G rec or di n gs.  If a 
mac hi ne -rea d Q Tc val ue is pr ol o n ge d, re peat meas ure me nts ma y  n ot be necessar y  if a 
q u alifie d p h y sicia n’s i nter pretati o n deter mi nes t hat t he Q Tc va l ues are i n t he acce pta ble 
ra n ge. 
Detaile d i nstr ucti o ns f or perf or mi n g E C Gs are pr o vi de d i n a se parate st u d y la b orat or y  
ma n ual ( Ce ntralize d E C G Pr oc e d ure Ma n ual). 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 5 5 7. 1. 5. Cli nic al L a b or at or y Tests 
Bl o o d / uri ne sa m ples f or ser u m c he mistr y , c oa g ulati o n, he mat ol o g y , a n d uri nal y sis will be 
c ollecte d at Scree ni n g, a n d eac h cli nic visit at M o nt hs 6, 1 2, 1 8, 2 4, 3 0, 3 6, 4 2, 4 8, 5 4, a n d 
6 0 ( E n d of St u d y  visit) or Earl y Ter mi nati o n Visit.  Bl o o d/ uri ne s a m ples will als o be 
c ollecte d at M o nt h 3 ( C o u ntries liste d i n A p pe n dix 4. 2 ). 
T he f oll o wi n g cli nical la b orat or y  para meters will be assesse d: 
Ser u m C he mistr y 
S o di u m Al ka li ne P h os p hatase Reti n ol bi n di n g pr otei n 
P otassi u m Gl uc ose Ga m ma gl ut a m y l tra nsferase 
C hl ori de T otal bilir u bi n C h olester ol 
Bicar b o nate T otal pr otei n Uric aci d 
Bl o o d Urea Nitr o ge n Al b u mi n T h y r oi d -sti m ulati n g h or m o ne 
Creati ni ne Gl o b uli n T otal t h y r o xi ne ( T 4) 
Calci u m I n or ga nic P h os p h or us Free T 4 
Ala ni ne 
a mi n otra nsferase ( A L T) As partate 
a mi n otra nsferase ( A S T) 
He m at ol o g y 
He m o gl o bi n ( H g b) W hite bl o o d cell c o u nt L y m p h oc y tes 
He mat ocrit Ne utr o p hils M o n oc y tes 
Re d bl o o d cell c o u nt L y m p h oc y tes E osi n o p hils 
Mea n c or p usc ular v ol u me Platelets Bas o p hils 
Mea n c or p usc ular 
he m o gl o b i n Mea n c or p usc ular 
he m o gl o bi n c o nce ntrati o n 
C ar di ac Bi o m ar kers 
N T -pr o B N P Tr o p o ni n I 
C o a g ul ati o n (t o be me as ure d i n site’s l oc al l a b or at or y) 
Pr ot hr o m bi n ti me ( P T) I nter nati o nal n or malize d rati o (I N R) 
Uri n al ysis 
p H Bl o o d (free H g b) 
Pr otei n Nitrit e
Gl uc ose Ur o bili n o ge n 
Ket o nes S pecific gra vit y
Bilir u bi n Le u k oc y te esterase 
Uri nal y sis will be a q ualitati ve deter mi nati o n b y  di pstic k at t he site.  If t he uri ne di pstic k 
de m o nstrates a p ositi ve bl o o d, pr o tei n, nitrites or le u k oc yte esterase res ult, t he s peci me n will 
be se nt t o t he Ce ntral La b orat or y  f or micr osc o pic e val uati o n.  I n t he e ve nt t hat a site is 
u na ble t o perf or m a uri ne di pstic k wit h all of t he re q uire d tests, it is acce pta ble f or t he sa m ple 
t o be se nt f or uri nal ys is i ncl u di n g a micr osc o pic e val uati o n i n place of a di pstic k.  T his 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 5 6 testi n g ca n be perf or me d at eit her t he ce ntral or l ocal la b orat or y .  At mi ni m u m, t his testi n g 
s h o ul d i ncl u de p H, pr otei n, gl uc ose, ket o nes, bilir u bi n, bl o o d (free H g b), nitrite, le u k oc y te 
esterase, ur o bili n o ge n, a n d s pecific gra vit y .  If t he testi n g ret ur ns a n a b n or mal res ult, 
a d diti o nal testi n g s h o ul d be perf or me d as dee me d necessar y  acc or di n g t o t he cli nical 
j u d g me nt of t he i n vesti gat or. 
S pecificati o ns f or sa m ple c olle cti o n are pr o vi de d i n t he st u d y  la b orat or y  ma n ual. 
7. 2. Pre g n a nc y Testi n g 
F or fe male s u bjects of c hil d beari n g p ote ntial, a uri ne pre g na nc y  test, wit h se nsiti vit y  of at 
least 2 5 mI U/ m L , will be perf or me d, bef ore i n vesti gati o nal pr o d uct a d mi nistrati o n at t he 
Scre e ni n g visit, at e ver y  cli nic visit, a n d at t he E n d of St u d y  or earl y ter mi nati o n visit. A 
pre g n a ncy test will als o be perf or me d at M o nt h 3 ( C o u ntries liste d i n A p pe n dix 4. 2 ).   A 
ne gati ve pre g na nc y  res ult is re q uire d bef ore t he s u bject ma y  recei ve t he i n vesti gati o nal 
pr o d u ct.  Pre g na nc y  tests will als o be d o ne w he ne ver 1 me nstr ual c y cle is misse d d uri n g t he 
acti ve treat me nt peri o d ( or w he n p ote ntial pre g na nc y  is ot her wise s us pecte d), a n d re peate d at 
all st u d y  visits a n d at t he e n d of t he st u d y t o c o nfi r m t he s u bject has n ot bec o me pre g na nt 
d uri n g t he st u d y.  Pre g na nc y tests ma y als o be re peate d as per re q uest of i nstit uti o nal re vie w 
b oar ds (I R Bs)/et hics c o m mittees ( E Cs) or if re q uire d b y  l ocal re g ulati o ns. 
I n t he case of a p osit i ve c o nfir me d pre g na nc y ,t he s u bject will be w it h dra w n fr o m 
a d mi nistrati o n of i n vesti gati o nal pr o d uct a n d fr o m t he st u d y .
7. 3. C o ntr ace pti o n C hec k 
F or fe male s u bjects w h o, i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or, are bi ol o gicall y ca pa ble of ha vi n g 
c hil dre n a n d are s e x uall y acti ve; at eac h tele p h o ne a n d cli nic v isit, disc uss wit h t he s u bject 
t he nee d t o use hi g hl y effecti ve c o ntrace pti o n c o nsiste ntl y  a n d c orrectl y , i nstr uct t he s u bject 
t o call i m me diatel y  if a selecte d birt h c o ntr ol met h o d is disc o nti n ue d or if pre g na n c y  is 
k n o w n or s us pecte d a n d d oc u me nt s uc h c o n versati o n i n t he case re p ort f or m.  S u bjects will 
be i nstr ucte d t o c o nti n ue use of birt h c o ntr ol f or at least [ADDRESS_733933] u d y  tele p h o ne call will be as ke d t o c o nfir m pre g na nc y  stat us. 
7. 4. Ot her Assess me nts 
7. 4. 1. Ne w Y or k He art Ass oci ati o n Cl assific ati o n 
S u bjects will be e val uate d usi n g t he Ne w Y or k Heart Ass ociati o n ( N Y H A) classificati o n 
(A p pe n di x 3) at t he Scree ni n g visit a n d at M o nt h 6, 1 2, 1 8, 2 4, 3 0, 3 6, 4 2, 4 8, 5 4, 6 0 ( or 
Earl y St u d y Disc o nti n uati o n visit).  N Y H A will als o be ev al u ate d at M o nt h 3 ( C o u ntries 
liste d i n A p pe n dix 4. 2 ). 
Ne w Y or k Heart Ass ociati o n ( N Y H A) Classificati o n: 
Cl a ss I: S u bjects wit h car diac disease b ut wit h o ut res ulti n g li mitati o ns of p h y sical acti vit y .  
Or di nar y  p h y sical acti vit y  d oes n ot ca use u n d ue fati g ue, pal pi[INVESTIGATOR_32455] o n, d y s p nea, or a n gi nal 
pai n. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 5 7 Cl ass II: S u bjects wi t h car diac disease res ulti n g i n sli g ht li mitat i o n of p h ysical acti vit y .  
T he y  are c o mf orta ble at rest.  Or di nar y  p h y sical acti vit y  res ults i n fati g ue, pal pi[INVESTIGATOR_32455] o n, 
d y s p nea, or a n gi na pai n. 
Cl ass III: S u bjects wit h car diac disease res ulti n g i n mar ke d li mita ti o n of p h y sical acti vit y .  
T he y  are c o mf orta b le at rest.  Less t ha n or di nar y  p h y sical acti vit y  ca uses fati g ue, pal pi[INVESTIGATOR_32455] o n, 
d y s p nea, or a n gi nal pai n. 
Cl ass I V: S u bjects wit h car diac disease res ulti n g i n i na bilit y  t o carr y  o n a n y  p h y sical acti vit y  
wit h o ut disc o mf ort.  S y m pt o ms of car diac i ns ufficie nc y or of t he a n gi nal s y n dr o me ma y  be 
prese nt e ve n at rest.  If a n y  p h y sical acti vit y  is u n derta ke n, disc o mf ort is i ncrease d. 
7. 4. 2. K a ns as Cit y C ar di o m y o p at h y Q uesti o n n aire 
T he Ka nsas Cit y Car di o m y o pat h y Q uesti o n naire ( K C C Q) ( Gree n 2 0 0 0) 3is a [ADDRESS_733934] of t hese s y m pt o ms , a n d healt h -relate d 
q ualit y  of life.  Res p o nse o pti o ns var y  b y  q uesti o n.  Sc ori n g y iel ds sc ores f or 8 d o mai ns 
( P h y sical li mitati o n, S y m pt o m sta bilit y , S y m pt o ms fre q ue nc y , S y m pt o m b ur de n, T otal 
s y m pt o m, Self efficac y , S ocial li mitati o n, a n d Q ualit y  of life ) a n d Cli nical s u m mar y sc ore, as 
well as a n O verall S u m mar y  sc ore.  D o mai n sc ores are tra nsf or me d t o a 0 t o 1 0 0 ra n ge; 
hi g her sc ores i n dicate better healt h stat us.  It ta kes a p pr o xi matel y  [ADDRESS_733935] t o 
c o m plet e t he K C C Q. 
S u bjects will c o m ple te t he K C C Q at t he Scree ni n g visit a n d at M o nt hs 6, 1 2, 1 8, 2 4, 3 0, 3 6, 
4 2, 4 8, 5 4, a n d 6 0 ( or Earl y  St u d y  Disc o nti n uati o n) as liste d i n t he Sc he d ule of Ac ti vities .  
S u bjects will als o c o m plete K C C Q at M o nt h 3 ( C o u ntries liste d i n A p pe n dix 4. 2 ). 
St u d y  sites will be pr o vi de d wit h a n a p pr o ve d tra nslate d versi o n of t he K C C Q.  T he K C C Q 
ca n be f o u n d i n A p pe n di x 2.
7. 4. 3. B o d y M ass I n de x/ M o difie d B o d y M ass I n de x 
Tra nst h y reti n, i n t he m o n o meric f or m, ca n e nter car diac a n d ne ural tiss ues.  As part of t he 
p ol y ne ur o pat h y , T T R ca n ca use se vere gastr oi ntesti nal pr o ble ms res ulti n g i n wasti n g.  A 
mea ns of deter mi ni n g if t here is gastr oi ntesti nal i n v ol ve me nt i n s u bjec ts is t o calc ulate t he 
m o difie d B o d y Mass I n de x ( m B MI).  B o d y M ass I n de x ( B MI) is calc ulate d as wei g ht 
( k g)/[ hei g ht ( meters)] 2.  T he m B MI is calc ulate d b y  m ulti pl y i n g B M I b y s er u m al b u mi n 
c o nce ntrati o n ( g/ L). 
7. 4. 4. T esti n g f or Li g ht C h ai n A m yl oi d 
S pecificati o ns f or testi n g sa m ples are pr o vi de d i n t he st u d y  la b orat or y  ma n ual.  El derl y 
s u bjects wit h re d uce d re nal f u ncti o n ma y  e x perie nce ele vati o ns i n le vels of free ka p pa li g ht 
c hai ns a n d free la m b da li g ht c hai ns wit h n o c ha n ge i n t he ka p pa/la m b da rati o.  S u bjects w it h 
ele vate d ser u m/ uri ne le vels of free ka p pa li g ht c hai n, free la m b da li g ht c hai n a n d a free 
ka p pa/la m b da rati o i n dicati ve of li g ht c hai n a m yl oi d osis ( M G U S) will re q uire c o nfir mat or y  0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733936] oc he mistr y  or sci nti gra p h y  [ See Secti o n 4. 1. 2 ], car diac or n o n - car diac tiss ue will 
be bi o psie d a n d teste d b y t he i n vesti gati o nal site as per t he site’s sta n dar d of care a n d 
eval uate d wit h C o n g o re d stai n or alcia n bl ue s tai n. 
Stai ne d tis s ue will be vie we d u n der p olarize d li g ht use d t o de m o nstrate a m yl oi d 
c haracteristic ‘a p ple -gree n’ birefri n ge nce.  F or s u bjects wit h o ut i de ntificati o n of a T T R 
varia nt a n d de m o nstrati o n of a m y l o i d de p ositi o n w h o ma y  ha ve a dia g n osis of wil d -t y pe 
A T T R - C M, a n al ys is will be perf or me d t o c o nfir m t he prec urs or pr otei n basis f or a m yl oi d 
de p ositi o n, b y  eit her: mass s pectr o metr y , i m m u n o hist oc he mistr y or sci nti gra p h y  [see 
Secti o n 4. 1. 2 ]. 
7. 4. 6. T T R Ge n ot y pi n g 
F or C o h ort B o nl y:  S u bjects wit h a d oc u me nte d pri or ge n ot y pi n g a n d t he ori gi nal la b orat or y  
res ult or c o p y f or s o urce d oc u me ntati o n will n ot re q uire a d diti o nal ge n ot y p i n g.  S u bjects 
wit h o ut pri or ge n ot y pi n g will re q uire c ollecti o n of a bl o o d sa m ple f or T T R ge n ot y p e testi n g.  
T he sa m ple will be se nt t o a refere nce la b orat or y  f or c o m plete ge n o mic se q ue nci n g. 
C o m plete i nf or mati o n o n sa m ple c ollecti o n, st ora ge, a n d sa m ple tra ns p ort f or ge n ot y pe 
c o nfir mati o n are detaile d i n a se parate la b orat or y  ma n ual. 
7. 5. B a n ke d Bi os peci me ns 
F or C o h ort B o nl y:  Ba n ke d bi os peci me ns will be c ollecte d fr o m s u bjects f or e x pl orat or y  
researc h relati n g t o t he dr u g res p o nse.  T hese c ollecti o ns are n ot t y pi[INVESTIGATOR_1306] y ass ociate d wit h a 
pla n ne d assess me nt descri be d i n t he pr ot oc ol .  T he y  will be ha n dle d i n a ma n ner t hat pr otects 
eac h s u bject’s pri vac y  a n d c o nfi de ntialit y .  Ba n ke d bi os peci me ns will be assi g ne d t he 
s u bject’s st u d y  i de ntificati o n c o de (I D) at t he site.  T he data ge nerate d fr o m t hese ba n ke d 
bi os peci me ns will als o be i n de xe d b y  t his I D.  Bi os peci me ns will be ke pt u ntil destr ucti o n i n 
facilities wit h access li mite d t o a ut h orize d pers o n nel, a n d bi os peci me n -deri ve d data will be 
st ore d o n pass w or d -pr otecte d c o m p uter s ys te ms.  T he ke y bet wee n t he s u bject’s I D a n d t he 
s u bject’s di rect pers o nall y  i de ntif y i n g i nf or mati o n (e g, na me, a d dress) will be hel d at t he 
st u d y  site.  Bi os peci me ns will be use d o nl y  f or t he p ur p oses descri be d i n t he pr ot oc ol a n d 
i nf or me d c o nse nt d oc u me nt; a n y  ot her u ses re q uire a d diti o nal et hical a p pr o val.  U nles s a 
ti me li mitati o n is re q uire d b y  l ocal re g ulati o ns or et hical re q uire me nts, bi os peci me ns will be 
st ore d f or ma n y ye ars ( n o ti me li mit) t o all o w f or researc h i n t he f ut ure, i ncl u di n g researc h 
c o n d ucte d d uri n g t he le n gt h y dr u g -de vel o p me nt pr ocess a n d als o p ost mar keti n g researc h.  
S u bjects ma y  wit h dra w t heir c o nse nt f or t he use of t heir ba n ke d bi os peci me ns at a n y  ti me b y  
ma ki n g a re q uest t o t he i n vesti gat or; i n t his case, a n y  re mai ni n g bi os peci me ns will be 
destr oye d, b ut data alrea d y  ge nerate d fr o m t he bi os p eci me ns will c o nti n ue t o be a vaila ble t o 
pr otect t he i nte grit y of e xisti n g a nal ys es. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 5 9 U nless pr o hi bite d b y  l ocal re g ulati o ns or et hics c o m mittee decisi o n, a 4-m L bl o o d ge n o mic 
ba n ke d bi os peci me n Pre p D 1 ( di p ot assi u m e detic aci d [et h yle ne di a mi netetr a acetic aci d] 
[ K 2E D T A] w h ole - bl o o d c ollecti o n o pti mize d f or D N A a n al ysis) will be c ollecte d at t he 
ti me s pecifie d i n t he Sc he d ule of Acti vities /St u d y Pr oce d u res secti o n of t he pr ot oc ol t o be 
retai ne d f o r p ote ntial p har mac o ge n o mic/ ge n o mic/ bi o mar ker a nal ys es relate d t o dr u g 
res p o nse.  F or e xa m ple, p utati ve safet y bi o mar kers, dr u g -meta b olizi n g e nz y me ge nes, 
dr u g -tra ns p ort pr otei n ge nes, or ge nes t h o u g ht t o be re late d t o t he mec ha nis m of dr u g acti o n 
ma y  be e xa mi ne d.  T he pri mar y  p ur p ose is t o e xa mi ne D N A; h o we ver, t he bi os peci me n ma y  
als o be use d t o st u d y  ot her m olec ules (e g, R N A, pr otei ns, a n d meta b olites). 
F or c o u ntries liste d i n A p pe n dix 6, a d diti o n al b a nke d bi o m arker s a m ples ( b l o o d: Pre p R 1 
o pti mize d f or R N A ;Pre p B 1o pti mize d f or pl as m a ;uri ne: Pre p M 2) will be c o llecte d at 
Scree ni n g ( D ay 0) f or p ote nti al rese arc h rel ate d t o t he dise ase u n der st u dy .See A p pe n dix 7
f or det ails. 
T he ba n ke d bi os peci me n s will be c ollecte d fr o m s u bjects i n u nless pr o hi bite d b y  l ocal 
re g ulati o ns or I R B/ E C decisi o n .  I t is p ossi ble t hat t he use of t hese bi os peci me ns ma y  res ult 
i n c o m merciall y via ble pr o d ucts.  S u bjects will be a d vise d i n t he i nf or me d c o nse nt d oc u me nt 
t hat t he y  will n o t be c o m pe nsate d i n t his e ve nt. 
7. 5. 1. A d diti o n al Rese arc h 
U nless pr o hi bite d b y  l ocal re g ulati o ns or I R B/ E C decisi o n, s u bjects will be as ke d t o i n dicate 
o n t he c o nse nt f or m w het her t he y  will all o w ba n ke d bi os peci me ns t o als o be use d t o desi g n 
a n d c o n d u ct researc h i n or der t o gai n a f urt her u n dersta n di n g of ot her diseases a n d t o 
a d va nce scie nce, i ncl u di n g de vel o p me nt of ot her me dici nes f or patie nts. 
S u bjects nee d n ot pr o vi de a d diti o nal bi os peci me ns f or t he uses descri be d i n t his secti o n; t he 
bi os peci me ns s pecifie d i n t he Ba n ke d Bi os peci me ns secti o n will be use d.  S u bjects ma y  still 
partici pate i n t he st u d y if t he y elect n ot t o all o w t heir ba n ke d bi os peci me ns t o be use d f or t he 
a d diti o nal p ur p oses descri be d i n t his secti o n. 
7. 6. C ar di a c Bi o m ar ker s N -Ter mi n al Pr o -H or m o ne Br ai n N atri uretic Pe pti de 
(N T -pr o B N P) a n d Tr o p o ni n I 
After Pr ot oc ol A me n d me nt 4, bl o o d sa m ple f or car diac bi o mar kers ( N T -pr o B N P a n d 
Tr o p o ni n I) will be c ollecte d at Scree ni n g, a n d eac h cli nic visit at M o nt hs 6, 1 2, 1 8, 2 4, 3 0, 
3 6, 4 2, 4 8, 5 4, a n d 6 0 ( E n d of St u d y  visit) or Earl y  Ter mi nati o n Visit.  S pecificati o ns f or 
sa m ple c ollecti o n ca n be f o u n d i n t he st u d y  la b orat or y  ma n ual.  N T -pr o B N P a n d Tr o p o ni n I 
will als o be c ollecte d at M o nt h 3 ( C o u ntries liste d i n A p pe n dix 4. 2 ). 
8. A D V E R S E E V E N T R E P O R T I N G 
8. 1. A d verse E ve nts 
All o bser ve d or v ol u nteere d A Es re gar dless of treat me nt gr o u p or s us pecte d ca usal 
relati o ns hi p t o t he i n vesti gati o nal pr o d uct will be re p orte d as descri be d i n t he f oll o wi n g 
secti o ns. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733937] p urs ue a n d o btai n i nf or mati o n a de q uate b ot h t o deter mi ne 
t he o utc o me of t he A E a n d t o assess w het her it meets t he criteria f or classificati o n as a 
seri o us a d verse e ve nt ( S A E) re q uiri n g i m me diate n otificati o n t o [COMPANY_007] or its desi g nate d 
re prese ntati ve.  F or all A Es, s ufficie nt i nf or mati o n s h o ul d be o btai ne d b y  t he i n vesti gat or t o 
deter mi ne t he ca usalit y  of t he A E.  T he i n vesti gat or is re q uire d t o assess ca usalit y .  
F oll o w -u p b y  t he i n vesti gat or ma y  be re q uire d u ntil t he e ve nt or its se q u elae res ol ve or 
sta bilize at a le vel acce pta ble t o t he i n vesti gat or, a n d [COMPANY_007] c o nc urs wit h t hat assess me nt. 
As part of o n g oi n g safet y re vie ws c o n d ucte d b y t he s p o ns or, a n y n o nseri o us A E t hat is 
deter mi ne d b y t he s p o ns or t o be seri o us will be r e p orte d b y  t he s p o ns or as a n S A E.  T o assist 
i n t he deter mi nati o n of case seri o us ness, f urt her i nf or mati o n ma y  be re q ueste d fr o m t he 
i n vesti gat or t o pr o vi de clarit y  a n d u n dersta n di n g of t he e ve nt i n t he c o nte xt of t he cli nical 
st u d y .
8. 2. Re p orti n g Peri o d 
F or S A Es, t he ac ti ve re p orti n g peri o d t o [COMPANY_007] or its desi g nate d re prese ntati ve be gi ns fr o m 
t he ti me t hat t he s u bject pr o vi des i nf or me d c o nse nt, w hic h is o btai ne d pri or t o t he s u bject’s 
partici pati o n i n t he st u d y , ie, pri or t o u n der g oi n g a n y  st u d y -relate d pr oc e d ure a n d/ o r 
recei vi n g i n vesti gati o nal pr o d uct, t hr o u g h a n d i ncl u di n g [ADDRESS_733938] after t he acti ve 
re p orti n g peri o d has e n de d s h o ul d be re p orte d t o t he s p o ns or if t he i n ve sti gat or bec o mes 
a ware of t he m; at a mi ni m u m, all S A Es t hat t he i n vesti gat or belie ves ha ve at least a 
reas o na ble p ossi bilit y  of bei n g relate d t o i n vesti gati o nal pr o d uct are t o be re p orte d t o t he 
s p o ns or. 
A Es (seri o us a n d n o n -seri o us) s h o ul d be r ec or de d o n t he case re p ort f or m ( C R F) fr o m t he 
ti me t he s u bject has ta ke n at least [ADDRESS_733939]’s last 
visit. 
8. 3. Defi niti o n of a n A d verse E ve nt 
A n A E is a n y u nt o war d me dical occ urre nce i n a cli nical i n vesti gati o n s u bject a d mi nis tere d a 
pr o d uct or me dical de vice; t he e ve nt nee d n ot necessaril y  ha ve a ca usal relati o ns hi p wit h t he 
treat me nt or usa ge.  E xa m ples of A Es i ncl u de b ut are n ot li mite d t o: 
A b n or mal test fi n di n gs; 
Cli nicall y  si g nifica nt s y m pt o ms a n d si g ns; 
C ha n ge s i n p h y sic al e xa mi nati o n fi n di n gs; 
H y perse nsiti vit y ;
Pr o gressi o n/ w orse ni n g of u n derl yi n g disease; 
Dr u g a b use; 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 6 1 Dr u g de pe n de nc y .
A d diti o nall y , t he y  ma y  i ncl u de t he si g ns or s y m pt o ms r es ulti n g fr o m: 
Dr u g o ver d ose; 
Dr u g wit h dra wal; 
Dr u g mis use; 
Dr u g i nterac ti o ns; 
E xtr a vasati o n; 
E x p os ure d uri n g pre g na nc y  ( E D P); 
E x p os ure via breastfee di n g; 
Me dicati o n err or; 
Occ u pati o nal e x p os ure. 
8. 4. Me dic ati o n Err ors 
Me dicati o n err ors ma y  res ult, i n t his st u d y , fr o m t he a d mi nistrati o n or c o ns u m pti o n of t he 
wr o n g pr o d uct, b y t he w r o n g s u bjec t, at t he wr o n g ti me, or at t he wr o n g d osa ge stre n gt h.  
S uc h me dicati o n err ors occ urri n g t o a st u d y partici pa nt are t o be ca pt ure d o n t he me dicati o n 
err or C R F, w hic h is a s pecific versi o n of t he A E pa ge, a n d o n t he S A E f or m w he n 
a p pr o priate.  I n t he e ve nt of me dicati o n d osi n g err or, t he s p o ns or s h o ul d be n otifie d 
i m me diatel y .
Me dicati o n err ors are re p orta ble irres pecti ve of t he prese nce of a n ass ociate d A E/ S A E, 
i ncl u di n g: 
Me dicati o n err ors i n v ol vi n g s u bject e x p os ure t o t he i n vesti gati o nal pr o d uct ;
P ote ntial me dicati o n err ors or uses o utsi de of w hat is f oresee n i n t he pr ot oc ol t hat d o 
or d o n ot i n v ol ve t he partici pati n g s u bject. 
W het her or n ot t he me dicati o n err or is acc o m pa nie d b y  a n A E, as deter mi ne d b y  t he 
i n vesti gat or, t he me dicati o n err or is c a pt ure d o n t he me dicati o n err or versi o n of t he A E pa ge 
a n d, if a p plica ble, a n y ass ociate d A E(s) are ca pt ure d o n a n A E C R F pa ge. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733940] fi n di n g s h o ul d be re p orte d as 
a n A E are as f oll o ws: 
Test res ult is ass ociate d wit h acc o m pa n yi n g s y m pt o ms; a n d/ or 
Test res ult re q uires a d diti o nal dia g n ostic testi n g or me dical/s ur gical i nter ve nti o n; 
a n d/ or 
Test res ult lea ds t o a c ha n ge i n st u d y  d osi n g or disc o nti n uati o n fr o m t he st u d y , 
si g nifica nt a d diti o n al c o nc o mita nt dr u g treat me nt, or ot her t hera p y;  a n d/ or 
Test res ult is c o nsi dere d t o be a n A E b y t he i n vesti gat or or s p o ns or. 
Merel y re peati n g a n a b n or mal test, i n t he a bse nce of a n y of t he a b o ve c o n diti o ns, d oes n ot 
c o nstit ute a n A E.  A n y a b n or mal test re s ult t hat is deter mi ne d t o be a n err or d oes n ot re q uire 
re p orti n g as a n A E. 
8. 6. Seri o us A d verse E ve nts 
A seri o us a d verse e ve nt is a n y  u nt o war d me dical occ urre nce at a n y  d os e t hat: 
Res ults i n deat h; 
Is life -t hreate ni n g (i m me diate ris k of deat h); 
Re q u ires i n pati e nt h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_1314] o n; 
Res ults i n persiste nt or si g nifica nt disa bilit y /i nca pacit y  (s u bsta ntial disr u pti o n of t he 
a bilit y  t o c o n d uct n or mal life f u ncti o ns); 
Res ults i n c o n ge nital a n o mal y / birt h defect. 
Me d ical a n d sc ie ntific j u d g me nt is e xercise d i n deter mi ni n g w het her a n e ve nt is a n i m p orta nt 
me dical e ve nt.  A n i m p orta nt me dical e ve nt ma y  n ot be i m me diatel y  life -t hreate ni n g a n d/ or 
res ult i n deat h or h os pi[INVESTIGATOR_1314] o n.  H o we ver, if it is deter mi ne d t hat t he e ve nt ma y  je o par dize 
t he s u bject or ma y  re q uire i nter ve nti o n t o pre ve nt o ne of t he ot her A E o utc o mes, t he 
i m p orta nt me dical e ve nt s h o ul d be re p orte d as seri o us. 
E xa m ples of s uc h e v e nts are i nte nsi ve treat me nt i n a n e mer ge nc y  r o o m or at h o me f or 
aller gic br o nc h os pas m; bl o o d d y scrasias or c o n v ulsi o ns t hat d o n ot res ult i n h os pi[INVESTIGATOR_1314] o n; 
or de vel o p me nt of dr u g de pe n de nc y  or dr u g a b use. 
8. 6. 1. Pr ot oc ol -S pecifie d Seri o us A d verse E ve nts 
T here are n o pr ot oc ol -s pecifie d S A Es i n t his st u d y .  All S A Es will be re p orte d b y  t he 
i n vesti gat or as descri be d i n pre vi o us secti o ns, a n d will be ha n dle d as S A Es i n t he safet y 
data base (see t he secti o n o n Seri o us A d verse E ve nt Re p orti n g Re q uire me nts ). 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733941] u g -I n d uce d Li ver I nj ur y 
A b n or mal val u es i n as par tate a mi n otra nsferase ( A S T) a n d/ or ala ni ne a mi n otra nsferase ( A L T) 
le vels c o nc urre nt wit h a b n or mal ele vat i o ns i n t otal bilir u bi n le vel t hat meet t he criteria 
o utli ne d bel o w i n t he a bse nce of ot her ca uses of li ver i nj ur y  are c o nsi dere d p ote ntial c ases of 
dr u g-i n d uce d li ver i nj ur y ( p ote ntial H y ’s la w cases) a n d s h o ul d al wa y s be c o nsi dere d 
i m p orta nt me dical e ve n ts. 
T he t hres h ol d of la b orat or y  a b n or malities f or a p ote ntial case of dr u g -i n d uce d li ver i nj ur y  
de pe n ds o n t he s u bject’s i n di vi d ual baseli ne val ues a n d u n derl yi n g c o n diti o ns.  S u bjects w h o 
prese nt wit h t he f oll o wi n g la b orat or y  a b n or malities s h o ul d be e val uate d f urt her t o 
defi niti vel y  deter mi ne t he eti ol o g y  of t he a b n or mal la b orat or y val ues: 
S u bjects wit h A S T or A L T a n d t otal bilir u bi n baseli ne val ues wit hi n t he n or mal ra n ge 
w h o s u bse q ue ntl y  prese nt wit h A S T or A L T val ues 3 ti mes t he u p per li mit of 
n or mal ( × U L N) c o nc urre nt wit h a t otal bilir u bi n val ue 2 × U L N wit h n o e vi de nce 
of he m ol y sis a n d a n al kali ne p h os p hatase val ue 2× U L N or n ot a vai la ble; 
F or s u bjects wit h pree xisti n g A L T O R A S T O R t otal bilir u bi n val ues a b o ve t he 
U L N, t he f oll o wi n g t hres h ol d va l ues s h o ul d be use d i n t he defi niti o n me nti o ne d 
a b o ve: 
F or s u bjects wit h pree xisti n g A S T or A L T baseli ne val ues a b o ve t he n or mal 
ra n ge: A S T o r A L T val ue s 2ti mes t he baseli ne val ues a n d 3 × U L N, or 
8 × U L N ( w hic he ver is s maller). 
C o nc urre nt wit h 
F or s u bjects wit h pree xisti n g val ues of t otal bilir u bi n a b o ve t he n or mal ra n ge: 
T otal bilir u bi n le vel i ncrease d fr o m baseli ne b y a n a m o u nt of at lea st 1 × U L N or 
if t he val ue reac hes 3 × U L N ( w hic he ver is s maller). 
T he s u bject s h o ul d ret ur n t o t he i n vesti gati o nal site a n d be e val uate d as s o o n as p ossi ble, 
prefera bl y wit hi n [ADDRESS_733942] bilir u bi n, ga m ma -gl uta m y l 
tra nsferase, pr ot hr o m bi n ti m e ( P T)/i nter nati o nal n or malize d rati o (I N R), a n d al kali ne 
p h os p hatase.  A detaile d hist or y , i ncl u di n g rele va nt i nf or mati o n, s uc h as re vie w of et ha n ol, 
aceta mi n o p he n , recreati o nal dr u g, a n d s u p ple me nt c o ns u m pti o n, fa mil y  hist or y , occ u pati o nal 
e x p os ure, se x u al hist or y , tra vel hist or y , hist or y  of c o ntact wit h a ja u n dice d pers o n, s ur ger y , 
bl o o d tra nsf usi o n, hist or y of li ver or aller gic disease, a n d w or k e x p os ure, s h o ul d be c ollecte d.  
F urt her testi n g f or ac ute he patitis A, B, or C i nfecti o n a n d li ver i ma gi n g (e g, biliar y  tract) 
ma y  be warra nte d.  All cases c o nfir me d o n re peat testi n g as meeti n g t he la b orat or y  criteria 
defi ne d a b o ve, wit h n o ot her ca use f or L F T a b n or malities i de ntifie d at t he ti me, s h o ul d be 
c o nsi dere d p ote ntial H y ’s la w cases irres pec ti ve of a va ila bilit y  of all t he res ults of t he 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 6 4 i n vesti gati o ns perf or me d t o deter mi ne eti ol o g y  of t he a b n or ma l L F Ts.  S uc h p ote ntial H y ’s 
la w cases s h o ul d be re p orte d as S A Es. 
8. 7. H os pit aliz ati o n 
H os pi[INVESTIGATOR_1314] o n is defi ne d as a n y i nitial a d missi o n (e ve n less t h a n 2 4 h o urs ) i n a h os pi[INVESTIGATOR_6879] 
e q ui vale nt healt hcare facilit y  or a n y  pr ol o n gati o n of a n e xisti n g a d missi o n.  A d missi o n als o 
i ncl u des tra nsfer wit hi n t he h os pi[INVESTIGATOR_307] t o a n ac ute/i nte nsi ve care u nit (e g, fr o m t he ps y c hiatric 
wi n g t o a me dical fl o or, me dical fl o o r t o a c or o nar y  care u nit, or ne ur ol o gical fl o or t o a 
t u berc ul osis u nit).  A n e mer ge nc y  r o o m visit d oes n ot necessaril y c o nstit ute a h os pi[INVESTIGATOR_1314] o n; 
h o we ver, t he e ve nt lea di n g t o t he e mer ge nc y  r o o m visit s h o ul d be assesse d f or me dical 
i m p orta nce. 
H os pi[INVESTIGATOR_464494] o n d oe s n ot i ncl u de t he f oll o wi n g: 
Re ha bilitati o n facilities; 
H os pi[INVESTIGATOR_4593]; 
Res pi[INVESTIGATOR_4594] (e g, care gi ver relief); 
S kille d n ursi n g facilities; 
N ursi n g h o mes; 
Sa me -d a y  s ur geries (as o ut patie nt/sa me -d a y /a m b ulat or y  pr oce d ures). 
H os pi[INVESTIGATOR_1314] o n or pr o l o n gati o n o f h os pi[INVESTIGATOR_1314] o n i n t he a bse nce of a preci pi[INVESTIGATOR_32455] n g, cli nical 
A E is n ot i n itself a n S A E.  E xa m ples i ncl u de: 
A d missi o n f or treat me nt of a pree xisti n g c o n diti o n n ot ass ociate d wit h t he 
de vel o p me nt of a ne w A E or wit h a w orse ni n g of t he pree xisti n g c o n diti o n (e g, f or 
w or k u p of persiste nt pretreat me nt la b orat or y  a b n or malit y ); 
S ocial a d missi o n (e g, s u bject has n o place t o slee p); 
A d mi nistrati ve a d missi o n (e g, f or ye arl y p h ys ical e xa mi nati o n); 
Pr ot oc ol -s pecifie d a d missi o n d uri n g a st u d y (e g, f or a pr oce d ure re q uire d b y  t he st u d y  
pr ot oc ol); 
O pti o nal a d missi o n n ot ass ociate d wit h a preci pi[INVESTIGATOR_32455] n g cli nical A E (e g, f or electi ve 
c os metic s ur ger y ); 
H os pi[INVESTIGATOR_1314] o n f or o bser vati o n wit h o ut a me dical A E; 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 6 5 Pre pla n ne d treat me nts or s ur gical pr oce d ures.  T hese s h o u l d be n ote d i n t he baseli ne 
d oc u me ntati o n f or t he e ntire pr ot oc ol a n d/ or f or t he i n di vi d ual s u bject. 
Dia g n ostic a n d t hera pe utic n o ni n vasi ve a n d i n vasi ve pr oce d ures, s uc h as s ur ger y , s h o ul d n ot 
be re p orte d as A Es.  H o we ver, t he me dical c o n diti o n f or w hic h t he pr oce d ur e was perf or me d 
s h o ul d be re p orte d if it meets t he defi niti o n of a n A E.  F or e xa m ple, a n ac ute a p pe n dicitis 
t hat be gi ns d uri n g t he A E re p orti n g peri o d s h o ul d be re p orte d as t he A E, a n d t he res ulti n g 
a p pe n dect o m y  s h o ul d be rec or de d as treat me nt o f t he A E. 
8. 8. S e verit y Assess me nt 
If re q uire d o n t he A E C R Fs, t he i n vesti gat or will use t he a djecti ves M I L D, M O D E R A T E, 
or S E V E R E t o descri be t he ma xi m u m i nte nsit y  of t he A E.  F or p ur p oses of c o nsiste nc y , 
t hese i nte nsit y  gra des are defi ne d as f oll o ws: 
MI L D D oe s n ot i nter fere wit h s u bject's us ual f u ncti o n. 
M O D E R A T E I nterferes t o s o me e xte nt wit h s u bject's us ual f u ncti o n. 
S E V E R E I nterferes si g nifica ntl y wit h s u bject's us ual f u ncti o n. 
N ote t he disti ncti o n bet wee n t he se verit y a n d t he seri o us ness of a n A E.  A se vere e ve nt is n ot 
necessaril y  a n S A E.  F or e xa m ple, a hea dac he ma y  be se vere (i nterferes si g nifica ntl y  wit h 
t he s u bject's us ual f u ncti o n) b ut w o ul d n ot be classifie d as seri o us u nless it met o ne of t he 
criteria f or S A Es, liste d a b o ve. 
8. 9. C a us alit y Assess me nt 
T he i n vesti gat or’s assess me nt of ca usalit y m ust be pr o vi de d f or all A Es (seri o us a n d 
n o n -seri o us); t he i n vesti gat or m ust rec or d t he ca usal relati o ns hi p i n t he C R F, as a p pr o priate, 
a n d re p ort s uc h a n assess me nt i n acc or da nce wit h t he S A E re p orti n g re q uire me nts if 
a p pl ica ble.  A n i n vesti gat or’s ca usalit y  assess me nt is t he deter mi nati o n of w het h er t here 
e xists a reas o na ble p ossi bilit y  t hat t he i n vesti gati o nal pr o d uct ca use d or c o ntri b ute d t o a n 
A E; ge nerall y  t he facts (e vi de nce) or ar g u me nts t o s u g gest a ca usa l relati o ns hi p s h o ul d be 
pr o vi de d.  If t he i n vesti gat or d oes n ot k n o w w het her or n ot t he i n vesti gati o nal pr o d uct ca use d 
t he e ve nt, t he n t he e ve nt will be ha n dle d as “relate d t o i n vesti gati o nal pr o d uct” f or re p orti n g 
p ur p oses, as defi ne d b y t he s p o ns or (see Re p orti n g Re q uire me nts ).  If t he i n vesti gat or's 
ca usalit y  assess me nt is " u n k n o w n b ut n ot relate d t o i n vesti gati o nal pr o d uct," t his s h o ul d be 
clearl y d oc u me nte d o n st u d y  rec or ds. 
I n a d diti o n, if t he i n vesti gat or deter mi nes t hat a n S A E is as s ociate d wit h st u d y  pr oce d ures, 
t he i n vesti gat or m ust rec or d t his ca usal relati o ns hi p i n t he s o urce d oc u me nts a n d C R F, as 
a p pr o priate, a n d re p ort s uc h a n assess me nt i n acc or da nce wit h t he S A E re p orti n g 
re q uire me nts, if a p plica ble. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 6 6 8. 1 0. E x p os ure D uri n g Pre g n a n c y 
F or b ot h u na p pr o ve d/ u nlice nse d pr o d ucts a n d f or mar kete d pr o d ucts, a n e x p os ure d uri n g 
pre g na nc y  occ urs if: 
1. A fe male bec o mes, or is f o u n d t o be, pre g na nt eit her w hile recei vi n g or ha vi n g bee n 
e x p ose d (e g, beca use of treat me nt or e n vir o n me ntal e x p os ure) t o t he i n vesti gati o nal 
pr o d uct; or t he fe male bec o mes or is f o u n d t o be pre g na nt after disc o nti n ui n g a n d/ or 
bei n g e x p ose d t o t he i n vesti gati o nal pr o d uct; 
A n e xa m ple of e n vir o n me ntal e x p os ure w o ul d be a case i n v ol vi n g direct c o ntact wit h 
a [COMPANY_007] p r o d uct i n apre g na nt w o ma n (e g, a n urse re p orts t hat s he is pre g na nt a n d has 
bee n e x p ose d t o c he m ot hera pe utic pr o d ucts). 
2. A male has bee n e x p ose d (e g , beca use of treat me nt or e n vir o n me ntal e x p os ure) t o t he 
i n vesti gati o nal pr o d uct pri or t o or ar o u n d t he ti me of c o nce pt i o n a n d/ or is e x p ose d 
d uri n g his part ner’s pre g na nc y . 
If a st u d y s u bject or st u d y s u bject’s part ner bec o mes or is f o u n d t o be pre g na nt d uri n g t he 
st u d y  s u bject’s treat me nt wit h t he i n vesti gati o nal pr o d uct, t he i n vesti gat or m ust s u b mit t his 
i nf o r mati o n t o t he [COMPANY_007] dr u g safet y u nit o n a n S A E re p ort f or m a n d a n E D P s u p ple me ntal 
f or m, re gar dless of w het her a n S A E has occ urre d .  I n  a d diti o n, t he i n vesti gat or m ust s u b mit 
i nf or mati o n re gar di n g e n vir o n me ntal e x p os ure t o a [COMPANY_007] pr o d uct i n a pre g na nt w o ma n (e g, a 
s u bject re p orts t hat s he is pre g na nt a n d has bee n e x p ose d t o a c y t ot o xic pr o d uct b y  i n halati o n 
or s pi[INVESTIGATOR_271542]) usi n g t he E D P s u p ple me ntal f or m.  T his m ust be d o ne irres pecti ve of w het her a n 
A E has occ urre d a n d wit hi n 2 4 h o urs of a ware ness of t he e x p os ure.  T he i nf or mati o n 
s u b mitte d s h o ul d i ncl u de t he a ntici pate d date of deli ver y  (see bel o w f or i nf or mati o n relate d 
t o ter mi nati o n of pre g na nc y ). 
F oll o w -u p is c o n d ucte d t o o btai n ge neral i nf or mati o n o n t he pre g na nc y  a n d its o utc o me f or 
all E D P re p orts wit h a n u n k n o w n o utc o me.  T he i n vesti gat or will f oll o w t he pre g na nc y  u ntil 
c o m pleti o n ( or u ntil pre g na nc y  ter mi nati o n) a n d n otif y  [COMPANY_007] of t he o utc o me as a f oll o w - u p 
t o t he i nitial E D P s u p ple me ntal f or m.  I n t he case of a li ve birt h, t he str uct ural i nte gr it y  of t he 
ne o nate ca n be assesse d at t he ti me of birt h.  I n t he e ve nt of a ter mi nati o n, t he reas o n(s) f or 
ter mi nati o n s h o ul d be s pecifie d a n d, if c li nicall y p ossi ble, t he str uct ural i nte grit y of t he 
ter mi nate d fet us s h o ul d be assesse d b y gr oss vis ual i ns p ecti o n ( u nl ess pre pr oce d ure test 
fi n di n gs are c o ncl usi ve f or a c o n ge nital a n o mal y a n d t he fi n di n gs are re p orte d). 
If t he o utc o me of t he pre g na nc y  me ets t he criteria f or a n S A E (ie, ect o pic pre g na nc y , 
s p o nta ne o us a b orti o n, i ntra uteri ne fetal de mise, ne o nata l deat h, or c o n ge nital a n o mal y [i n a 
li ve -b or n ba b y, a ter mi nate d fet us, a n i ntra uteri ne fetal de mise, or a ne o natal deat h]), t he 
i n vesti gat or s h o ul d f oll o w t he pr oce d ures f or re p orti n g S A Es. 
A d diti o nal i nf or mati o n a b o ut pre g na nc y  o utc o mes t hat are re p orte d as S A Es f oll o ws: 
S p o nta ne o us a b orti o n i ncl u des miscarria ge a n d misse d a b orti o n; 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 6 7 Ne o natal deat hs t hat occ ur wit hi n [ADDRESS_733943]. 
A d diti o nal i nf or mat i o n re gar di n g t he E D P ma y  be re q ueste d b y  t he i n vesti gat or.  F urt her 
f oll o w - u p of birt h o utc o mes will be ha n dle d o n a c ase -b y -case basis (e g, f oll o w - u p o n 
preter m i nfa nts t o i de ntif y de vel o p me ntal dela y s).  I n t he case of pater nal e x p os ure, t he 
i n vesti gat o r will pr o vi de t he st u d y  s u bject wit h t he Pre g na nt Part ner Release of I nf or mati o n 
F or m t o deli ver t o his par t ner.  T he i n vesti gat or m ust d oc u me nt i n t he s o urce d oc u me nts t hat 
t he s u bject was gi ve n t he Pre g na nt Part ner Release of I nf or mati o n F or m t o pr o vi de t o his 
part ner. 
8. 1 1. Occ u p ati o n al E x p os ure 
A n occ u pati o nal e x p os ure occ urs w he n, d uri n g t he perf or ma nce of j o b d uties, a pe rs o n 
( w het her a healt hcare pr ofessi o nal or ot her wise) gets i n u n pla n ne d direct c o ntact wit h t he 
pr o d uct, w hic h ma y  or ma y  n ot lea d t o t he occ urre nce of a n A E. 
A n occ u pati o nal e x p os ure is re p orte d t o t he dr u g safet y u nit wit hi n 2 4 h o urs of t he 
i n vesti gat or’ s a ware ness, usi n g t he S A E re p ort f or m, re gar dless of w het her t here is a n 
ass ociate d A E/ S A E.  Si nce t he i nf or mati o n d oes n ot pertai n t o a s u bject e nr olle d i n t he st u d y , 
t he i nf or mati o n is n ot re p orte d o n a C R F; h o we ver, a c o p y  of t he c o m plete d S A E re p ort f or m 
is mai ntai ne d i n t he i n vesti gat or site file. 
8. [ADDRESS_733944] a w al D ue t o A d verse E ve nts ( See Als o t he Secti o n o n S u bject Wit h dr a w al )
Wit h dra wal d ue t o A Es s h o ul d be disti n g uis he d fr o m wit h dra wal d ue t o ot her ca us es, 
acc or di n g t o t he defi niti o n of A E n ote d earlier, a n d rec or de d o n t he a p pr o priate A E C R F 
pa ge. 
W he n a s u bject wit h dra ws beca use of a n S A E, t he S A E m ust be re p orte d i n acc or da nce wit h 
t he re p orti n g re q uire me nts defi ne d bel o w. 
8. [ADDRESS_733945] or 
le gall y  acce pta ble re prese ntati ve will be q uesti o ne d a b o ut A E s. 
8. 1 4. Re p orti n g Re q uire me nts 
Eac h A E is t o be assesse d t o deter mi ne if it meets t he criteria f or S A Es.  If a n S A E occ urs, 
e x pe dite d re p orti n g will f oll o w l ocal a n d i nter nati o nal re g ulati o ns, as a p pr o priate. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733946] be ma de 
i m me diatel y , irres pecti ve of t he e xte nt of a vaila ble A E i nf or mati o n.  T his ti me fr a me als o 
a p plies t o a d diti o nal ne w i nf or mati o n (f oll o w- u p) o n pre vi o usl y  f or war de d S A E re p orts as 
well as t o t he i nitial a n d f oll o w- u p re p orti n g of E D P, e x p os ure via breastfee di n g, a n d 
occ u pati o nal e x p os ure cases. 
I n t he rare e ve nt t hat t he i n v esti gat or d oes n ot bec o me a ware of t he occ urre nce of a n S A E 
i m me diatel y  (e g, if a n o ut patie nt st u d y  s u bject i nitiall y  see ks treat me nt else w here), t he 
i n vesti gat or is t o re p ort t he e ve nt wit hi n [ADDRESS_733947] a w are ness of t he A E. 
F or all S A Es, t he i n vesti gat or is o bli gate d t o p urs ue a n d pr o vi de i nf or mati o n t o [COMPANY_007] i n 
acc or da nce wit h t he ti me fra mes f or re p orti n g s pecifie d a b o ve.  I n a d diti o n, a n i n vesti gat or 
ma y  be re q ueste d b y  [COMPANY_007] t o o btai n s peci fic a d diti o nal f oll o w- u p i nf or mati o n i n a n 
e x pe dite d fas hi o n.  T his i nf or mati o n c ollecte d f or S A Es is m ore detaile d t ha n t hat ca pt ure d 
o n t he A E C R F.   I n ge neral, t his will i ncl u de a descri pti o n of t he A E i n s ufficie nt detail t o 
all o w f or a c o m plete me dica l assess me n t of t he case a n d i n de pe n de nt deter mi nati o n of 
p ossi ble ca usalit y .  I nf or mati o n o n ot her p ossi ble ca uses of t he e ve nt, s uc h as c o nc o mita nt 
me dicati o ns, vacci nes, a n d/ or ill nesses, m ust be pr o vi de d.  I n t he case of a s u bject deat h, a 
s u m mar y  of a vaila ble a u t o ps y  fi n di n gs m ust be s u b mitte d as s o o n as p ossi ble t o [COMPANY_007] or its 
desi g nate d re prese ntati ve. 
8. 1 4. 2. N o nseri o us A d verse E ve nt Re p orti n g Re q ui re me nts 
All A Es will be re p orte d o n t he A E pa ge(s) of t he C R F.  I t s h o ul d be n ote d t hat t he f or m f or 
c ollec ti o n of S A E i nf or mati o n is n ot t he sa me as t he A E C R F.  W here t he sa me data are 
c ollecte d, t he f or ms m ust be c o m plete d i n a c o nsiste nt ma n ner.  F or e xa m ple, t he sa me A E 
ter m s h o ul d be use d o n b ot h f or ms.  A Es s h o ul d be re p orte d usi n g c o ncise me dical 
ter mi n ol o g y  o n t h e C R Fs as well as o n t he f or m f or c ollecti o n of S A E i nf or mati o n. 
8. 1 4. 3. S p o ns or’s Re p orti n g Re q uire me nts t o Re g ul at or y A ut h orities 
A E re p orti n g, i ncl u di n g s us pecte d u ne x pecte d seri o us a d verse reacti o ns, will be carrie d o ut 
i n acc or da nce wit h a p plica ble l ocal re g u lati o ns. 
9. D A T A A N A L Y SI S/ S T A TI S TI C A L M E T H O D S 
Detaile d met h o d ol o g y  f or s u m mar y  a n d statistical a nal ys es of t he data c ollecte d i n t his st u d y  
will be d oc u me nte d i n a statistical a nal y sis pla n ( S A P), w hic h will be mai ntai ne d b y  t he 
s p o ns or.  T his d oc u me nt ma y  m o dif y  t he pla ns o utli ne d i n t he pr ot oc ol; h o we ver, a n y maj or 
m o dificati o ns of t he pri mar y  e n d p oi nt defi niti o n a n d/ or its a nal y sis will als o be reflecte d i n a 
pr ot oc ol a me n d me nt. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 6 9 F or C o h ort A, a nal ys es will be perf or me d usi n g tafa mi dis/tafa mi dis a n d place b o /tafa mi dis 
treat me nt gr o u ps.  S u bjects ra n d o mize d t o tafa mi dis i n pare nt st u d y  B [ADDRESS_733948] u d y  B 3 4 6 1 0 4 5 will be gr o u pe d as tafa mi dis/tafa mi dis.  
S u bjects ra n d o mize d t o place b o i n st u d y  B [ADDRESS_733949] b o/tafa mi dis. 
F or C o h ort B, si nce s u bjects i n t his c o h ort will all be a d mi nistere d t he sa me d ose, o nl y 
o verall descri pti ve statistics will be pr o vi de d. 
9. 1. S a m ple Size Deter mi n ati o n 
T h ere is n o f or mal sa m ple size calc ulati o n f or t his pr ot oc ol.  S u bjects w h o meet e nr oll me nt 
criteria are eli gi ble; u p t o 2 0 0 0 s u bjects are e x pecte d t o e nr oll i n Pr ot oc ol B 3 4 6 1 0 4 5. 
9. 2. A n al ysis of Ot her E n d p oi nts 
9. 2. 1. M ort alit y ( C ar di o v asc ul ar- rel ate d) 
F or C o h ort A, ti me t o car di o vasc ular -relate d m ortalit y  will be calc ulate d fr o m t he first d ose 
of t he ra n d o mize d treat me nt ( St u d y B 3 4 6 1 0 2 8).  Ka pla n -Meier s ur vi val c ur ves f or eac h 
treat me nt gr o u p al o n g wit h me dia n s ur vi val ti mes (if a p plica ble) will be prese nte d. 
S u bje ct s w h o disc o nti n ue f or tra ns pla ntati o n (ie, heart tra ns pla ntati o n a n d c o m bi ne d heart 
a n d li ver tra ns pla ntati o n) or f or i m pla ntati o n of a car diac mec ha nical assist de vice, will be 
ha n dle d i n t he sa me ma n ner as deat h.  Data fr o m s u bjects w h o dr o p o ut f or a li ver - o nl y 
tr a ns pla ntati o n will be ha n dle d i n t he sa me ma n ner as t he data fr o m all ot her ce ns ore d 
s u bjects. 
F or C o h ort B, ti me t o car di o vasc ular relate d m ortalit y  will be calc ulate d fr o m t he first d ose 
of treat me nt.  T he Ka pla n Meier s ur vi val c ur ve al o n g w it h me dia n s u r vi val ti me 
(if a p plica ble) will be prese nte d. 
9. 2. 2. H os pit aliz ati o n 
F or C o h orts A a n d B, t he fre q ue nc y  of h os pi[INVESTIGATOR_1314] o ns (all -ca use a n d car di o vasc ular- relate d) 
d uri n g t he st u d y will be s u m marize d descri pti vel y. 
9. 2. 3. K a ns as Cit y C ar di o m y o p at h y Q uesti o n n a ire 
F or C o h ort A, t he Ka nsas Cit y  Car di o m y o pat h y  Q uesti o n naire ( K C C Q, A p pe n di x 2) will be 
s u m marize d b y  t he f oll o wi n g s u m mar y  sc ores calc ulate d usi n g t he g ui del i nes esta blis he d i n 
t he K C C Q Sc ori n g I nstr ucti o n Ma n ual: 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733950] ure d c o varia nce matri x ( or as a p pr o priate) wit h s u bjects as a 
ra n d o m effect a n d treat me nt, visit, T T R ge n ot y pe ( varia nt a n d wil d -t y pe), a n d 
visit -b y -treat me nt i nteracti o n, as fi xe d effects a n d baseli ne sc ore a s c o variate .  Data will als o 
be s u m marize d b y  eac h sc he d ule d assess me nt. 
F or C o h ort B, descri pti ve statistics will be pr o vi de d. 
9. 2. 4. Ne w Y or k He art Ass oci ati o n 
F or C o h orts A a n d B, s u bjects will be e val uate d usi n g t he Ne w Y or k Heart Ass ociati o n 
( N Y H A) classific ati o n ( A p pe n di x 3).  Descri pti ve statistics will be prese nte d b y cli nic visit 
f or eac h clas sificati o n: Class I,  Class II, Class III, a n d Class I V (see A p pe n di x 3f or 
defi niti o ns).  T he n u m ber a n d pe rce nta ge of s u bjects w h o i m pr o ve d, w orse ne d, or wit h n o 
c ha n ge fr o m baseli ne will als o be prese nte d at eac h visit. 
9. 2. 5. B o d y M ass I n de x/ m o difie d B o d y M ass I n de x 
F or C o h orts A a n d B, B MI  a n d m B MI val ues at eac h visit a n d c ha n ge fr o m baseli ne will be 
prese nte d i n s u m mar y  ta bles a n d data listi n gs.  Descri pti ve statist ics will be pr o vi de d b y visit. 
9. 2. 6. C ar di ac Bi o m ar kers N T- pr o B N P a n d Tr o p o ni n I 
F or C o h orts A a n d B, descri pti ve statistics f or c ha n ge fr o m baseli ne (i nitiati o n of tafa mi dis) 
i n N T- pr o B N P a n d Tr o p o ni n I c o n ce ntrati o n will be s u m marize d. 
9. 3. S afet y A n al ysis 
T he safet y assess me nts i n t his st u d y  are liste d i n Secti o n 7. [ADDRESS_733951] u d y  treat me nt.  E xce pt f or all -ca use m ortalit y ( Secti o n 9. 3. 1 ), all safet y  e n d p oi nts i n 
Secti o n 9. 3 will be a nal yze d descri pti v el y  f or C o h orts A a n d B. 
9. 3. 1. M ort alit y ( All -c a use) 
F or C o h ort A, ti me t o all- ca use m ortalit y  will be calc ulate d fr o m t he first d ose of t he 
ra n d o mize d treat me nt ( St u d y B 3 4 6 1 0 2 8).  Treate d s u bjects fr o m t he pare nt s t u d y B [ADDRESS_733952] u d y  will als o be i ncl u de d i n t his a nal y sis. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733953]; p- val ues will be fr o m t he 
l o g -ra n k test.  Ka pla n -Meier s ur vi val c ur ves f or eac h treat me nt g r o u p al o n g wit h me dia n 
s ur vi val ti mes (if a p plica ble) will be prese nte d. 
All- ca use m ortalit y will als o be a nal yz e d usi n g C o x pr o p orti o nal hazar ds m o del wit h 
treat me nt a n d T T R ge n ot y pe ( varia nt a n d wil d -t y pe) as fact ors. 
S u bjects w h o disc o nti n ue f or tra ns p la ntati o n ( ie, heart tra ns pla ntati o n a n d c o m bi ne d heart 
a n d li ver tra ns pla ntati o n) or f or i m pla ntati o n of a car diac mec ha nica l assist de vice, will be 
ha n dle d i n t he sa me ma n ner as deat h.  Data fr o m s u bjects w h o dr o p o ut f or a li ver - o nl y 
tra ns pla ntati o n wil l be ha n dle d i n t he sa me ma n ner as t he data fr o m all ot her ce ns ore d 
s u bjects. 
F or C o h ort B, ti me t o all -ca use m ortalit y will be calc ulate d fr o m t he first d ose of treat me nt.  
T he Ka pla n Meier s ur vi val c ur ve al o n g wit h me dia n s ur vi val ti me (if a p plica ble) wi ll be 
prese nte d. 
9. 3. 2. A d verse E ve nts 
All A E data c ollecte d o n t he C R F will be prese nte d i n s u m mar y  ta bles a n d data listi n gs. 
All a d verse e ve nts t hat are o bser ve d fr o m t he ti me of first d osi n g wit h st u d y me dicati o n u ntil 
t he e n d of st u d y partici pati o n will be i ncl u de d i n t he safet y a nal ys is.  A d verse e ve nts t hat 
occ urre d d uri n g treat me nt will be re p orte d se paratel y if t he e ve nt occ ur re d pri or t o 
ra n d o mizati o n. 
All a d verse e ve nts will be c o de d acc or di n g t o t he Me dical Dicti o nar y f or Re g ulat or y  
Acti vities ( Me d D R A ) a n d will be s u m marize d b y  treat me nt gr o u p.  T he i nci de nce of 
treat me nt -e mer ge nt a d verse e ve nts will be ta b ulate d b y  treat me nt gr o u p a n d b y  s ys te m or ga n 
class.  T he i nci de nce of treat me nt -e mer ge nt a d verse e ve nts will be dis pla y e d b y  se verit y a n d 
attri b uti o n.  I n a d d iti o n, t he i nci de nce of seri o us a d verse e ve nts a n d a d verse e ve nts t hat ca use 
wit h dra wal will be ta b ulate d.  All a d verse e ve nts will be liste d. 
9. 3. 3. P h ysic al E x a mi n ati o ns a n d Vit al Si g ns 
P h y sical e xa mi nati o ns a n d vital si g ns (l y i n g a n d sta n di n g bl o o d press ure a n d p ulse, 
res pi[INVESTIGATOR_1305] y  rate, a n d te m perat ure) will be s u m marize d usi n g descri pti ve statistics. 
9. 3. 4. Use of C o nc o mit a nt Me dic ati o ns 
All data o n c o nc o mita nt me dicati o n usa ge c ollecte d o n t he C R F will be prese nte d i n 
s u m mar y  ta bles a n d i n data listi n gs. 
9. 3. 5. C li nic al L a b or at or y Tests 
All cli nical la b orat or y  data (ser u m c he mistr y , c oa g ulati o n, he mat ol o g y , a n d uri nal y sis ) will 
be s u bjecte d t o cli nical re vie w a n d s u m marize d b y fre q ue nc y  of e ve nts a n d mea n c ha n ges 
fr o m baseli ne. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733954] u d y f or heart rate, P R i nter val, Q R S wi dt h, Q T i nter val, a n d Q Tc B ( Bazett’s c orrecti o n) 
a n d Q Tc F ( Fri dericia’s c o rrecti o n) val ues.  A d diti o nall y , t he i nci de nce of cate g orical 
i ncreases i n Q Tc i nter vals will be pr o vi de d.  Cate g ories f or Q Tc B a n d Q Tc F are 4 5 0 msec, 
4 8 0 msec, a n d 5 0 0 msec.  Cate g ories f or Q Tc B a n d Q Tc F as c ha n ge fr o m baseli ne are: 
3 0 msec i ncrease, 6 0 msec i ncrease, a n d [ADDRESS_733955] u d y  will use a n e xter nal data m o nit ori n g c o m mittee ( E- D M C ) t hat is i n de pe n de nt fr o m 
[COMPANY_007].  I nf or mati o n re gar di n g t he E - D M C ca n be f o u n d i n t he E xter nal Data M o nit ori n g 
C o m mittee c harter, i ncl u di n g t he me m ber s hi p of t he c o m mittee. 
T he E -D M C will be res p o nsi ble f or o n g oi n g m o nit ori n g of t he safet y of s u bjec ts i n t he st u d y  
acc or di n g t o t he c harter.  T he rec o m me n dati o ns ma de b y t he E -D M C t o alter t he c o n d uct of 
t he st u d y  will be f or war de d t o [COMPANY_007] f o r fi nal decisi o n.  [COMPANY_007] will f or war d s uc h decisi o ns, 
w hic h ma y  i ncl u de s u m maries of a g gre gate a nal y ses of e n d p oi nt e ve nts a n d of safet y data 
t hat are n ot e n d p oi nts, t o re g ulat or y  a ut h orities, as a p pr o priate. 
[ADDRESS_733956] t o e ns ure t hat 
t he pr ot oc ol a n d G o o d Cli nical Practices ( G C Ps) are bei n g f oll o we d.  T he m o nit ors ma y  
re vie w s o urce d oc u me nts t o c o nfir m t hat t he data rec or de d o n C R Fs are acc urate.  T he 
i n vesti gat or a n d i nstit uti o n will all o w [COMPANY_007] m o nit ors/a u dit ors or its a ge nts a n d a p pr o priate 
re g ulat or y  a ut h orities direct access t o s o urce d oc u me nts t o perf or m t his verificati o n.  T his 
verificati o n ma y  als o occ ur after st u d y  c o m pleti o n. 
D uri n g st u d y c o n d uct a n d/ or after st u d y c o m pleti o n, t he st u d y  site ma y  be s u bject t o re vie w 
b y  t he i nstit uti o nal re vie w b oa r d (I R B)/et hics c o m mittee ( E C), a n d/ or t o q ualit y  ass ura nce 
a u dits perf or me d b y [COMPANY_007], or c o m pa nies w or ki n g wit h or o n be half of [COMPANY_007], a n d/ or t o 
i ns pecti o n b y  a p pr o priate re g ulat or y  a ut h orities. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 7 3 T he i n vesti gat or(s) will n otif y [COMPANY_007] or its a ge nts i m me d iatel y  of a n y  re g ulat or y  i ns pecti o n 
n otificati o n i n relati o n t o t he st u d y .  F urt her m ore, t he i n vesti gat or will c o o perate wit h [COMPANY_007] 
or its a ge nt s t o pre par e t he st u d y  site f or t he i ns pecti o n a n d will all o w [COMPANY_007] or its a ge nt, 
w he ne ver feasi ble, t o be pre se nt d uri n g t he i ns pecti o n.  T he i n vesti gat or will pr o m ptl y  
pr o vi de c o pi[INVESTIGATOR_1309] t he i ns pecti o n fi n di n gs t o [COMPANY_007] or its a ge nt.  Bef ore res p o nse s u b missi o n 
t o t he re g ulat or y  a ut h orities, t he i n vesti gat or will pr o vi de [COMPANY_007] or its a ge nts wit h a n 
o p p ort u nit y  t o re vie w a n d c o m me nt o n res p o nses t o a n y  s uc h fi n di n gs. 
It is i m p orta nt t hat t he i n vesti gat or(s) a n d t heir rele va nt pers o n nel are a vaila ble d uri n g t he 
m o ni t ori n g visits a n d p ossi ble a u dits or i ns pecti o ns a n d t hat s ufficie nt ti me is de v ote d t o t he 
pr ocess. 
1 1. D A T A H A N D LI N G A N D R E C O R D K E E PI N G 
1 1. 1. C ase Re p ort F or ms/ Electr o nic D at a Rec or d 
As use d i n t his pr ot oc ol, t he ter m C R F s h o ul d be u n derst o o d t o refer t o eit her a pa per f or m or 
a n electr o nic data rec or d or b ot h, de pe n di n g o n t he data c ollecti o n met h o d use d i n t his st u d y .
A C R F is re q uire d a n d s h o ul d be c o m plete d f or eac h i ncl u de d s u bject.  T he c o m plete d 
ori gi nal C R Fs are t he s ole pr o pert y of [COMPANY_007] a n d s h o ul d n ot be ma de a vaila ble i n a n y  f or m t o 
t hir d parties, e xce pt f or a ut h orize d re prese ntati ves of [COMPANY_007] or a p pr o priate re g ulat or y  
a ut h orities, wit h o ut writte n per missi o n fr o m [COMPANY_007]. 
T he i n vesti gat or has ulti mate res p o nsi bilit y  f or t he c ollecti o n a n d re p o rti n g of al l cli nical, 
safet y, a n d la b orat or y data e ntere d o n t he C R Fs a n d a n y ot her data c ollecti o n f or ms ( s o urce 
d oc u me nts) a n d e ns uri n g t hat t he y are acc urate, a ut he ntic/ ori gi nal, attri b uta ble, c o m plete, 
c o nsiste nt, le gi ble, ti mel y  (c o nte m p ora ne o us), e n d uri n g, a n d a vaila ble w he n re q uire d.  T he 
C R Fs m ust be si g ne d b y t he i n vesti gat or or b y a n a ut h orize d staff me m ber t o attest t hat t he 
data c o ntai ne d o n t he C R Fs are tr ue.  A n y c orrecti o ns t o e ntries ma de i n t he C R Fs or s o urce 
d oc u me nts m ust be date d, i niti ale d, a n d e x plai ne d (if necessar y ) a n d s h o ul d n ot o bsc ure t he 
ori gi nal e ntr y . 
I n m ost cases, t he s o urce d oc u me nts are t he h os pi[INVESTIGATOR_307]'s or t he p h ys icia n's s u bject c hart.  I n 
t hese cases, data c ollecte d o n t he C R Fs m ust matc h t he data i n t h ose c harts. 
I n s o m e cases, t h e C R F, or part of t he C R F, ma y  als o ser ve as s o urce d oc u me nts.  I n t hese 
cases, a d oc u me nt s h o ul d be a vaila ble at t he i n vesti gati ve site as well as at [COMPANY_007] a n d clearl y 
i de ntif y  t h ose data t hat will be rec or de d i n t he C R F, a n d f or w hic h t he C R F will sta n d as t he 
s o urce d oc u me nt. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 7 4 1 1. 2. Rec or d Rete nti o n 
T o e na ble e val uati o ns a n d/ or a u dits fr o m re g ulat or y  a ut h orities or [COMPANY_007], t he i n vesti gat or 
a grees t o kee p rec or ds, i ncl u di n g t he i de ntit y of all partici pati n g s u bjects (s ufficie nt 
i nf or mati o n t o li n k re c or ds, e g, C R Fs a n d h os pi[INVESTIGATOR_21036]), all ori gi nal si g ne d i nf or me d 
c o nse nt d oc u me nts, c o pi[INVESTIGATOR_3951] C R Fs, s afet y  re p orti n g f or ms, s o urce d oc u me nts, a n d 
detaile d rec or ds of treat me nt dis p ositi o n, a n d a de q uate d oc u me ntati o n of rele va nt 
c orres p o n de nce (e g, letters, mee ti n g mi n utes, a n d tele p h o ne call re p orts).  T he rec or ds s h o ul d 
be retai ne d b y t he i n vesti gat or ac c or di n g t o t he I C H g ui deli nes, acc or di n g t o l ocal 
re g ulati o ns, or as s pecifie d i n t he cli nical st u d y a gree me nt ( C S A), w hic he ver is l o n ger. 
If t he i n vesti gat or bec o mes u na ble f or a n y  reas o n t o c o nti n ue t o retai n st u d y  rec or ds f or t he 
re q uire d peri o d (e g, re tire me nt, rel ocati o n), [COMPANY_007] s h o ul d be pr os pecti vel y n otifie d.  T he 
st u d y  rec or ds m ust be tra nsferre d t o a desi g nee acce pta ble t o [COMPANY_007], s uc h as a n ot her 
i n ve sti gat or, a n ot her i nstit uti o n, or a n i n de pe n de nt t hir d part y  arra n ge d b y  [COMPANY_007].  
I n vesti gat or re c or ds m ust be ke pt f or a mi ni m u m of [ADDRESS_733957] o btai n [COMPANY_007]'s writte n per missi o n bef ore dis p osi n g of a n y rec or ds, 
e ve n if ret e nti o n re q uire me nts ha ve bee n met. 
1 2. E T HI C S 
1 2. 1. I nstit uti o n al Re vie w B o ar d/ Et hics C o m mittee 
It is t he res p o nsi bilit y  of t he i n vesti gat or t o ha ve pr os pecti ve a p pr o val of t he st u d y  pr ot oc ol, 
pr ot oc ol a me n d me nts, i nf or me d c o nse nt d oc u me nts, a n d ot her rele va nt d oc u m e nts, 
e g, recr uit me nt a d vertise me nts, if a p plica ble, fr o m t he I R B/ E C.  All c orres p o n de nce wit h t he 
I R B/ E C s h o ul d be retai ne d i n t he i n vesti gat or fil e.  C o pi[INVESTIGATOR_1309] I R B/ E C a p pr o vals s h o ul d be 
f or war de d t o [COMPANY_007]. 
T he o nl y  circ u msta nce i n w hic h a n a me n d me nt ma y be i nitiate d pri or t o I R B/ E C a p pr o val is 
w here t he c ha n ge is necessar y  t o eli mi nate a p pare nt i m me diate hazar ds t o t he s u bjects.  I n 
t hat e ve nt, t h e i n vesti ga t or m ust n otif y  t he I R B/ E C a n d [COMPANY_007] i n writi n g i m me diatel y  after 
t he i m ple me ntati o n. 
[ADDRESS_733958] u d y  will be c o n d ucte d i n acc or da nce wit h le gal a n d re g ulat or y  re q uire me nts, as well as 
t he ge neral pri nci ples set f ort h i n t he I nter nati o nal Et hical G ui deli nes f or Bi o me dical 
Researc h I n v ol vi n g H u ma n S u bjects ( C o u ncil f or I nter nati o nal Or ga nizati o ns of Me dical 
Scie nces 2 0 0 2), G ui deli nes f or G C P (I C H 1 9 9 6), a n d t he Declarati o n of Helsi n ki ( W orl d 
Me dical Ass ociati o n 1 9 9 6 a n d 2 0 0 8). 
I n a d d iti o n, t he st u d y  will be c o n d ucte d i n acc or da nce wit h t he pr ot oc ol, t he I C H g ui deli ne 
o n G C P, a n d a p plica ble l ocal re g ulat or y  re q uire me nts a n d la ws. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733959]’s n u meri cal c o de t o his or her act ual i de ntit y .  I n case of data tra nsfer, [COMPANY_007] will 
mai ntai n hi g h sta n dar ds of c o nfi de ntialit y a n d pr otecti o n of s u bjects’ pers o nal data c o nsiste nt 
wit h a p plica ble pri vac y  la ws. 
T he i nf or me d c o nse nt d oc u me nts m ust be i n c o m plia nc e wit h I C H G C P, l ocal re g ulat or y  
re q uire me nts, a n d le gal re q uire me nts, i ncl u di n g a p plica ble pri vac y  la ws. 
T he i nf or me d c o nse nt d oc u me nts use d d uri n g t he i nf or me d c o nse nt pr ocess m us t be 
re vie we d a n d a p pr o ve d b y t he s p o ns or, a p pr o ve d b y  t he I R B/ E C bef ore us e, a n d a vaila ble f or 
i ns pecti o n. 
T he i n vesti gat or m ust e ns ure t hat eac h st u d y  s u bject ( or his or her le gall y acce pta ble 
re prese ntati ve) is f ull y i nf or me d a b o ut t he nat ure a n d o bje cti ves of t he st u d y  a n d p ossi ble 
ris ks ass ociate d wit h partici pa ti o n. 
W he n e ver c o nse nt is o btai ne d fr o m a s u bject’s le gall y acce pta ble re prese ntati ve, t he 
s u bject’s asse nt (affir mati ve a gree me nt) m ust s u bse q ue ntl y be o btai ne d w he n t he s u bject has 
t he ca pa cit y  t o pr o vi de asse nt, as deter mi ne d b y  t he I R B/ E C.  If t he i n v esti gat or d eter mi nes 
t hat a s u bject’s decisi o nal ca pacit y is s o li mite d he/s he ca n n ot reas o na bl y be c o ns ulte d, t he n, 
as per mitte d b y t he I R B/ E C a n d c o nsiste nt wit h l ocal re g ulat or y a n d le gal r e q uire me nts, t he 
s u bject’s asse nt ma y  be wai ve d wit h s o urce d oc u me ntati o n o f t he reas o n asse nt was n ot 
o btai ne d.  If t he st u d y s u bject d oes n ot pr o vi de his or her o w n c o nse nt, t he s o urce d oc u me nts 
m ust rec or d w h y t he s u bject di d n ot pr o vi de c o nse nt (e g, mi n or, decisi o nall y  i m paire d a d ult), 
h o w t he i n vesti gat or deter mi n e d t hat t he pers o n si g ni n g t he c o nse nt was t he s u bject’s le gall y 
acce pta ble re prese ntati ve, t he c o nse nt si g ner’s relati o ns hi p t o t he st u d y  s u bject (e g, pare nt, 
s p o use), a n d t hat t he s u bject’s asse nt was o btai ne d, or wai ve d.  If asse nt is o btai ne d ver ball y 
it m ust be d oc u me nte d i n t he s o urce d oc u me nts. 
T he i n vesti gat or, or a pers o n desi g nate d b y t he i n vesti gat or, will o btai n writte n i nf or me d 
c o nse nt fr o m eac h s u bject or t he s u bject’s le gall y acc e pta ble re prese ntati ve bef ore a n y 
st u d y -s pecific acti vit y  is per f or me d.  T h e i n vesti gat or will retai n t he ori gi nal of eac h s u bject's 
si g ne d c o nse nt d oc u me nt. 
[ADDRESS_733960] u d y .0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 7 6 1 2. 5. Re p orti n g of S afet y Iss ues a n d Seri o us Bre ac he s of t he Pr ot oc ol or I C H G C P 
I n t he e ve nt of a n y pr o hi biti o n or restricti o n i m p ose d (ie , cli nical h ol d) b y a n a p plica ble 
c o m pete nt a ut h orit y i n a n y area of t he w orl d, or if t he i n vesti gat or is a ware of a n y ne w 
i nf or mati o n t hat mi g ht i nfl ue nce t he e val uati o n of t he be nefits a n d ris ks of t he i n vesti gati o nal 
pr o d uct, [COMPANY_007] s h o ul d be i nf or me d i m me diatel y . 
I n a d diti o n, t he i n vesti gat or will i nf or m [COMPANY_007] i m me diatel y  of a n y  ur ge nt safet y meas ures 
ta ke n b y t he i n vesti gat or t o pr otect t he st u d y s u bjects a gai nst a n y  i m me diat e hazar d, a n d of 
a n y  seri o us breac hes of t his pr ot oc ol or of I C H G C P t hat t h e i n vesti gat or bec o mes a ware of. 
[ADDRESS_733961] u d y  as 
state d i n t he re g ulat or y  a p plicati o n (ie, cli nical trial a p plicati o n [ C T A]) a n d et hics a p plicati o n 
i n t he Me m ber State.  P o or recr uit me nt (recr uiti n g l ess t ha n t he a ntici pate d n u m ber i n t he 
C T A) b y  a Me m ber State is n ot a reas o n f or pre ma t ure ter mi nati o n b ut is c o nsi dere d a 
n or mal c o ncl usi o n t o t he st u d y  i n t hat Me m ber State. 
[ADDRESS_733962] u d y  ma y  occ ur beca use of a re g ulat or y  a ut h orit y  decisi o n, 
c ha n ge i n o pi [INVESTIGATOR_9384] o n of t he I R B/ E C, or i n vesti gati o nal pr o d uct safet y  pr o bl e ms, or at t he 
discreti o n of [COMPANY_007].  I n a d diti o n, [COMPANY_007] retai ns t he ri g ht t o disc o nti n ue de vel o p me nt of 
tafa mi dis at a n y ti me. 
If a st u d y is pre mat urel y ter mi nate d or disc o nti n ue d, [COMPANY_007] will pr o m ptl y  n otif y  t he 
i n vesti gat or.  After n otificati o n, t he i n vesti gat or m ust c o ntact all partici pati n g s u bjects a n d 
t he h os pi[INVESTIGATOR_307] p har mac y  (if a p plic a ble) wit hi n [ADDRESS_733963] u dies o n w w w.cli nicaltrials. g o v ( Cli nical Trials. g o v), t he E ur o pea n Cli nical Trials 
Data base ( E u dra C T), a n d/ or w w w . pfizer.c o m , a n d ot her p u blic re gistries i n acc or da nce wit h 
a p plica ble l ocal la ws/re g ul ati o ns. 
I n all cases, st u d y res ults are re p orte d b y [COMPANY_007] i n a n o bjecti ve, acc urate, bala nce d, a n d 
c o m plete ma n ner a n d are re p orte d re gar dless of t he o utc o me of t he st u d y  or t he c o u ntr y  i n 
w hic h t he st u d y  was c o n d ucte d. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733964] u dies c o n d ucte d i n patie nts t hat e val uate t he safet y a n d/ or efficac y of a [COMPANY_007] 
pr o d uct, re gar dless of t he ge o gra p hical l ocati o n i n w hic h t he st u d y is c o n d uc te d.  U S Basic 
Res ults are s u b mitte d f or p osti n g wit hi n [ADDRESS_733965] u dies i n pe diatric p o p ulati o ns. 
w w w. pfizer.c o m 
Pfiz er p osts P u blic Discl os ure S y n o pses (cli nical st u d y  re p ort s y n o pses i n w hic h a n y  data 
t hat c o ul d be use d t o i de ntif y  i n di vi d ual patie nts ha ve bee n re m o ve d) o n w w w. pfizer .c o m f or 
Pf izer -s p o ns ore d i nter ve nti o nal st u dies at t he sa me ti me t he U S Basic Res ults d oc u me nt is 
p oste d t o w w w.cli nicaltrials. g o v. 
[ADDRESS_733966] u d y (c ollecti vel y, “ P u blicati o n”) 
bef ore it is s u b mitte d or ot her wise discl ose d. 
T he i n ve sti gat or will pr o vi de a n y  p u blicati o n t o [COMPANY_007] at least [ADDRESS_733967] u d y  res ults. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733968] y  wit h rec o g nize d et hical 
sta n dar ds c o ncer ni n g p u blicati o ns a n d a ut h ors hi p, i ncl u di n g Secti o n II -“ Et hical 
C o nsi dera ti o ns i n t h e C o n d uct a n d Re p orti n g of Researc h” of t he U nif or m Re q uire me nts f or 
Ma n uscr i pts S u b mitte d t o Bi o me dical J o ur nals, htt p:// w w w.ic mje. or g/i n de x. ht ml #a ut h ors hi p, 
esta blis he d b y  t he I nter nati o nal C o m mittee of Me dical J o ur nal E dit ors. 
P u blicati o n of st u d y  res ul ts is als o pr o vi de d f or i n t he C S A bet wee n [COMPANY_007] a n d t he 
i nstit uti o n.  I n t his secti o n e ntitle d P u blicati o ns b y  I n vesti gat ors , t he defi ne d ter ms s hall ha ve 
t he mea ni n gs gi ve n t o t he m i n t he C S A. 
If t here is a n y c o nflic t bet wee n t he C S A a n d a n y Attac h me nts t o it, t he ter ms of t he C S A 
c o ntr ol.  If t here is a n y c o nflict bet wee n t his pr ot oc ol a n d t he C S A, t his pr ot oc ol will c o ntr ol 
as t o a n y  iss ue re gar di n g treat me nt of st u d y  s u bjects, a n d t he C S A will c o ntr ol as t o all ot h er 
iss ues. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733969] h yr eti n a n d 
tetra mer sta bilizati o n i n ser u m fr o m patie nts wit h fa milial a m y l oi d otic p ol y ne ur o pat h y 
b y  a n i o di nate d difl u nisal deri vati ve.  Bi oc he m. J. 2 0 0 4; 3 8 1: 3 5 1 - 5 6. 
2.  Gertz M A , S ki n n er M, C o n n ors L H, et al.  Selecti ve bi n di n g of nife di pi [INVESTIGATOR_050] t o a m y l oi d 
fi brils. A m J Car di ol. 1 9 8 5; 5 5 ( 1 3 Pt 1): 1 6 4 6. 
3. Gree n C P, P orter C B, Bres na ha n D R, et al.  De vel o p me nt a n d e val uati o n of t he Ka nsas 
Cit y  Car di o m y o pat h y  Q uesti o n naire: a n e w healt h s tat us m eas ure f or heart fail ure. J A m 
C oll Car di ol o g y  2 0 0 0; 3 5: [ADDRESS_733970] h y reti n -relate d a m yl oi d oses a n d t he heart: a cli nical o ver vie w. 
Nat Re v Car di ol 2 0 1 0; 7: 3 9 8- 4 0 8. 
5. R u bi n o w A, S ki n ner M, a n d C o he n A S.  Di g o xi n se nsiti vi t y  i n a m yl oi d 
car d i o m y o pat h y. Circ ulati o n 1 9 8 1; 6 3: 1 2 8 5 - 8 8. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733971] u d y  a gree me nt 
C T A cli nical trial a p plicati o n 
C T C A E C o m m o n Ter mi n ol o g y  Criteria f or A d verse E ve nts 
D AI d osa ge a n d a d mi nistrati o n i nstr ucti o ns 
D M C data m o nit ori n g c o m mittee 
D N A de o x yri b o n uc leic aci d 
D U dis pe nsa ble u nit 
E C et hics c o m mittee 
E C G electr ocar di o gra m 
E D M C e xter nal data m o nit ori n g c o m mittee 
E D P e x p os ure d uri n g pre g na nc y 
E D T A e detic aci d (et h yl e ne dia mi netetraacetic aci d) 
E u dra C T E ur o pea n Cli nical Trials Data base 
FD A F o o d a n d Dr u g A d mi nistrati o n ( U nite d States) 
F S H f ollicle -sti m ulati n g h or m o ne 
G C P G o o d Cli nical Practice 
H F p E F heart fail ure wit h preser ve d ejecti o n fracti o n 
I B i n vesti gat or’s br oc h ure 
I C D i nf or me d c o nse nt d oc u me nt 
I C H I nter nati o nal C o nfere nce o n Har m o nisati o n 
I D i de ntificati o n 
I N D i n vesti gati o nal ne w dr u g a p plicati o n 
I N R i nter nati o nal n or malize d rati o 
I R B i nstit uti o nal re vie w b oar d 
I R C i nter nal re vie w c o m mittee 
I R T i nteracti ve res p o nse tec h n ol o g y 
I U D i ntra uteri ne de vice 
I U S i ntra uteri ne s yste m 
I V R interacti ve v oice res p o nse 
K2E D T A di p otassi u m et h y le ne dia mi netetraacetic aci d 
K C C Q Ka nsas Cit y  Car di o m y o pat h y  Q uesti o n naire 
L F T li ver f u ncti o n test 
m B MI M o difie d B o d y Mass I n de x 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 8 1 A b bre vi ati o n Ter m 
M G U S M o n ocl o nal ga m m o pat h y of u n deter mi ne d si g nifica nce 
M R M ol ar rati o 
N/ A n ot a p plica ble 
N S AI D n o n -ster oi dal a nti -i nfla m mat or y  dr u g 
N T -pr o B N P N-ter mi nal pr o -h or m o ne brai n natri uretic pe pti de 
N Y H A Ne w Y or k Heart Ass ociati o n 
P T pr ot hr o m bi n ti me 
Q Tc ( B a n d F) C orrecte d E C G Q T I nter val usi n g t he Bazett’s or Fri der icia’s 
c orr ecti o n 
S A E seri o us a d verse e ve nt 
S A P statistical a nal y sis pla n 
SI B s uici dal i deati o n a n d be ha vi or 
S O P sta n dar d o perati n g pr oce d ure 
S P C s u m mar y  of pr o d uct c haracteristics 
S R S D si n gle refere nce safet y d oc u me nt 
S SI D st u d y -s pecific i de ntifica ti o n n u m ber 
T T R tra nst h y reti n 
A T T R -P N tra nst h y reti n p ol y ne ur o pat h y 
T T R -C M or 
A T T R -C M tra nst h y reti n car di o m y o pat h y 
U L N u p per li mit of n or mal 
U S U nite d States 
U S PI U nite d States pac ka ge i nsert 
W O C B P W o ma n of C hil d Beari n g P ote ntial 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 8 2 A p pe n di x 2. K a ns as Cit y C ar d i o m y o p at h y Q uesti o n n aire 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) C O P Y RI G H T E D M A T E RI A L 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 8 3 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) C O P Y RI G H T E D M A T E RI A L 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 8 4 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) C O P Y RI G H T E D M A T E RI A L 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 8 5 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) C O P Y RI G H T E D M A T E RI A L 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 8 6 A p pe n di x 3. Ne w Y or k He art Ass oci ati o n Cl assific ati o n 
A d o pte d fr o m: D ol g i n M, e dit or.  N o me nclat ure a n d Criteria f or Dia g n osis of Diseases of t he Heart a n d Great Vessels.  T he 
Criteria C o m mittee of t he Ne w Y or k Heart Ass ociati o n.  9t h e d. B ost o n: Little Br o w n & C o, 1 9 9 4: 2 5 3 –2 5 6. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) C O P Y RI G H T E D M A T E RI A L 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733972] u d y D ur ati o n 
Fra nce a n d Ger ma n y o nl y: T he B [ADDRESS_733973] u d y Pr oce d ures 
Fra nce a n d Ger ma n y o nl y: S u bjects are re q uire d t o ret ur n t o t he st u d y  site f or a d diti o nal 
pr oce d ures at M o nt h 3. 
Ja pa n o nl y : Per l ocal c ust o m, st u d y  sites t o c o ntact all e nr olle d s u bjects b y t ele p h o ne at 
2wee ks ( ± 1 wee k) a n d 1 m o nt h ( ± 1 wee k) after i nitiati o n of tafa mi dis 6 1 m g t o c hec k f or 
a d verse e ve nts/ m o n it or safet y. 
A p pe n di x 4. 3. Fr a nce C o ntr at U ni q ue 
T his i nf or mati o n relates t o re q uire me nts f or G C P Trai ni n g, I n vesti gati o nal P r o d uct, a n d 
I ns pecti o ns i n Fra nce.  T he f oll o wi n g s u p ple me ntar y  te xt s h o ul d be rea d i n c o nj u ncti o n wit h 
t his pr ot oc ol: 
G C P Trai ni n g: Pri or t o e n r oll me nt of a n y s u bjects, t he i n vesti gat or a n d a n y 
s u b -i n vesti gat ors will c o m plete t he [COMPANY_007]- pr o vi de d G o o d Cli nical Pract ice trai ni n g 
c o urse (“ [COMPANY_007] G C P Trai ni n g”) or trai ni n g dee me d e q ui vale nt b y  [COMPANY_007].  A n y  
i n vesti gat ors w h o later j oi n t he St u d y  will c o m plete t he [COMPANY_007] G C P Trai ni n g or 
e q ui vale nt bef ore perf or mi n g St u d y -relate d d uties.  F or st u dies of a p plica b le d urati o n , 
t he i n vesti gat or a n d s u b -i n vesti gat ors will c o m plete [COMPANY_007] G C P Trai ni n g or 
e q ui vale nt e ver y  t hree ye ars d uri n g t he ter m of t he St u d y,  or m ore ofte n if t here are 
si g nifica nt c ha n ges t o t he I C H G C P g ui deli nes or c o urse materials. 
I n vesti gati o n al Pr o d uct: N o s u bjects or t hir d -part y  p a y ers will be c har ge d f or 
i n vesti gati o nal pr o d uct. 
I ns pecti o ns: T he i n vesti gat or(s) will n otif y [COMPANY_007] o r its ser vice pr o vi der i m me diatel y  
of a n y re g ulat or y  i ns pecti o n n otificati o n i n relati o n t o t he st u d y .  F urt her m ore, t he 
in vesti gat or will c o o perate wit h [COMPANY_007] or its ser vice pr o vi der t o pre pare t he st u d y  site 
f or t he i ns pecti o n a n d will all o w [COMPANY_007] or i ts ser vice pr o vi der (if n ot pr o hi bite d b y  
la w) t o be prese nt d uri n g t he i ns pecti o n.  T he st u d y site a n d i n vesti gat or will 
pr o m ptl y  res ol ve a n y discre pa ncies t hat are i de ntifie d bet wee n t he st u d y data a n d t he 
s u bject's me dical rec or ds.  T he i n vesti gat or wil l pr o m ptl y  pr o vi de c o pi[INVESTIGATOR_1309] t he 
i ns pecti o n fi n di n gs t o [COMPANY_007] or its ser vice pr o vi der.  Bef ore res p o nse s u b mis si o n t o 
t he re g ulat or y  a ut h orities, t he i n vesti gat or will pr o vi de [COMPANY_007] or its ser vice pr o vi der 
wit h a n o p p ort u nit y  t o re vie w a n d c o m me nt o n res p o nses t o a n y  s uc h fi n di n gs. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733974] u d y  sites i n t he f oll o wi n g c o u ntries ma y s cree n/e n r oll s u bjects i n C o h ort B: 
A ustralia; 
Ar ge nti na; 
Bel gi u m; 
Ca na da; 
Czec h Re p u blic; 
Fra nce; 
H o n g K o n g; 
Ja pa n; 
Net herla n ds; 
S pai n; 
S we de n; 
Tai wa n; 
U nite d States. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733975] u d y  si tes i n c o u ntries liste d bel o w ma y  partici pate i n t he ser u m, plas ma, a n d uri ne 
bi o mar ker sa m ple c ollecti o n detaile d i n A p pe n di x 7. 
A ustralia ;
Fra nce ;
S pai n .0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B [ADDRESS_733976] si n C o u ntries Liste d i n A p pe n di x 6
O bjecti ve s: 
C ollecti o n of bl o o d a n d uri ne sa m ples t o s u p p ort i de ntificati o n a n d c haracterizati o n 
of bi o m ar kers of tra nst h yreti n a m y l oi d osis .
C ollecti o n of a d diti o nal ba n ke d bi o mar ker sa m ples t o s u p p ort e x pl orat or y  researc h 
relati n g t o dr u g res p o nse a n d ot her disease s. 
Visit I de ntifier Scree ni n g 
P o p ulati o n C o h ort B 
( w it h o ut disease 
d oc u me ntati o n) C o h ort B 
( w it h disease 
d oc u me ntati o n) 
Visit Wi n d o w D a y  -[ADDRESS_733977] olic i nter ve ntric ular se ptal wall 
t hic k ness ( m m) a, b X X
Rec or d left ve ntric ular p osteri or w all t hic k ness ( m m) a, b 
X X
Rec or d left ve ntric ular ejecti o n fracti o n ( %) a, b 
X X
a. O nl y f or ne wl y e nr olli n g s u bjects i n c o u ntries liste d i n A p pe n di x 6.
b. C ollect t his data fr o m me dical hist or y o nl y if a n ec h ocar di o gra p h perf or me d i n last [ADDRESS_733978] u d y visit. 
At t he Scree ni n g visit ( Da y 0), bl o o d a n d uri ne sa m ples will be c ollec te d fr o m ne wl y  
e nr ol le d s u bjects i n t he c o u ntries i de ntifie d i n A p pe n di x 6.  T hese s u bjects will ha ve 
c o nfir me d dia g n osis of A T T R -C M b ut ha ve ne ver ta ke n tafa mi dis.  T hese sa m ples will be 
use d t o s u p p ort i de ntificati o n a n d c haracterizati o n of ser u m, plas ma , or uri nar y bi o mar k ers of 
tra nst h y r e ti n a m yl oi d osis. Res ults of t hese a nal ys es will be re p orte d else w here. 
I d e ntifie d bi o mar kers will be f urt her c haracterize d a n d vali date d usi n g sa m ples fr o m ot her 
st u dies i n patie nts wit h heart fail ure wit h preser ve d ej ecti o n fracti o n ( H F p E F), or i ma gi n g 
evi de nce c o nsiste nt wit h or s u g gesti ve of H F p E F or A T T R -C M w h o ha ve bee n 
c o m pre he nsi vel ye val uate d f or A T T R -C M.   
At t he Scree ni n g visit ( Da y 0) t he f oll o wi n g pr oce d ures will be c o n d ucte d: 
A d diti o nal I nf or me d c o nse nt f or sa m pl e c ollecti o n .0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 
Tafa mi dis me gl u mi ne ( P F -0 6 2 9 1 8 2 6) 
B 3 4 6 1 0 4 5 
Fi nal Pr ot oc ol A me n d me nt 5, 2 4 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 9 1 C ollect bl o o d a n d uri ne sa m ples f or t he f oll o wi n g: 
A T T R bi o mar ker i de ntificati o n: 
4 5 m L  bl o o d ( 7. 5 m L  i n eac h of 6 t u bes) i ncl u di n g 2 K2-E D T A plas ma 
sa m ples, 2 lit hi u m he pari n plas ma sa m ples, a n d 2 ser u m sa m ple t u bes ;
1 0 m L  u ri ne .
Ba n ke d Bi os peci me ns: 
2. 5 m L  w h ole bl o o d Pre p R 1 o pti mize d f or R N A; 
1 0 m L  w h ole bl o o d Pre pB 1 o pti mize d f or plas ma ;
1 0 m L  u ri ne ( Pre p M 2). 
C ollect t he f oll o wi n g ec h ocar di o gra p h y para meters fr o m patie nt me dical rec or ds 
fr o m t he pre vi o us [ADDRESS_733979] re ce nt 
ec h ocar di o gra p h s h o ul d be use d if t here are m ulti ple res ults fr o m t he pre vi o us 
1 2 m o nt hs.   
E n d -Diast olic i nter ve ntric ular se ptal wall t hic k ness ( m m) ;
Left ve ntric ular p os teri or wall t hic k ness ( m m) ;
Left ve ntric ula r ejecti o n fracti o n ( %) .
Ba n ke d Bi os p eci me ns will be c ollecte d as l ocal re g ulati o ns a n d I R Bs/ E Cs all o w. 
Ba n ke d Bi os peci me ns ma y  be use d f or e x pl orat or y  researc h relati n g t o t he dr u g res p o nse , t he 
disease u n der s t u d y a n d ot her disease s as descri be d i n Secti o ns 7. 5 a n d 7. 5. 1 .  Ge nes a n d 
ot her a nal yt es (e g, pr otei ns, R N A, n o n dr u g meta b olites) ma y  be st u die d usi n g t he ba n ke d 
sa m ples. 
Detaile d i nstr ucti o ns o n c ollecti o n, p r o cessi n g, st ora ge, s hi p me nt a n d c o ntact i nf or mati o n 
will be pr o vi de d t o t he i n vesti gat or site i n t he st u d y la b orat or y  ma n ual. 0 9 0 1 7 7 e 1 9 2 a d a c 7 4\ A p pr o v e d\ A p pr o v e d O n: 2 8- J a n- 2 0 2 0 1 2: 2 3 ( G M T) 